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chapter 1
INtRoDuCtIoN
Cardiovascular disease (CVD), particularly atherosclerosis, is the leading cause of morbidity and 
mortality in the Western world, despite increasing awareness of a healthy lifestyle and wide 
prescription of cholesterol-lowering drugs1. In developing countries, the disease is quickly 
becoming the leading cause of mortality, and therefore now accounting for a fifth of all deaths 
worldwide2, 3. Disease progression is usually slow and remains asymptomatic until either arterial 
blood flow becomes obstructed or a plaque rupture occurs precipitating clinical events4, 5. Clinical 
manifestations include angina pectoris, myocardial infarction stroke, aneurism and transient 
ischemic attacks (TIA)6. 
The development of atherosclerosis is a complex multifactorial process. Two major factors 
contributing to the pathophysiology of atherosclerosis are hyperlipidemia and inflammation7. 
Many other risk factors have been identified, including both genetic (hypertension, dysglycemia) 
and environmental factors (smoking, high intake of saturated fats). 
Biology of AtherosClerosis
Atherosclerosis is a progressive inflammatory auto-immune-like disease of the large and medium 
sized arteries characterized by the accumulation of lipids, fibrous components and debris in the 
vessel wall1, 2. Already in 1977, Ross et al., launched his “response to injury” concept in which 
atherosclerotic lesion development is viewed as a pathogenic response to endothelial injury8. 
Endothelial injury changes the permeability of the arterial wall, leading to an influx of low density 
lipoproteins (LDL), which elicits in turn an inflammatory response in the vascular wall. Subsequent 
binding of monocytes and T-cells to the endothelium results in increased migration of cells into 
the intimal layer of the arterial wall, where monocytes differentiate into macrophages. Macrophages 
ingest modified lipoproteins, which transforms them into foam cells. As a result, other macrophages 
produce several cytokines and proteases that further damage the vessel wall. This vicious circle 
of lipid-driven inflammation can lead to narrowing of the vessel lumen. 
Atherosclerotic lesions develop at sites of low and disturbed shear stress close to arterial 
bifurcations and branching points9 where enhanced expression of inflammatory markers and 
increased leukocyte adherence can be observed. Lesions may already start developing in these 
areas from the second decade of life onwards. Early lesions and fatty streaks, which consist of 
the above described foam cells and T lymphocytes in the intima, are already common in infants 
and young children. Further development of an atherosclerotic lesion to a more intermediate 
lesion is characterized by accumulation of more macrophages and smooth muscle cells. In more 
advanced stages, the plaque has a large lipid core covered by a fibrous cap. Advanced lesions are 
predominantly found in people at the age of 30 years and older, and are characterized by extra-
cellular deposition of amorphous lipids, preceding the influx of macrophages and T lymphocytes10. 
The advanced plaque may be at risk to rupture (so-called vulnerable plaque)11, which may trigger 
acute clinical complications such as stroke, peripheral vascular disease and myocardial infarction, 
depending on the anatomical location of the plaque. 
In the cascade of events from an early fatty streak to a vulnerable plaque, inflammatory cells are 
continuously recruited. The classical vulnerable plaque that is prone to rupture is characterized 
by a thin fibrous cap (<70 μm), a large lipid-rich necrotic core (>40% of the plaque area) and many 
inflammatory cells in the shoulder regions of the cap12. The degree of inflammation is not only 
2012110 proefschrift Brigit den Adel_def.indd   8 22-01-13   21:49
| 9
introduction
determined by the number of macrophages, but also by the activity of these macrophages. 
Expression of molecular markers like matrix metalloproteinases and scavenger receptors are thus 
also indices of the vulnerability of the plaque.
Figure 1 shows an illustration of the different processes and molecules involved in atherosclerosis 
over time. Increased expression of leukocyte adhesion markers is one of the earliest hallmarks of 
atherosclerosis. Molecules like P-selectin, E-selectin, VCAM-1 and ICAM-1 may serve as biomarkers 
for vascular inflammation. In later plaque stages monocyte and macrophage accumulation can 
be important markers to detect. 
figure 1 | Atherosclerotic plaque development. Atherosclerotic plaques develop as a chronic inflammatory healing 
response, secondary to endothelial damage. The top panels show a cross section of a normal muscular 
artery without atherosclerosis. The vessel lumen is covered by endothelial cells that rest upon a basement 
membrane.  The vessel wall consists of 3 layers, the tunica intima, separated from the tunica media by the 
lamina elastica interna, and the tunica adventia. The human intima generally consists of a layer of endothelial 
cells and smooth muscle cells scattered within the intimal extracellular matrix. The media consists of 
multiple layers of smooth muscle cells, embedded in an elastin as well as collagen-rich matrix. The 
adventitia, the outer layer of arteries, contains mast cells, nerve endings and microvessels.
 Endothelial dysfunction leads to fatty streak formation and thickening of the intima and the accumulation 
of lipids as visualized in the middle panels. The initial steps of atherosclerosis include leukocyte adhesion 
to the endothelium, migration of the leukocytes into the intima, maturation of monocytes into macrophages, 
and their uptake of lipids, leading to the formation of foam cells. Lesion progression, in the lower panels, 
involves the migration of SMCs from the media to the intima, the proliferation of resident intimal SMCs 
and media-derived SMCs, and the increased synthesis of extracellular matrix molecules such like collagen 
and elastin. Plaque macrophages and SMCs can die in advancing lesions leading to the accumulation of 
their lipids and formation of a necrotic core in the central region of a plaque. Advancing plaques also 
contain cholesterol crystals and microvessels and may have sites of thrombosis.
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chapter 1
A more detailed overview of biomarkers for vulnerable atherosclerotic plaque and targeted 
contrast agents to image the presence of these biomarkers is presented in chapter 2.
experimental models for atherosclerosis
The availability of clinically relevant experimental models of atherosclerosis is essential to study 
the underlying biological mechanisms. Wild-type mice are highly resistant to atherosclerosis as 
a result of high levels of HDL (anti-atherosclerotic) and low levels of LDL and VLDL (pro-
atherogenic), even at advanced age, which makes them unsuitable for atherosclerosis research. 
The lesion-prone C57Bl/6 mice strain only develops small fatty-streak-like lesions when fed a 
high-cholesterol diet13. 
Therefore, all the current mouse models for atherosclerosis are based on modulations of 
lipoprotein metabolism through genetic manipulations and dietary interventions. The most 
commonly used mouse models are the apolipoproteinE-deficient mouse (ApoE-/-)14 and the 
LDLreceptor deficient (LDLr-/-)15 mouse. The ApoE-/- mouse develops spontaneously advanced, 
complex atherosclerotic lesions throughout the arterial tree, especially in the aortic arch16. Lesions 
are characterized by foam cell and lipid accumulation, a fibrous smooth muscle cell cap, and the 
presence of a necrotic core16. These lesions progress well beyond the fatty streak and resemble 
human lesions. This highly pro-inflammatory model is suitable to study the cellular aspects of 
lesion development and has been used for years to that end.
Although ApoE-/- mice develop advanced lesions, they do not develop aneurisms or vulnerable 
plaques. To that end a double transgenic mouse has been developed; the ApoE-/--eNOS-/- mouse. 
We used this mouse to study the treatment window of peroxisome proliferator-activated receptor 
gamma (PPARγ) ligand rosiglitazone in atherosclerosis as described in chapter 8.
LDLr-/- mice are based on a mutation found in patients with familial hypercholesterolemia. These 
mice are modestly hypercholesterolemic on a chow diet. As a result these mice develop lesions 
more slowly and lesions are generally more macrophage-rich and less progressed than in ApoE-
/- mice. Atherosclerosis development is enhanced when LDLr-/- mice are fed a lipid-rich diet. The 
LDLr-/- mouse thus represents a more moderate model than the ApoE-/- model. One of the main 
advantages of this mouse model is the possibility to combine it with bone marrow transplantations 
to repopulate the hematopoietic lineage with donor bone marrow. This technique is used to 
specifically address the role of cells originating from the hematopoietic lineage in atherosclerosis 
development. An application of this method is described in chapter 5.
DeteCtion of AtherosClerotiC lesions
Early detection of atherosclerosis is important for preventive measures like lifestyle changes and 
pharmacological interventions. The diagnosis of vulnerable atherosclerotic plaques is important 
for screening of high-risk patients among patients with established coronary artery disease. 
Our understanding of the pathogenesis of CVD has advanced considerably in the past decades 
and led to the development of a vast range of therapeutic and surgical interventions4. However, 
progress in the detection of both early as well as high-risk atherosclerotic lesions is lagging behind 
and still mainly limited to anatomical features, i.e. the degree of stenosis or vessel occlusions. 
However, the anatomical severity of stenosis is not sufficient to predict the risk of vascular events17. 
In fact vulnerable plaques are often only moderately stenotic due to outward remodeling of the 
vessel, and as a result difficult to recognize as presenting a high risk18. Non-invasive imaging 
techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), positron 
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emission tomography (PET), single photon emission computed tomography (SPECT) and 
ultrasonography (US) all provide limited information on vessel wall characteristics and plaque 
composition. As the vulnerability of an atherosclerotic plaque is mainly dependent on plaque 
composition, there is an urgent need for imaging modalities capable to specifically detect 
vulnerable plaques.
Molecular imaging
Over the last decade researchers worldwide have worked extensively on the development of 
more sensitive and more advanced imaging techniques. One of the major changes in radiology 
is the concept of molecular imaging. While conventional imaging techniques depict gross 
anatomical or functional changes, molecular imaging visualizes the molecular and cellular 
processes of pathology. In general, molecular imaging requires fast, sensitive and high-resolution 
techniques, combined with the application of contrast agents that are tailored to recognize a 
particular molecular target.
Two traditional imaging modalities in the field of molecular imaging are positron emission 
tomography (PET) and single-photon emission computed tomography (SPECT) that detect 
radionuclides. Both are characterized by phenomenal sensitivity with detection  limits at sub-
nanomolar concentrations. Yet the spatial resolution of these techniques is intrinsically low (around 
5-10 mm in humans) without anatomical detail. MRI on the other hand is anticipated to become 
one of the prominent non-invasive imaging techniques for disease diagnosis. Its advantages 
include a high spatial resolution (~1 mm in humans and still improving) without the use of a 
ionizing radiation source. MRI can also detect multiple sources of image contrast, thereby 
providing both physiological and anatomical information of soft tissue. A major limitation of MRI, 
however, remains its inherently low sensitivity (sub-millimolar range). Only the most abundant 
endogenous biochemical molecules can be imaged directly by magnetic resonance spectroscopy 
(MRS-I). Therefore, specific and sensitive targeted contrast agents are needed to visualize 
molecular epitopes. To address this sensitivity problem, MRI contrast agents with a high relaxivity 
have been developed19. The general principle of MRI contrast agents is discussed in this chapter. 
Specific applications of MRI contrast agents to detect atherosclerotic lesions are presented in 
chapters 2 – 9.
Mri 
Magnetic resonance images are predominantly produced by the detection of water protons. 
Water molecules can be detected due to a property of hydrogen nuclei called spin. Spin is the 
random spinning motion of an electric charge that produces a magnetic moment20. 
When a spin is placed in a strong magnetic field (B0), these spins lose their random orientation 
and align within the magnetic field. For hydrogen, two energy states or orientations are possible: 
N+1/2 spin ‘up’ (low energy) and N-1/2 spin‘down’ state (high energy). The Boltzmann distribution 
shows that at body temperature, slightly more spins occupy the lower energy state. The resulting 
net magnetic moment generates the MRI signal. To enable the detection of this magnetic moment 
of the protons within the magnetic field, an external resonant radio-frequency field is applied in 
the form of a short pulse, creating an additional magnetic field (B1). This pulse causes spins to 
flip from their alignment with the magnetic field and turns the net magnetization towards the 
transverse plane. After the pulse, the generated B1 field ceases to exist and the nuclear spins 
return to their equilibrium state in the main magnetic field. This process is called relaxation. The 
time required to return to the ground state is termed relaxation time. 
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Relaxation occurs through two processes named longitudinal (T1) and transverse (T2) relaxation. 
The return of the alignment around the z-axis to equilibrium is termed the spin-lattice or 
longitudinal relaxation T1. T2 relaxation is the local dephasing of spins in the transverse plane. 
T2* is a composite relaxation time, determined by molecular interactions (T2 relaxation) and local 
magnetic field non-uniformities. Due to these small differences in magnetic field the protons 
precess at slightly different frequencies, resulting in rapid dephasing and loss of transverse 
magnetization. The T1 and T2 relaxation mechanisms are independent, though T1 is inherently 
always longer than T2, and T2 is always longer than T2*.
T1, T2 and T2* are properties of the water environment and thus of different tissue types. They 
differ between tissues due to the different physicochemical microenvironments of tissues like 
water mobility, the presence of microstructures, macromolecules and membranes. MRI contrast 
may be generated by tuning the imaging parameters to optimize the T1 or T2 contrast between 
tissues.
Mri contrast agents
Most MRI contrast agents work by reducing the longitudinal (T1) or transverse (T2) relaxation 
times of the target tissue, and are thus commonly described as either “T1-agent” or “T2-agent” 
depending on whether their relative reduction in relaxation time is greater for the T1 or T2 
relaxation times. The ability of the agent to reduce the T1 and T2 relaxation times is described by 
the r1 and r2 relaxivity values.
Generally speaking, T1 agents increase the spin-lattice relaxation rate (1/T1) of hydrogen protons 
in tissue. This T1 lowering effect increases the signal intensity on T1 weighted images (figure 2A). 
Due to the increase of signal intensity on T1-weighted images, T1 agents are also called positive 
contrast agents. On the other hand, T2 agents largely influence the spin-spin relaxation rate (1/
figure 2 | t1 and t2 contrast principle. Schematic representation of the effect of positive and negative contrast 
agents. A. Positive contrast agents cause a reduction in the T1 relaxation time, generating spots with 
increased signal intensity on T1 weighted images.
 B. Negative contrast agents produce predominantly spin spin relaxation effects (local field inhomogeneities), 
which results in shorter T1 and T2 relaxation times that appear as dark spots on MRI. 
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T2) by decreasing T2. This results in the decrease of signal intensity on T2-weighted images (figure 
2B). Thus, these agents have been named negative contrast agents. 
t1 contrast agents
The most commonly used positive or T1 contrast agents are chelates of the lanthanide gadolinium 
(Gd3+). As many other metal ions, free Gd3+ is toxic, therefore it is used in a stable non-toxic form 
in a protective chelate. Several clinically approved low-molecular weight gadolinium complexes 
are available, including Magnevist® (Gd(DTPA)2-), dotarem® (Gd(DOTA)-) and Prohance® 
(Gd(HPDO3A)). The relaxivity of these compounds is sufficient to visualize the blood pool, yet too 
low to image sparse molecular epitopes. Nevertheless, these small compounds have been shown 
to enhance the vessel wall in atherosclerotic lesions using delayed contrast enhancement 
techniques in mouse and rabbit models of atherosclerosis21, 22.
There has been considerable effort to use Gd-based probes to target specific plaque components. 
Gd offers the benefit of positive image contrast on T1-weighted images. The majority of work to 
date has been preclinical, with the exception of the fibrin-targeted probe EP-2104R, for which 
limited data in humans have been reported23.
Nanoparticles, such as gadolinium-containing micelles24, liposomes25 and oil-in-water emulsions26, 
27 and lipoproteins28, 29 have the potential to deliver high payloads of contrast generating material 
and are used to overcome sensitivity problems.Gd-loaded nanoparticles to image atherosclerotic 
lesions have been applied in chapter 3, 4 and 8.
t2 contrast agents
Most T2 contrast agents consist of a coated (mostly with dextran) iron-oxide nanoparticle in the 
order of 4 to 50 nm. They are also depending on their size, coating and structure referred to as 
superparamagnetic iron oxide particles (SPIO 60-150 nm), ultrasmall SPIO (USPIO 20-50 nm), 
micron-sized iron oxide particles (MPIO ~ 1 μm), very small superparamagnetic iron oxide particles 
(VSOP < 4 nm), monocrystalline iron oxide nanoparticles (MION, 30-50 nm)30 and crosslinked 
iron oxide (CLIO, 30-60 nm)31. Iron oxide particles can contain up to thousands of magnetic iron 
oxides and therefore these particles have a very large net magnetic moment. T2 contrast agents 
generate strong local field gradients, which leads to  a shortening of T2 and particularly T2*, 
causing hypointense spots on T2-weighted MRI. On T2*-weighted images, these hypointense 
areas may be much larger than the actual area covered by the particles, a process called the 
blooming effect. 
The association of iron oxide particles with cells can occur via passive or active targeting. Dextran-
coated USPIO nanoparticles are inherently sequestered by monocytes/macrophages because of 
phagocytosis, which is therefore referred as passive targeting to monocytes/macrophages32. This 
is valuable for atherosclerotic plaque imaging as high macrophage content is considered a 
hallmark of plaques vulnerable to rupture1. Ruehm et al. were the first to show that once these 
particles are internalized within the intraplaque macrophages, significant T2*-weighted MR signal 
loss occurs, allowing the detection of plaques that are macrophage rich33. We applied this passive 
targeting of intraplaque macrophages in chapter 7 of this thesis, in which we assess plaque stage 
based on the imaging of both E-selectin and intraplaque macrophages.
targeted Mri contrast agents
A targeted MRI contrast agent in general consists of 2 main components: 1) a ligand with high 
affinity for a biological relevant marker. Antibodies, peptides or other small molecules can serve 
as ligands for contrast agents. 2) a component that can be detected by MRI. To obtain a high 
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target-to-background ratio, a contrast agent should have favorable pharmacokinetics, high target-
binding efficacy and specificity and low background binding. An imaging probe should also have 
low toxicity. 
The nature of the target of choice generally dictates the type of contrast agent that can be used. 
Highly abundant molecular markers can be targeted using small contrast agents. Sparse molecules 
on the other hand require the use of high-payload contrast agents such as micelles and liposomes 
that deliver hundreds to thousands contrast agent moieties. The location of the target of choice 
is also of great importance; this determines the chance of successful targeting. During the 
development of atherosclerotic plaques, many potential biomarkers, such as adhesion molecules 
[vascular cell adhesion molecules (VCAMs), intercellular adhesion molecules (ICAMs), selectins], 
macrophages and their scavenger receptors, matrix metalloproteinases (MMPs), oxidized low-
density lipoprotein (oxLDL), αvβ3 integrin, extracellular matrix, and fibrin (summarized in chapter2), 
are upregulated. It is important to point out that these molecules are often not unique to 
cardiovascular diseases, but they are present at increased levels under these disease conditions 
as compared to disease-free conditions. 
Markers that are present on the endothelium like the leukocyte adhesion molecules VCAM-1 and 
E-selectin are relatively easy to reach via the blood stream with contrast agents ranging in size 
from very small to larger nanoparticles. In later stages of atherosclerosis the processes “specific” 
for that stage are generally found inside the plaque, like the scavenger receptor (SR) on 
macrophages as well as VCAM-1 on macrophages and vascular smooth muscle cells. These sites 
are not as readily accessible, and contrast agent penetration is of importance for successful 
targeting. The application of VCAM-1 targeted USPIO is described in chapter 6, E-selectin and 
SR-A1 targeted USPIO were validated in chapter 5 and chapter 7 respectively. 
Outlook of molecular MRI for atherosclerosis
Targeted molecular MRI of atherosclerosis is already playing an important role in basic science, 
and the development and testing of novel pharmaceuticals. Although the clinical translation of 
these techniques holds much promise, safety, regulatory, and economic hurdles will need to be 
addressed.
The recent human experience with EP-2104R is in many ways encouraging. 
The optimal approach to prevent cardiovascular events remains an area of signify cant debate 
and activity. It is unlikely, however, that a genomic- and biomarker-based approach alone will 
suffice to that end in the future, and complementary information provided by imaging techniques 
such as molecular MRI may ultimately become crucial. 
AiM AnD outline of the thesis
This thesis describes the use of a variety of MRI contrast agents and vessel wall parameters to 
non-invasively image different stages of atherosclerosis.
Chapter 2 gives an overview of the different MRI contrast agents targeted towards the vulnerable 
plaque that have been presented in literature. 
Chapter 3 illustrates that paramagnetic micelles and liposomes are able to accumulate in 
atherosclerotic plaques, yet have a complex kinetic behavior when followed for longer periods 
of time. This knowledge was further applied in chapter 4 and chapter 8 of this thesis. In chapter 
4 the use of self-gated cine MRI was validated to detect contrast agent accumulation in 
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atherosclerotic plaques and assess the vessel wall compliance. The potential of both techniques 
to monitor plaque progression and anti-atherosclerotic therapy was assessed. In chapter 5 we 
developed and validated a scavenger receptor A1 targeted USPIO to detect vulnerable lesions. 
Chapter 6 describes the application of a VCAM-1 targeted USPIO. Imaging at different time points 
after injection, allows to discriminate early plaques from advanced lesions. We show how this 
imaging technique could be used to monitor treatment response in ApoE-/- mice. In Chapter 7 
an E-selectin targeted USPIO to detect atherosclerotic lesions was validated. This USPIO allowed 
discrimination of lesions rich in macrophages from early lesions. In Chapter 8 we developed a 
micelle-based nanoparticle encapsulating rosiglitazone. Targeted delivery to the plaque lead to 
a good anti-atherosclerotic response without cardiac side-effects. Finally in Chapter 9 the 
potentials and pitfalls in the histological validation of MRI contrast agents for atherosclerosis are 
illustrated.
The results I obtained in these studies and their (pre)clinical relevance are discussed in General 
Discussion and recommendations for future research are formulated.
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Molecular MRI of the vulnerable plaque
Is it possible?
Chapter 2
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AbStRACt
Recent advances in molecular resonance imaging of atherosclerosis make it possible to visualize 
atherosclerotic plaques in vivo using molecular targeted contrast agents. This offers unprecedented 
opportunities to use these imaging techniques to study atherosclerosis development and plaque 
vulnerability non-invasively to establish novasive tools for drug discovery. In this review paper, 
we discuss MRI contrast agents targeted towards the vulnerable plaque and illustrate how these 
new imaging platforms could assist in our understanding of atherosclerosis and aid in its treatment. 
In particular we highlight the challenges, including the limitations of the different contrast agent 
systems and the steps to be taken with the different compounds to allow them into clinical 
practice. 
 
GloSSARy of tERMS
term Definition 
Atheroma: Accumulation of cells or cellular debris that contain lipids, 
calcium, and fibrous connective tissue between the 
endothelium lining and the smooth muscle cell–rich medial 
wall of arteries 
CLIO: Cross-linked Iron Oxide particle, iron-based T2 contrast agent 
with a hydrodynamic core of ~ 30 nm (see also iron oxide 
nanoparticle)
Chelate: chemical that forms complex molecules with certain metal 
ions like Gd, thereby inactivating the ion so that they cannot 
normally react with other elements or ions converting them 
to a chemically inert form that can be excreted without further 
(toxic) interaction with the body.
Fibrous cap: A layer of fibrous connective tissue in the intima 
Foam cells: Cells in an atheroma that consist of monocyte macrophages 
containing numerous lipid inclusions rich in cholesteryl 
esters 
Immunomicelle: micelle-based contrast agent coupled to an antibody (see 
also micelle)
Intima: The innermost layer of a blood vessel 
Intimal thickening: Accumulation in the intima of smooth muscle cells and lipids 
within a matrix of proteoglycans 
Iron-oxide nanoparticle: A nanoparticle with an superparamagnetic iron oxide core, 
usually coated with dextrans (see also CLIO, MION, USPIO).
Lipid-based nanoparticle: small contrast agents with a lipid layer like micelles and 
liposomes
Liposome: A vesicle composed of a phospholipid bilayer. They may also 
contain mixed lipid chains with surfactant properties. Gd-
chelates and targeting ligands can be incorporated in the lipid 
bilayer.
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Micelle: A spherical aggregation of a monolayer of surfactant or lipid 
molecules that can carry Gd-chelates and targeting ligands 
in the lipid layer, with a size of ~10-100 nm.
MPIO: Micro Particles of Iron Oxide, T2* and T1 contrast agents with 
a size of ~ 1 μm 
Nanoparticle: A microscopic particle having one or more dimensions of the 
order of 100nm or less
Superparamagnetic iron oxide: microcrystalline magnetite particles with strong T2* and T1 
relaxation (depending on size)
Thin-cap fibroatheroma (TCFA): A thin fibrous cap infiltrated with macrophages and 
lymphocytes, rare smooth muscle cells, and an underlying 
lipid-rich necrotic core 
USPIO: Ultra Small Particles of Iron Oxide, superparamagnetic iron 
oxide particles with a hydrodynamic size of ~ 50nm. Strong 
T2*/T1 contrast 
Vulnerable plaque: A plaque with a thin fibrous cap that is prone to rupture and 
may cause thrombosis
INtRoDuCtIoN
With the increased attention for preventive medicine combined with novel clinical intervention 
modalities, major advances have been made in the treatment of atherosclerosis1. Yet, in the 
Western world atherosclerotic diseases, including acute coronary syndrome (ACS) and stroke, 
are responsible for nearly 50% of deaths and among the leading causes of morbidity2.
One of the first known descriptions of atherosclerosis belongs to Leonardo da Vinci (1452-1519), 
who admirably described it as “debility through lack of blood and deficiency of the artery which 
nourishes the heart and other lower members”. Today we know that atherosclerosis is an 
inflammatory disease of the arteries characterized by intimal thickening and plaque development. 
Although the pathology by itself is relatively benign, severe clinical complications such as angina 
pectoris, limb ischaemia, renal problems and hypertension are relatively common. However, the 
most severe complications arise from ruptured atherosclerotic plaques that can cause arterial 
thrombosis and precipitate acute vascular/ischemic events like myocardial infarction or ischemic 
stroke3. These rupture-prone plaques, also described as thin cap fibroatheromas (TCFA), are called 
vulnerable plaques, a term first instituted by Muller et al4.
Atherosclerotic plaque development
About 200 years ago, Joseph Hodgson already proposed that atherosclerosis is an inflammatory 
disease. Ultimately, it took till 1976 to revive this theory, due to the extensive studies and 
publications of Russel Ross (1929–1999) who introduced the “response-to-injury” concept5, 6. 
Atherosclerotic plaques develop as a chronic inflammatory healing response, secondary to 
endothelial damage, as focal thickenings in lesion prone areas in the intima of large and 
medium-sized arteries (figure 1). Cardiovascular risk factors such as chronic smoking, 
hypertension and dislipidemia are risk factors for the development of dysfunctional endothelium, 
a crucial pathophysiological factor in the development of atherosclerosis7,8.
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Histopathologically, atherosclerosis is characterized by a progressive accumulation of lipoproteins, 
specific cell types (smooth muscle cells, monocytes, and T-lymphocytes) and deposition of 
extracellular matrix in the arterial wall. Subendothelial retention of lipoproteins and immune cells 
in the vessel wall comprises the first stage of atherosclerosis (figure 1B, 2A). As the lesion advances, 
upon ingestion of modified LDL, macrophages become foam cells and release inflammatory 
cytokines and proteases that induce fibrous cap thinning. Lipid-loaded foam cells eventually die, 
thereby leading to growth of the necrotic core (figure 2A). The progression of atherosclerosis 
from an initial fatty streak to the complex advanced lesion has been described using Stary’s six-
stage histological classification9. It is now widely established that inflammatory processes are 
involved in each step of the pathology. 
In patients suffering from the consequences of the rupture of a previously vulnerable plaque, the 
necrotic lipid core is proportionally larger and eccentrically positioned in the plaque, covered by 
a thin fibrous cap and an increased level of intraplaque vasa vasorum angiogenesis is present3. A 
vulnerable plaque has specific morphological characteristics: a macrophage infiltrated thin fibrous 
cap, inflammatory cells, a large lipid (or necrotic) core and increased concentrations of oxidized 
LDL, a relatively low abundance of smooth muscle cells as well as a reduced amount of collagen. 
The technological development in the field of plaque imaging is making remarkable progress in 
the detection of different structures of the vulnerable plaques. 
figure 1 | Development of atherosclerosis. Atherosclerosic plaques develop as a chronic inflammatory healing 
response, secondary to endothelial damage . Panel A1 and A2 show a cross section of a normal muscular 
artery without atherosclerosis. The vessel lumen is covered by endothelial cells that rest upon a basement 
membrane.  The vessel wall consists of 3 layers, the tunica intima, separated from the tunica media by the 
lamina elastica interna, and the tunica adventia. The human intima generally consists of a layer of endothelial 
cells and smooth muscle cells scattered within the intimal extracellular matrix. The media consists of 
multiple layers of smooth muscle cells, embedded in an elastin as well as collagen-rich matrix. The 
adventitia, the outer layer of arteries, contains mast cells, nerve endings and microvessels.
 B. Endothelial dysfunction leads to fatty streak formation and thickening of the intima by recruitment of 
inflammatory cells and the accumulation of lipids. The initial steps of atherosclerosis include adhesion of 
leukocytes to activated endothelium, migration of the leukocytes into the intima, maturation of monocytes 
(the most numerous of the recruited leukocytes) into macrophages, and their uptake of lipids, leading to 
the formation of foam cells.
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Plaque identification
It is increasingly recognized that the availability of noninvasive, reliable and sensitive atherosclerosis 
imaging techniques can be used to guide early interventional or medical therapies. In addition to 
that, the availability of these techniques combined with animal models of atherosclerosis provides 
unique opportunities for the investigation of molecular disease mechanisms, and in vivo monitoring 
of novel therapeutic approaches as well as disease progression. 
Over the past decade, much effort has been put in the development of novel methods to identify 
vulnerable atherosclerotic plaques with different imaging techniques. If vulnerable plaques can 
be identified (which conventional cardiac catheterization is unable to), vulnerable plaques can 
be targeted for intervention (angioplasty, stent, or bypass surgery), while avoiding unnecessary 
treatment of the stable plaques.
Several invasive methods such as intravascular ultrasound, palpography and optical coherence 
tomography are currently clinically applied in patients. Because of their invasive nature these 
intravascular imaging modalities are not suited to screen patients with subclinical disease.
Noninvasive assessment of plaque vulnerability targets a different patient population, i.e. 
asymptomatic individuals who have not (yet) presented with an acute vascular event but are at 
risk to develop one. Relying on inflammation as a central pathogenic aspect of plaque vulnerability, 
circulating inflammatory biomarkers of vulnerable plaques have been identified. They provide 
valuable diagnostic and prognostic information10. However, they do not provide insight in the 
anatomic localization of individual vulnerable plaques. Thus, timely and anatomically precise 
imaging of vulnerable plaques is a medical need, since angiographic and pathological studies 
demonstrate that arteries frequently occlude acutely without preceding flow limiting stenosis11, 
12. These findings indeed stress that the biological characteristics of plaques rather than the degree 
of luminal narrowing determine the risk for clinical complications.
Traditionally the gold standard for the diagnosis and assessment of atherosclerosis severity has 
been X-ray angiography, which visualizes the reduction in arterial luminal diameter. However, 
it is increasingly recognized that significant atherosclerotic plaque can be present within the 
arterial wall long before the lumen is compromised13, 14. Angiographic modalities, which give 
limited information about the vessel wall, cannot adequately delineate plaque composition and 
routinely underestimate atherosclerotic burden.
MRI has emerged as one of the rapidly evolving non-invasive imaging modalities of atherosclerotic 
disease due to its ability to assess the arterial lumen, plaque burden and plaque components 
in an accurate and non-invasive manner. Clinically these assessments are mainly used in the 
carotid arteries, but research continues to use similar MRI methods in other arteries, such as 
aortic, peripheral and coronary arteries. Several in vitro and in vivo studies have demonstrated 
the ability of MRI to differentiate the major components of atherosclerotic plaque without the 
use of contrast agents. In addition, MRI can accurately and reproducibly measure arterial wall 
dimensions. This has led to its use as the imaging efficacy end-point in therapeutic trials of 
plaque regression15, 16. 
Possibly the biggest breakthrough in the imaging field is the development of novel targeted 
contract agents, thereby creating the novel field of molecular imaging.  The use of molecular 
targeted contrast agents in combination with MRI has, albeit often still in a pre-clinical phase, 
already proven to be effective in detection of different stages of atherosclerosis.
In this article we review recent developments in molecular MRI concerning atherosclerosis, 
highlighting the detection of the vulnerable plaque as a key structure of plaque pathology, pre- 
view some of the new opportunities molecular MRI offers to atherosclerosis diagnosis and 
comment on the challenges faced by the field.
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MolECulAR MRI
High resolution MRI has emerged as the potential leading noninvasive in vivo imaging modality 
for atherosclerotic plaque characterization, in particular suitable to detect intraplaque hemorrhage, 
cholesterol deposits and the extend of the lipid core17, 18. MRI differentiates plaque components 
on the basis of chemical composition, water content, physical state, and molecular motion or 
diffusion. 
Molecular MRI offers the potential to image events at the cellular and subcellular level which has, 
depending on the target of choice, added value over traditional contrast agents. The introduction 
of targeted MR contrast agents has enabled the imaging of relatively sparsely expressed biological 
targets in vivo. 
During the development of atherosclerotic plaques, many potential biomarkers, such as adhesion 
molecules [vascular cell adhesion molecules (VCAMs), intercellular adhesion molecules (ICAMs), 
selectins], macrophages and their scavenger receptors, matrix metalloproteinases (MMPs), oxidized 
low-density lipoprotein (oxLDL), αvβ3 integrin, extracellular matrix, and fibrin, are upregulated. 
It is important to point out that these molecules are often not unique to atherosclerosis or 
cardiovascular diseases, but they are present at increased levels under these disease conditions 
as compared to disease free conditions. Moreover, these molecular targets are often present at 
relatively low levels (10−9 to 10−13 M/g tissue). To overcome sensitivity issues, high payload contrast 
agent vehicles have been developed for molecular MRI to generate sufficient signal change. 
Nanoparticle-facilitated imaging is at this point the most promising approach for molecular MR 
imaging purposes, since nanoparticles exhibit the possibility to include a high contrast agent 
payload, may be of relatively small size to facilitate penetration into tissue, and have a tunable 
circulation half-life, a large surface area available for conjugation of functional groups, and the 
potential to function as both imaging and therapeutic (i.e. ‘theragnostic’) agents.
The biological processes described above and their accompanying molecular and cellular events 
create numerous opportunities for targeting the atherosclerotic plaque using nanoparticles. 
Several novel nanoparticle platforms have emerged in molecular MRI that allow the visualization 
of vulnerable plaques. These will be highlighted here in the context of their relevance to plaque 
vulnerability.
INtRA-PlAquE tARGEtING
lesional macrophages 
A large body of evidence associates macrophages with the formation, progression, and 
pathogenicity of atherosclerosis. Monocytes from the peripheral circulation migrate into the 
plaque and differentiate there into macrophages, which in turn may engulf large quantities of 
low-density lipoprotein, to become resident foam cells 19,20 (figure 2A and 2C). In mouse models 
it has been shown that in the absence of monocyte and macrophage migration into the vessel 
wall, atherosclerosis development is delayed, even in the presence of severe hyperlipidemia21. In 
man, high macrophage content in plaques is associated with vulnerability to rupture22, 23. In acute 
coronary syndromes, the lipid core of the responsible lesions is rich in macrophage-derived foam 
cells and other inflammatory cells22, 23. Different macrophage subsets, which differentially 
contribute to plaque infiltration and to atherosclerosis complications, have been identified. In the 
last years, it has become widely accepted that classically activated macrophages (or M1) and 
alternatively activated MØ (or M2) are two extremes (inflammatory versus remodelling) of a 
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spectrum of macrophage phenotypes that both contribute to plaque development progression 
and vulnerability24.
M2 alternatively activated macrophages
Myeloid-related protein (Mrp)-8/14 is a member of the S100-family of Ca2+- modulated proteins 
with an important role for the Mrp complex in the inflammatory response to injury via the activation 
of innate immune pathways. Mrp8/14 is abundantly detected in human and mouse atherosclerotic 
plaques and localizes to rupture prone areas of plaque typified by large necrotic cores and high 
macrophage content25. Indeed, a subset of macrophages (the alternatively activated M2 subset 
that is causally linked to plaque vulnerability) expressing dimerized Mrp have been demonstrated 
in human atherosclerosis and predominate in rupture-prone lesions compared to stable plaques24, 
26. Consistent with its extracellular abundance and signaling, levels of Mrp have been shown to 
be an independently prognostic marker of cardiovascular risk27.
Recently Maiseyeu et al. developed a multivalent theragnostic (combination of therapeutical and 
diagnostical compound) nanoparticle composed of phosphatidyl-serine (PS), ω-carboxynonanoyl-
cholesteryl ester and Gd lipids which were targeted to M2 macrophages using an anti-Mrp14 
polyclonal antibody (IgG)28. Proof of principle of the contrast agent both in vitro on cultured 
ApoE-/- monocytes and in vivo in atherosclerotic mice showed enhanced binding potential to 
Mrp+ monocytes and endothelial cells. Although long term experiments to explore its preclinical 
therapeutic and diagnostic potential remains to be performed, this is the first time a contrast 
agent specifically targeting the vulnerable subset of macrophages has been successfully applied. 
Further optimization of the agent is required since the targeting vector (an IgG) may be 
immunogenic and the compound may target other sites than atherosclerotic plaques29.
lipoproteins
Lipoproteins are nanoparticles that are naturally present in most species, and in humans are essential 
to control lipid metabolism. These lipoproteins, including high-density lipoprotein (HDL) and LDL, 
interact with plaques through a natural conduit. Exploiting or mimicking this inherent plaque affinity 
of lipoproteins has been shown to be a powerful approach to target plaques. Oxidized low-density 
lipoprotein (oxLDL) plays a key role in the initiation, progression, and destabilization of atherosclerotic 
plaques and is present in macrophages and the lipid pool (figure 2C). 
Targeting this oxidation epitope has been exploited with several compounds. Both Gd-based 
immunomicelles as well as lipid-coated iron oxide particles containing murine (malondialdehyde 
(MDA)-lysine MDA2 and E06) or human (IK17) antibodies that bind unique oxidation-specific 
epitopes (i.e. oxLDL), induced significant enhancement in MR images of the aorta wall of apoE−/− 
mice30-32. Similar MDA-targeted immunomicelles functionalized with manganese (Mn2+) chelates 
were recently developed in response to the finding that if Mn is delivered into a cell, interaction 
with intracellular components and metalloproteinase results in significant (>20-fold) increases in 
MR efficacy compared to the chelated form33. In vivo plaque imaging findings with these Mn-
based compounds were comparable with the previous results however background signal from 
the Mn-based contrast agent in blood was very low allowing a better plaque definition.
Lipoproteins themselves are ideal for the delivery of drug and imaging agents since they are able 
to circulate in the blood- stream for a significant amount of time, the hydrophobic core facilitates 
the incorporation of poorly soluble drugs or imaging agents, and they are highly amenable to 
bioconjugation. 
The LDL particle itself naturally homes to a plaque after intravenous administration. LDL particles 
that are enriched with a hydrophobic contrast agent, manganese-mesoporphyrin, cause reduction 
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in T1 in foam cell pellets that were incubated with this agent34. Despite the potential of these 
nanoparticles, extensive in vivo MRI of atherosclerotic plaque with these LDL nanoparticles has 
not (yet) been reported. Yamakoshi et al. recently reported the first successful in vivo application 
in both hypercholesterolemic ApoE-/- and LDLr-/- mice of a LDL particle functionalized with a 
GdDO3A-monoamide chelate35. 
Given the key role of LDL itself in plaque progression it is presently unclear whether an LDL based 
compound can be optimized for safe use in the clinic.
In contrast to the LDL, HDL forms smaller lipid nanoparticles (5–12 nm) stabilized by the 
interactions of surface apolipoprotein A-1 (ApoA-1). HDL nanoparticles have some advantages 
for atherosclerotis imaging: During reverse cholesterol transport, HDL binds to scavenger receptor 
B type I (SR-BI) and ATP-binding cassette transporters and thus “naturally” targets to macrophages 
expressing these receptors. High HDL cholesterol levels are associated with reduced atherosclerotic 
plaque burden and lipid content whereas LDL promotes the disease36. Second, their small size 
(~10 nm) enables them to penetrate the vessel wall more easily than LDL. This led to the 
development of a vast array of HDL based contrast agents in the past decade.
The first MRI HDL particles that were synthesized contained Gd-chelating phospholipids in the 
lipid layer (rHDL)37, 38. In hyperlipidemic apoE−/− mice these paramagnetic rHDL nanoparticles 
showed enhanced accumulation in atherosclerotic plaques after intravenous administration. 
The targeting of rHDL to macrophages may be further enhanced by the addition of P2fA2, a 
lipopeptide derived from the low density lipoprotein receptor (LDLR) binding domain of apoE, 
into the lipid layers39. P2fA2-modified HDL resulted in a doubling of the enhancement ratio of the 
aortic vessel wall at 24 h postinjection, compared to the rHDL particle. 
A clear increase in MR signal was also observed in the aortic wall of apoE−/− mice in vivo 24 hours 
after injection of the paramagnetic Au HDL and QD-HDL, while a clear decrease of MR intensity 
in the aortic wall was observed using FeO-HDL particles40.
Thus far the application potential of the HDL particles seems promising and due to its biological 
resemblance to autogenous HDL and the ease to produce the particle further development in 
the near future is likely to occur.
scavenger receptors 
The macrophage scavenger receptor (SR) is a macrophage-specific cell-surface protein, and not 
expressed on cells in the normal vessel wall41. Both class A and B SR (SR-A and SR-B) are involved 
in the progression of atherosclerosis42, 43 (figure 1B and 2A), playing an important role in (oxidized) 
low-density lipoprotein uptake as well as in clearance of debris, including necrotic and apoptotic 
cell fragments44. SR-A is a high-affinity receptor, in the picomolar to nanomolar range (depending 
on the ligand), and as macrophages are present through all stages of atherosclerosis, the scavenger 
receptor forms an excellent target for molecular imaging45. Both SR-A and SR-B are instrumental 
in the development of atherosclerosis and collectively are responsible for binding and uptake of 
75 to 90% of modified LDL uptake by macrophages46.
Amirbekian et al. developed ~110 nm large immunomicelles containing Gd targeted to SR-A 
(CD204) via the conjugation of a monoclonal antibody47. These micelles showed improved in vivo 
detection of murine atherosclerosis with a high correlation between the signal intensity on MRI 
and the number of macrophages in the region of interest48.
Gd-loaded lipid-based nanoparticles targeting CD36, a class B scavenger receptor (SR-B), 
showed significant uptake by human macrophages in vitro, improved signal intensity of ex vivo 
aortic atherosclerotic plaque, and were shown to bind to resident macrophages in atherosclerotic 
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plaque using confocal microscopy49. The CD36 labeled particles created the largest signal 
intensity in regions of fibrous plaque at the periphery of lipid-rich plaque. These data suggest 
that lipid based nanoparticles targeting CD36 may improve detection and characterization of 
atherosclerotic plaque and determine the degree of plaque inflammation by assessing 
macrophage density.
Both contrast agents were successful in the visualization of macrophages. Conjugation with a 
full antibody will however hamper repeated application of the agent due to an immune response. 
Another limitation in the use of particles targeting the scavenger receptors may be the fact that 
intravenous administration of this imaging agent will suffer from first pass retention in the liver 
due to binding to scavenger receptors expressed on the surface of Kuppfer cells. For clinical 
application of the agent for vulnerable plaque detection these hurdles will need to be taken.
ENzyME ACtIVIty
MMPs
MMPs are a large family of zinc-dependent endopeptidases that selectively digest matrix and 
other key proteins during reorganization of vascular matrix scaffold, thereby facilitating cell 
migration. With the progression of atherosclerosis, oxidized LDL increases MMP-1 and -3 
expression50. In addition to their inherent catalytic effect, constitutive MMP expression in VSMCs 
is induced by inflammatory cytokines, and their expression leads to migration and phenotypic 
modulation of macrophages50.
Previous histological studies demonstrated strong expression of MMPs and in situ matrix-degrading 
gelatinolytic activity in the fibrous cap of human atherosclerotic plaques51, as well as in 
atherosclerotic lesions that were induced in experimental models52. Presence of MMP-1, -3, and 
-9 has been observed in macrophages, VSMC, lymphocytes, and endothelial cells especially at 
the vulnerable shoulder region of plaques51. Recent work has demonstrated that overexpression 
of MMPs led to cardinal features of plaque rupture in a mouse model of atherosclerosis53. 
Therefore, MMPs play a key role in the pathological remodeling cascade associated with the 
natural history of the atherosclerotic plaques, from the initial formation of lesions and outward 
arterial remodeling to the thinning and weakening of the extra-cellular matrix scaffold forming 
the fibrous cap favoring plaque instability and rupture54. 
Protease imaging has used two generic approaches: a) targeting labeled small molecules to 
specific protein pockets, typically the active site55, 56 and b) the use of ‘smart’ MRI probes that are 
bound to a synthetic graft copolymer consisting of a cleavable backbone, which become activated 
and detectable upon cleavage57-59.
MMP binding contrast agents
An Example of the first approach is the broad-spectrum MMP inhibiting peptide, P947, with an 
attached Gd-DOTA chelate (Guerbet, France) that has been developed to visualize vulnerable 
plaques. P947 accumulates in MMP-rich atherosclerotic plaques of ApoE-/- mice56, 60. Variations 
in MMP-related enzymatic activity in atherosclerotic plaques of rabbits subjected to dietary 
changes were detected ex vivo. Translation of this imaging technology to the clinical field could 
give deeper insights into the role of MMPs in arterial wall remodeling in vivo and a clinical 
modality to image and monitor markers previously associated with plaque progression and 
instability61.
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Cleavable MMP substrates
Successful attempts of the second approach at in vivo MRI of matrix metalloproteinase (MMP) 
activity have been based on the use of MMP substrates conjugated to Gd-DOTA, with a N-terminal 
hydrophobic chain and a C-terminal PEG chain62. MMP cleaves the hydrophilic PEG from Gd-
DOTA, thereby decreasing the water solubility of the remaining Gd-DOTA fragment. This approach 
gives a small but significant increase (approximately 0.015 s−1) in proton relaxation rate due to 
MMP-2 activity57 allowing in vivo detection of MMP-2 activity in a mouse model of mammary 
carcinoma. This specific probe has thus far not been applied in atherosclerosis, and though 
conceptually very interesting, the sensitivity of such approaches is a major issue for the in vivo 
translation of this approach.
Another MRI-dedicated MMP-2/MMP-9-sensitive probe in development uses nanoparticles loaded 
with gadolinium. Upon proteolysis, the nanoparticles exhibit highly cationic molecules that trigger 
attachment and uptake into cells58, 59. Initial reports indicate a potential use for cancer targeting 
in vivo, but no study has yet assessed the utility of such agents in CVD.
figure 2 |   Atherosclerotic plaque progression. In panel A the different steps in lesion progression are depicted. 
Lesion progression involves the migration of SMCs from the media to the intima, the proliferation of resident 
intimal SMCs and media-derived SMCs, and the increased synthesis of extracellular matrix molecules such 
like collagen and elastin. Plaque macrophages and SMCs can die in advancing lesions leading to the 
accumulation of their lipids and formation of a necrotic core in the central region of a plaque, as visualized 
in panel A and B2. Advancing plaques also contain cholesterol crystals and microvessels. 
 Thrombosis, the ultimate complication of atherosclerosis, often complicates a physical disruption of the 
atherosclerotic plaque. In panel B1 a thrombus in the vessel lumen is depicted. In panel B2 intraplaque 
hemorrhage is shown, this usually occurs in the shoulder region of a plaque and is an indicator of 
progression towards an unstable plaque phenotype. When a plaque ruptures, blood coming in contact 
with the tissue factor in the plaque coagulates. Platelets activated by thrombin generated from the 
coagulation cascade and by contact with the intimal compartment instigate thrombus formation. Several 
contrast agents have been developed targeting factors in the coagulation cascade.
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Myeloperoxidase
Myeloperoxidase (MPO) is involved in free radical generation with a central role in atherosclerotic 
plaque instability. Although generally abundant in granulocytes, MPO within atheromata 
originates mainly from macrophages and foam cells. MPO catalyzes chloride oxidation to 
hypochlorous acid (HOCl) and generates other highly reactive moieties such as chlorine, tyrosyl 
radicals, and aldehydes. These contribute to the microbicidal and viricidal properties of 
phagocytes as part of its function in innate host defense mechanisms63. The reactive species 
formed, however, are cytotoxic and may damage normal tissues, contributing to the inflammatory 
injury. MPO-generated oxidants participate in multiple processes relevant to cardiovascular 
disease development and outcomes, including induction of foam cell formation, endothelial 
dysfunction, development of vulnerable plaque, and ventricular remodeling following acute 
myocardial infarction (reviewed in64, 65). 
The peptide serotonin (hydroxytryptamine), when oxidized by MPO, tends to aggregate into dimers 
and oligomers. This principle was used for a gadolinium-serotonin chelate, capable of sensing 
myeloperoxidase activity in vivo66. Once the serotonin moiety in the chelate is activated by 
myeloperoxidase, the probe assembles into dimers, trimers and even pentamers that tend to be 
retained locally. This polymerization decreases the tumbling rate of Gd giving the imaging agent 
a significantly higher longitudinal relaxivity than the parent compound66, 67. The presence of MPO 
has been successfully imaged in vivo with this probe, both in a mouse model of myositis and in 
a model of myocardial infarction67, 68 serving as a surrogate of the inflammatory response and 
thereby prognosis. Imaging in the context of a vulnerable atherosclerotic plaque has not been 
reported thus far.
luMINAl tARGEtS foR MolECulAR IMAGING
thrombosis
The event of plaque rupture from a previously vulnerable plaque resulting in thrombosis plays a 
central role in myocardial infarction, stroke, atrial fibrillation and venous thromboembolism. 
Moreover, intraplaque and endothelial fibrin has recently been recognized to play an important 
role in the progression of atherosclerosis (figure 2A2 and 2B). A recent study showed that the 
leakage of fragile neovessels formed during plaque development might represent a route for fibrin 
to enter atherosclerotic plaque prior to rupture69. Tavora et al. hypothesised that the extravasation 
of fibrin from newly formed blood vessels may be the defining trigger for the formation of a 
necrotic core and thus for the transition between early and late stage plaques69. Fibrin is suggested 
to be a novel biomarker for the intraplaque necrotic core and the differentiation between pre-
atheroma from atheroma.
Extensive experience with in vivo MRI of thrombosis has been obtained with EP2104R, currently 
named FTCA (Epix Pharmaceuticals, Lexington, USA), a small Gd-chelate targeted to fibrin70. 
Studies with EP2104R in rabbits and swine reported the ability of the agent to detect acute and 
chronic arterial and venous thrombi71, 72. The contrast agent was effectively applied to detect 
thrombi in vessels and heart chambers in 52 patients with suspected thrombosis in a phase II 
clinical trial, underlining its translational potential73. 
Recently the feasibility of intraplaque and endothelial fibrin detection using the fibrin-targeted 
contrast-agent was assessed in vivo in ApoE-/- mice. The atherosclerotic plaques investigated 
were not associated with luminal thrombi in contrast to previous studies22, 74. FTCA was selectively 
visualized at the location of atherosclerotic plaque in these mice, while surrounding blood and 
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soft tissue signal remained suppressed. Late stage atherosclerotic plaque showed the strongest 
signal enhancement after FTCA administration. These findings suggest that the contrast agent 
may not only be useful to detect thrombi but also plaques at risk, which in itself may be a 
contradictory imaging endpoint but represents in both cases plaques at risk of further clinical 
events. In 2009, EPIX Pharmaceuticals entered into an Assignment for the Benefit of Creditors. 
To the authors best knowledge the development and clinical trials of FTCA did not proceed 
thereafter.
Another fibrin-targeted contrast agent, a much larger Gd-bis-oleate nanoparticle , with a higher 
relaxivity, has also been shown to effectively detect thrombi in vitro and in an animal model, but 
this particle has not yet been investigated in mouse models of human atherosclerosis or patients75, 
76. Owing to its size, this contrast agent will be mainly suitable for the detection of luminal fibrin 
clots and less for the detection of intraplaque fibrin and thus for plaques at risk.
VASCulAR tARGEtING: CEllulAR ADHESIoN MolECulES
Dysfunctional endothelium is a crucial pathophysiological factor in atherosclerosis, causing 
increased permeation of macromolecules such as lipoproteins, increased expression of 
chemotactic molecules (for example, monocyte chemotactic protein 1) and adhesion molecules 
(for example, intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1), as well as E-selectin and P-selectin), and enhanced recruitment and accumulation of 
monocytes7.
VCAM-1 (CD106)
VCAM-1 is an appealing target as it is differentially upregulated on the endothelium related to 
atherosclerotic plaque and lesion prone areas of the artery77 (figure 1B). McAteer et al. have recently 
reported a microparticle iron oxide (MPIOs) approach to VCAM-1 imaging that provides quantifiable 
contrast in mouse vascular inflammation78, 79. Due to their size and incompressible nature, MPIO 
are less susceptible to nonspecific vascular egress or uptake by endothelial cells. Therefore, MPIO 
may be useful contrast agents for detection of strictly endovascular molecular targets by MRI.
Nahrendorf et al. functionalized monocrystalline iron oxide nanoparticles with vascular cell 
adhesion molecule-1 (VCAM-1) targeting peptides80, 81. In vivo MR imaging revealed that the aortic 
root of apoE−/− mice became hypointense (dark) after injection of this contrast agent, which was 
confirmed through fluorescence imaging both ex vivo and in vitro in macrophages that over-
expressed VCAM-1.
Burtea et al. recently developed much smaller Gd-DOTA as well as Ultra Small Particle of Iron 
Oxide (USPIO) based VCAM-1 targeted compounds82, 83. The Gd-based compound has shown 
preliminary potential in the ability to image atherosclerotic plaques in hypercholesterolemic 
ApoE-/- mice. The strength of this approach relies in the ability of the smaller particles to penetrate 
into the plaque and thereby potentially target the plaque macrophage population that expresses 
VCAM-1.  On the other hand, the Gd payload may be too low for detection of smaller plaques. 
integrin alphav-beta3
Integrins are a family of heterodimeric cell surface glycoprotein adhesion molecules, that mediate 
cell-extracellular matrix and cell-cell interactions, and are involved in cell adhesion, proliferation, 
migration, differentiation, and finally serve as potential targets for imaging of vascular remodeling. 
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The αvβ3 integrin is among others expressed by endothelial cells (ECs), VSMCs84, platelets, growth 
factor-stimulated monocytes and T lymphocytes (figure 2A)85, 86. Human atherosclerosic lesions 
show extensive expression of αvβ387, which functions in thrombus formation88, smooth muscle 
cell migration89, (adventitial) neovascularization32, 33, as well as many other processes. Although 
αvβ3 is expressed on a variety of cells, its expression seems to be predominant in smooth muscle 
cells and endothelial cells87, 90. Macrophages also express αvβ3 during foam cell formation91. Most 
interesting is that αvβ3 expression is an early event in plaque formation92, 93 and is also correlated 
to plaque instability94, 95. 
The Wickline group from Washington systematically developed several integrin targeting imaging 
compounds over the past decade; Lanza et al have developed a nanoparticle with a perfluorocarbon 
core covered with a monolayer of lipids  including paramagnetic lipids (Gd-DTPA-bis-oleate)96. 
The perfluorocarbon nanoparticles targeted to the αvβ3-integrin to detect angiogenesis in a rabbit 
model of atherosclerosis97. For imaging of plaque-associated angiogenesis, Winter et al. have 
successfully developed a relatively large (273 nm) paramagnetic nanoparticle contrast agent 
targeted specifically to αvβ3 integrins using a Arg-Gly-Asp mimetic (RGD)97. Although very efficient from the 
relaxometric point of view, this agent has the drawback of its large size that limits not only blood 
clearance, but also its diffusion into the targeted tissue. Based on the perfluorocarbon particles, 
this group not only used proton relaxation, but also direct detection of the 19F MRI signal to 
specifically image the contrast agent in vivo98, 99.
A smaller, low molecular weight non-peptidic RGD mimetic covalently attached to a Gd-DTPA 
chelate was developed for the imaging of plaque-associated angiogenesis100, 101. This contrast 
agent was able to penetrate the atherosclerotic plaque, allowing visualization of neovascularisation. 
Specificity for angiogenic vessels may be decreased, however, when diffusible rather than pure 
intravascular imaging probes are used because inflammatory cells and fibroblasts can express 
many of these integrins.
One of the major drawbacks of the previously mentioned approaches is the use of RGD-like 
peptides to target αvβ3 integrins. RGD-peptides are used as an imaging biomarker for both diagnosis 
of atherosclerosis and monitoring therapies targeting the αvβ3 integrin as well as for the 
development of potentially anti-angiogenic therapies in general. It has been known for a long 
time that RGD-peptides and small ligands can bind integrins that are not fully activated, whereas 
larger ligands such as fibrinogen and fibronectin cannot. More importantly, RGD is not only a 
potent ligand for αvβ3. All five αv integrins, two β1 integrins (α5, α8) and αIIbβ3 share the ability to 
recognise ligands containing an RGD tripeptide active site102, 103. Binding specificity of RGD-
nanoparticles is thus not limited to endothelial cells yet also to several (circulating) immune cells 
and fibroblasts.
Imaging biomarkers as widely expressed as αvβ3 integrin without plaque stage specificity need to 
be extensively evaluated, in particular for late-stage clinical studies, to determine whether they 
have any clinical relevance as read-out of therapeutic efficacy104.
Anti-angiogenic therapies are postulated to provide a powerful treatment option for atherosclerosic 
because plaques contain angiogenic microvessels that probably play an important role in plaque 
development. Recently, Winter et al presented positive results on a theragnostic approach of MR 
molecular imaging and drug targeting in a rabbit model of atherosclerosis by loading fumagillin, 
a water-insoluble angiostatic drug, in αvβ3- integrin-targeted liposomes105. One week after the 
first treatment of atherosclerotic rabbits, smaller plaques were observed in the aortic wall of the 
rabbits treated with αvβ3-integrin-targeted fumagillin loaded particles, which was not the case for 
targeted liposomes without fumagillin105. In a subsequent report on these αvβ3-targeted fumagillin 
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liposomes the anti-angiogenic effects appeared acute, but the effect can be prolonged when 
combined with atorvastatin106.
selectins
Selectins are a group of pro-inflammatory endothelial cell adhesion molecules. They mediate the 
first step in leucocyte adhesion, characterized by rolling and tethering of these cells to the 
endothelial surface (and to platelets and other leukocytes). When endothelial cells are activated 
during inflammation or ischemia-reperfusion damage (figure 1B), P-selectin is translocated to the 
endothelial cell surface107, 108. E-selectin expression in contrast, is linked to the attraction of Ly6C+ 
cells and as a consequence is linked to plaque vulnerability109, 110. The latter recent finding makes 
E-selectin in particular an attractive imaging target for vulnerable plaque detection as they are 
easily approachable in the vessel.
Kang et al. have functionalized cross-linked iron oxide (CLIO) nanoparticles with anti human 
E-selectin antibody fragments111. A three times larger CLIO-induced MR signal decrease on T2*-
weighted images was observed in human umbilical vein endothelial cells implanted into mice in 
response to interleukin-1β (a cytokine that induces E-selectin expression) treatment compared 
to untreated controls111. 
Boutry et al. targeted E-selectin with a synthetic mimetic of sialyl Lewis(x) (sLe(x)), a natural ligand 
of E-selectin expressed on leukocytes, on the dextran coating of ultrasmall particles of iron oxide 
(USPIO) 112. In vitro results on endothelial cells showed a high binding affinity. In vivo experiments 
have thus far only been performed in a concavalinA-induced hepatitis model and application for 
the detection of atherosclerotic plaques remains to be proven.
Theoretically, the specificity of plaque targeting could be improved by using different ligands 
for two independent targets on the same particle. Such a dual targeted strategy has been used 
to image endothelial adhesion molecules in apoE−/− mice, where microparticles of iron oxide 
were conjugated with monoclonal antibodies against VCAM-1 (VCAM-MPIO) and/or P-selectin 
(P-selectin-MPIO)79. Using ex vivo MR imaging, dual targeted particles indeed showed higher 
affinity to the endothelium under flow conditions in comparison to single targeted ones, but 
no in vivo studies have been published yet.
Technical challenges
In this review, we have highlighted several contrast agent platforms for molecular imaging 
of atherosclerosis and in particular the vulnerable plaque. Each contrast agent and target 
has its own advantages and disadvantages in terms of ease of synthesis, toxicity, payload, 
and biodistribution. Among the nanoparticle platforms discussed, lipid-based systems, such as 
micelles, liposomes, and HDL, are relatively easy to synthesize. Iron oxide nanoparticles that are 
more complex to prepare, are on the other hand of interest since they can be degraded by the 
liver and therefore have low toxicity and exhibit good biocompatibility113. Gd chelates are attractive 
since the untargeted variants are the only clinically approved contrast agents to date. 
However, the sensitivity of these small chelates is up to a factor of 104 lower than that of the 
larger nanoparticles because the latter particles in general have a higher contrast payload. Small 
particles, however, can penetrate deeper into tissue, which offers advantages for targeting 
extravascular biomarkers in cardiovascular diseases114. Molecular imaging of cardiovascular 
disease faces several challenges as compared to other pathologies, such as cancer. First, as 
atherosclerosis is a systemic disease it requires investigators to focus on different anatomical 
structures, including the carotids, the aortic root and arch, the abdominal aorta, the renal 
arteries, the aortic bifurcation and femoral arteries. Moreover, movement, flow effects, the 
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beating of the heart, as well as the small size of vessels hamper molecular imaging sensitivity. 
Therefore, nanoparticles used for cardiovascular imaging usually need to be specifically designed 
to allow their detection with superb sensitivity and should strongly and very specifically bind 
to the targeted biomarker to enable sufficient accumulation of the contrast-generating material. 
Furthermore for these diagnostic compounds to reach clinical application contrast agents need 
to fulfill multiple requirements including favorable toxicity profile and elimination kinetics.
PlAquE VulNERAbIlIty
The present review deals with the interplay between the complex vascular biology involved in 
plaque vulnerability and the potential use of MR contrast agents in this interplay. The identification 
of suitable target-ligand combinations specific for a vulnerable plaque (or other pathology) is a 
complex process. Molecular imaging requires the identification of a disease-specific target with 
high expression levels, and a targeting ligand with favorable binding characteristics (IC50, Kd) for 
the target. Moreover the aspecific binding should be as low as possible, and the binding of the 
contrast agents should generate a robust contrast change. 
Plaque rupture is a major cause of atherothrombosis; unfortunately there is no animal model 
for plaque rupture with consequences such as sudden death, brain or myocardial infarction 
and therefore the development validation pipeline for these contrast agents for the detection 
of vulnerable plaques is complex. 
At this point multiple MRI contrast agents have been developed that allow the detection of 
different markers and stages in atherosclerosis. Of all the suggested markers for vulnerability, 
three appear to give robust pre-clinical results that should translate to the clinic. Firstly, fibrin-
targeted compounds that detect thrombi provide the closest link to actual vulnerable plaques.
Secondly, plaque neovascularization has shown robust results in a range of animal models. 
Biologically, neovascularization is not an atherosclerosis specific marker yet a robust indicator of 
plaque progression and vulnerability. Thirdly, VCAM-1 and ICAM-1 seem promising for early 
detection of endothelial activation. 
As for the contrast moiety, the biodistribution of the particles will play a decisive role in ultimate 
translation to the clinic. Many of the nanoparticle approaches will probably not lead to clinical 
translation, as the kinetics of these particles are slow (in the order of hours to days), and therefore 
not optimal for an efficient clinical workflow. Exceptions are the small Gd-chelates and MIONs, 
which are cleared rapidly, and have optimal imaging time points within 1-2 hours from 
injection. 
Apart from clinical sensitivity and practicality, the use of targeted contrast agents naturally requires 
an excellent safety profile: toxicity issues of many particles regarding liver uptake and Gd complex 
stability will have to be determined and resolved. Translation of these particles to the clinic will 
largely depend on the interest of imaging and nanotechnology companies to invest in the long 
process of FDA approval. Up to now, not a single targeted compound has successfully passed 
the entire approval trajectory, and future research into targeted agents will need to address the 
requirements for ultimate FDA approval from the very first design.
Despite these hurdles, molecular imaging of the vulnerable plaque may provide more insights in 
the (temporal) pathophysiological mechanisms of atherosclerosis, aiding in drug selection and 
monitor treatment effects. The successful implementation of molecular imaging in the clinic to 
detect subclinical atherosclerotic disease and to identify vulnerable plaques may profoundly 
impact the management of patients with atherosclerosis.
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AbStRACt
Background
High-resolution contrast-enhanced imaging of the murine atherosclerotic vessel wall is difficult 
due to unpredictable flow artifacts, motion of the thin artery wall and problems with flow 
suppression in the presence of a circulating contrast agent.
Methods and results
We applied a 2D-FLASH retrospective-gated cine MRI method at 9.4T to characterize atherosclerotic 
plaques and vessel wall distensibility in the aortic arch of aged ApoE-/- mice after injection of a 
contrast agent. The method enabled detection of contrast enhancement in atherosclerotic 
plaques in the aortic arch after i.v. injection of micelles and iron oxides resulting in reproducible 
plaque enhancement. Both contrast agents were taken up in the plaques, which was confirmed 
by histology. Additionally, the retrospective-gated CINE method provided images of the aortic 
wall throughout the cardiac cycle, from which the vessel wall distensibility could be calculated. 
Reduction in plaque size by statin treatment resulted in lower contrast enhancement and reduced 
wall stiffness.
Conclusions
The retrospective-gated CINE MRI provides a robust and simple way to detect and quantify 
contrast enhancement in atherosclerotic plaques in the aortic wall of ApoE-/- mice. From the 
same scan, plaque-related changes in stiffness of the aortic wall can be determined. In this mouse 
model, a correlation between vessel wall stiffness and atherosclerotic lesions was found.
Abbreviations
ApoE:  apolipoprotein E
CNR:  contrast to noise ratio
ECG:  electrocardiogram
Gd-DTPA-BSA:  Gd-DTPA-bis(stearylamide)
PEG2000-DSPE:   1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy
 polyethyleneglycol)-2000]
NIR664-DSPE:  nearinfrared664 - 1,2-distearoyl-sn-glycero-3-phosphoethanolamine
USPIO:  ultrasmall superparamagnetic iron oxide
ROI:  region of interest
 
INtRoDuCtIoN
Cardiovascular diseases, in particular carotid and other peripheral atherosclerotic diseases are 
the leading causes of death in the western world1. Remodeling of the arterial wall intima, media 
and adventitia layers leads to the formation of an atherosclerotic plaque that may over time 
progress towards a vulnerable, rupture-prone phenotype2. Rupture of a plaque and subsequent 
myocardial infarction or stroke account for more than 50% of all cardiovascular deaths1. 
Clinical predictors for cardiovascular events due to vulnerable plaque rupture are plaque 
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components like intraplaque macrophage content and the extent of the lipid core. Apart from 
the composition of atherosclerotic plaques, arterial stiffness and distensibility are independent 
predictor of cardiac morbidity. Despite this independency, atherosclerotic plaques do contribute 
significantly to the vessel wall stiffness, and changes in plaque burden or aortic compliance could 
help to identify early cardiovascular disease in patients before an actual plaque rupture, as well 
as monitor the results of the therapeutic interventions3, 4. Hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors, or statins, are well known to exert beneficial effects on the elastic properties 
of the arterial wall5. They are widely applied in both the clinic as well as in preclinical studies.
Much effort has been put into development of non-invasive techniques such as MRI to image 
the presence of atherosclerotic plaque directly using (targeted) contrast agents6-10. Separately, 
MRI techniques have been employed to image arterial stiffness, also called vascular compliance11-16 
and distensibility through cyclic strain calculations. 
In this report we describe the simultaneous determination of plaque burden in the aortic arch 
and the stiffness and distensibility of the vessel wall of mice using retrospective-gated CINE 
MRI. 
Retrospective-gating provides a method to depict both contrast agent enhancement in the 
atherosclerotic plaque at atheroprone vessels, such as the ascending aorta, which are characterized 
by motion due to the beating heart as well as oscillatory flow. This self-gated navigator-based 
CINE MRI technique is nowadays widely applied for cardiac MRI, allowing continuous acquisition 
of data points without the need for respiratory and ECG sensors17. The technique is based on the 
acquisition of a navigator signal with every k-space line, followed by sorting data points according 
to their origin in the cardiac and respiratory cycle18. As the vessel wall images are reconstructed 
separately for different phases in the cardiac cycle, cine movies can be created of vascular 
diameter, from which the vascular compliance can be determined.
In this study, we used the ApoE-/- mouse model that spontaneously develops atherosclerotic 
lesions of morphology similar to that observed in humans19-21 to investigate the value of 
retrospective-gated CINE MRI of the aortic arch for atherosclerotic plaque detection and 
assessment of wall stiffness after injection of contrast agents that home to macrophages9, 22, 23. 
Retrospective-gated MRI was done in young (12 weeks) and aged (12-14 months) ApoE-/- mice 
with advanced atherosclerotic plaques in the bases of the aortic arch, assessing the presence of 
atherosclerotic plaques and vascular compliance as a function of disease progression, as well as 
during a therapeutic intervention with atorvastatin.
MAtERIAlS AND MEtHoDS
In vivo experiments
All experiments were conducted in accordance with the Dutch guidelines for research animal 
care. Two groups (n=5 per group) of 12 weeks old male ApoE-/- mice on a C57BL/6/Jico 
background were fed a normal chow diet. Four groups of 12-to-14-month-old mice (n=5 per 
group) were either fed (n=2 groups) a Western high fat diet (1% cholesterol, Ab Diets) or a (n=2 
groups) Western diet supplemented with 0.01% wt/wt atorvastatin (Lipitor, Pfizer) (=0.1g statin / 
kg bodyweight) for 12 weeks. 
Plaque imaging was performed with contrast enhancement using either Gd-containing micelles 
or ultra-small iron oxide particles. Optimal time points for contrast agent accumulation in the 
plaque were determined in a pilot time-course study in which contrast agent accumulation was 
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followed over time for 7 days with intervals ranging from 30 minutes to 6 hours (supplemental 
figure 1). The optimal time point was defined as the time at which the highest contrast-to-noise 
ratio was observed (see below), and was determined to be 12 h p.i. for the Gd-micelles24, and 24 
h for the USPIO particles. The blood circulation half-time of the micelles in the circulation is 8.3 
hours and the half-time of the USPIOs is 10.4 hours.
Each mouse was scanned before administration of contrast agent and at the optimal time point 
after intravenous injection of micelles equivalent to 50 μmol Gd3+-DTPA lipid/kg bodyweight 
diluted in 200 μl, or 250 μmol Fe/kg bodyweight USPIO in 200 μl dextrose solution. Mice were 
anesthetized with isoflurane (2% in 1:1 oxygen:air). During the examination, the respiration rate 
was continuously measured with a balloon pressure sensor connected to the ECG/respiratory 
unit. The isoflurane concentration was adjusted to keep the respiration rate between 50 and 90 
respirations/min.  
figure 1 | Contrast-to-noise determination in the aortic arch. Region of interest (ROI) placement in 
the MR images were used to determine the contrast to noise ratios (CNR) in the atherosclerotic 
plaques in black blood images of a cross section of the aortic arch. ROI1 is placed in the 
atherosclerotic plaque in the vessel wall (Iwall). ROI2 is positioned in a muscle and used for 
normalization purposes (Imuscle). Noise levels were determined in ROI 3, placed in a region 
without signal. The standard deviation of the noise (stdevnoise) was used for normalization 
purposes.
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Contrast Agents
Gadolinium-based T1 contrast agent
Micelles were prepared by lipid film hydration25. A mixture of the appropriate amounts of lipids 
(typically 120 mol of total lipid) was dissolved in chloroform/methanol 3:1 (v/v) and evaporated 
to dryness by rotary evaporation at 37°C. Gd-DTPA-BSA (Gd-DTPA-bis(stearylamide), PEG2000-
DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol) 
-2000]) (all Avanti Polar lipids Inc) were used at a molar ratio of 1.5/1.35. For fluorescent detection, 
0.1 mol% NIR664-DSPE (SyMO-CHEM B.V., Eindhoven, The Netherlands) was added. The lipid 
film was subsequently hydrated in HEPES buffered saline (HBS), containing 20 mM HEPES and 
135 mM NaCl (pH 7.4) and vigorously stirred at 65°C for 45 min. The size and size distribution of 
the micelles were determined by dynamic light scattering (DLS) at 25°C with a Malvern 4700 
system (Malvern ZetaSizer Nano S, Malvern, UK). The micelles had a mean size of 16 nm and a 
polydispersity index below 0.1, which indicates a narrow size distribution. The relaxivity was 
measured at 37°C and 9.4 T. The phospholipid content of the liposome preparations was 
determined by phosphate analysis according to Rouser after destruction with perchloric acid 26.
Iron-oxide-based T2* contrast agent
ultra-small superparamagnetic iron oxides (USPIO, Sinerem®) were obtained from Guerbet 
(Guerbet group, Aulnay sous Bois, France). An equivalent of 250 μmol Fe/kg bodyweight was 
injected i.v.
Mri protocols
All experiments were performed with a vertical 89-mm bore 9.4 T magnet (Bruker, Ettlingen, 
Germany) supplied with an actively shielded Micro2.5 gradient system of 1 T/m and a 30 mm 
transmit/receive birdcage RF coil, using Paravision 4.0 software. 
At the start of each examination, several 2D Fast Low Angle Shot (FLASH) scout images were 
recorded in the transverse and axial plane of the heart to determine the orientation of the aortic 
arch.  A modified 2D FLASH sequence with a navigator echo (IntraGate, Bruker) was used for 
retrospective CINE MRI with the following parameters: Hermite-shaped RF pulse 1 ms; FA 15°; 
TR 31.4 ms; TE 2.96 ms; navigator echo points 64; 10 cardiac frames; FOV 1.8*1.8 cm2 ; matrix 
128*96, zero-filled to 128*128; in-plane resolution 141 μm; 6 concomitant slices covering the 
inner curvature of the aortic arch; slice thickness 0.4 mm; number of repetitions 400; total 
acquisition time approximately 20 min. Images were positioned both perpendicular to and in line 
with the aortic arch according to an external placed reference to assure maintenance of the 
positioning plane pre and post contrast agent injection.
We performed aortic diameter measurements with 5, 8, 12, 15, 20 and 40 frames to assess the 
variability in the diameter measurements in a group of 3 months old (hemodynamically stable) 
ApoE-/- mice (n=5) in relation to the frame number. All further analysis were performed using 10 
reconstructed frames (supplemental figure 2).
image Analysis
Images were analyzed using ImageJ software. For contrast to noise determination, black blood 
images in 3 to 4 adjacent cross-sectional slices (the ones that had the lowest signal intensity, i.e. 
black-blood) through the aortic arch were analyzed (Figure 1). ROIs were semi-automatically 
drawn around the vessel wall (Iwall) in all 10 movie frames. A 2nd ROI was drawn in the surrounding 
muscle tissue of the shoulder girdle (Imuscle). Furthermore, an ROI was placed outside the animal 
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figure 2 | navigator signals for the reconstruction of self-gated Mri. Analysis of navigator signals for reconstruction 
of the self‐gated MR acquisitions. A. Example of a raw navigator signal with corresponding filtered respiratory 
and cardiac signals. B. Under unstable physiological situations it is still possible to gather correct cardiac 
and respiratory traces. With the filtered reconstruction signals of both, it is possible to re‐order data points 
in such a way a clear image of the aortic arch can still be generated. C. Representative black blood image 
before injection of contrast agent from the same animal shown above, with impaired cardiac and respiratory 
function. Retrospective gating led to a stable reconstruction of the aortic arch (arrow).
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to measure the noise level (SDnoise). The contrast–to-noise ratio was defined in the 3 to 4 adjacent 
movie frames with the lowest signal intensity in the vessel lumen as follows:
Cnr= (iwall – imuscle) / sDnoise       [eq1] 
CNR values are presented as mean ± standard deviation.
To calculate the vessel wall stiffness, the cross-sectional diameter and area of the aortic arch 
were segmented manually in each frame. MRI slices were positioned orthogonal to the aortic 
arch, the frames that were obtained just before and after the branch of the left carotid artery 
had a stable circular shape and were used for this analysis (supplemental figure 3). To reduce 
the standard error when outlining cross-sections, all segmentations were repeated four times 
by the same observer (BdA). For the evaluation of the aortic stiffness β index the following 
formula was used:
β index= ln (Psys/Pdias)/(ΔD/Ddias)     [eq2]
where Psys and Pdias are assumed values of the systolic and diastolic arterial blood pressure in age 
and gender matched ApoE-/- mice from literature (using a similar anesthesia setup)27, 28, Ddias is the 
aortic diastolic diameter, and ΔD is the difference between the systolic and diastolic diameter of 
the aortic arch.
For the determination of the circumferential strain as a measure of distensibility we assumed 
the deformation through the thickness of the vessel and in the axial direction was small 
compared to the circumferential deformation as described by Morrison et al.29. Assuming a 
circular cross section of the aorta, the following expression was used to calculate the 
circumferential cyclic strain,
eΘ = [A(t)/A(t0)– 1]/2       [eq3]
where A is the cross sectional area of the aortic arch15. 
histology
Aortic arches were frozen in Tissue Tek® (Sakura Finetek Europe, Zoetermeer, The Netherlands) 
and cut into serial 5-μm sections. Sections were stained with hematoxylin and eosin for gross 
morphology and Oil Red O for lipid deposition as described previously30, followed by bright-field 
microscopy. Lesion size was calculated from 8-10 consecutuve H&E stained sections of the aortic 
arch. Iron deposits were visualized using Perl’s Prussian blue staining. Presence of Gd-containing 
micelles was indirectly detected by staining of the DTPA chelate present in the micelles as recently 
described in den Adel et al.31. In short, sections were incubated overnight at room temperature 
with a rabbit polyclonal primary antibody against Gd-DTPA (1:20, BioPAL Inc). Goat-anti-rabbit 
conjugate (1:200, DAKO) with normal goat serum diluted in PBS was incubated for 1 h at room 
temperature as secondary antibody. Biotin labelling was followed by development using black 
alkaline phosphatase (Vector Laboratories Inc., United Kingdom) and counterstaining was done 
with Mayer’s hematoxylin. 
statistical analysis
Data are represented as the mean ± standard deviation. Statistical analyses were performed 
using SPSS 17.0.2 (SPSS, Inc., Chicago, IL, USA). Statistical significance between groups was 
assessed using (paired) t-test, one-way analysis of variance (ANOVA), followed by a Bonferroni 
correction for multiple testing in case of significance. Results were considered statistically 
significant at p < 0.05.
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figure 3 | Atherosclerotic plaque detection in a cross-section of the aortic arch, including the effect of gd-loaded 
micelles. A. Ten movie frames of a cross section of the aortic arch are generated. The black blood images 
used for positive contrast agent detection in the aortic arch are typically as those in image 6-8 (underlined). 
Circles indicate the region of the aortic arch cross section. White blood images 1-3 (dashed line), were 
used for the analysis of negative contrast agents B. A cross section of the aortic arch is shown before 
injection of micelles. Presumptive plaque regions are difficult to discriminate (arrow). C. Cross section of 
the aortic arch 12 hours after injection of micelles shows contrast enhancement on the basis of the aortic 
arch (arrow) D. Contrast to Noise Ratio and delta CNR of atherosclerotic plaques on the inner curvature 
of the aortic arch in 3 months old and 12-14 months old ApoE-/- mice on a western diet.
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RESultS 
self-gated cine Mri in cardiovascular unstable animals
All mice included in these experiments had a relatively low variation in heart rate and respiratory 
rate throughout the examinations, ranging from 490 to 520 beats/min and from 50 to 80 
respirations/min respectively (data not shown). The navigator echo in this sequence was used to 
demerge a cardiac and respiratory signal and subsequently reconstruct the sample point according 
to the cardiac cycle (figure 2A). However, even in cardiac and respiratory unstable mice it was 
feasible to obtain artifact-free MR images by specifically selecting the cardiac and respiratory 
weighting and periods used (figure 2B). With retrospective-gated CINE MRI, the image 
reconstruction could be optimized after sampling all the data points; while maintaining the usual 
scan time, we could still generate correct and stable images of the aortic arch allowing for plaque 
detection and vessel wall delineation (figure 2C). 
imaging of contrast agent uptake 
The aortic arches of ApoE-/- mice (young and aged) were imaged with the retrospective-gated 
MRI protocol pre- and post-injection of a micellar T1 contrast agent. Throughout the cardiac 
cycle, 10 movie frames of 6 transversal slices were made (figure 3A). Pre contrast agent injection, 
figure 4 | Detection of atherosclerotic lesions in the aortic arch using usPios. T2* effects of USPIO were observed 
on the basis of the aortic arch 24 hours after i.v. contrast agent injection. CNR significantly decreased from 
2.1 ± 1.3 before injection of contrast agent to -9.7 ± 0.7, 24 hours after injection of micelles. The typical 
blooming effect by the USPIOs (arrow) was best observed in frontal views (B) of the aortic arch. C. CNR 
and delta CNR of both age groups before and 24 hours after USPIO injection.
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the plaque burden in the inner curvature of the aorta was difficult to discriminate from healthy 
vessel wall, with only slightly elevated CNR in the plaque (arrow in figure 3B). After injection of 
Gd-containing micelles, a distinct hyperintensity was observed in the inner curvatures of the aortic 
arch and carotid arteries at the well-documented locations where atherosclerotic plaque is found 
in these ApoE-/- mice (figure 3C)32. The hyper enhancement was largest in the aged animals, but 
could be distinguished in the younger animals as well. 
The CNR values for these mice were determined after micelle injection for the images in the 
cardiac cycle with black blood (figure 3A, frames 6-8). Quantitative CNR values for the young and 
aged animals are summarized in Figure 3D. The CNR increased significantly after the injection of 
micelles in both groups, but both the CNR and ΔCNR of the aged animals were systematically 
higher than in the younger animals. 
We applied a similar imaging strategy to detect the contrast changes pre- and post-injection of 
an ultrasmall iron-oxide particle (USPIO). Because USPIOs induce large signal voids in the artery 
wall, the bright blood frames of the retrospective-gated cine MRI were more suitable for CNR 
quantification (figure 4A&B). CNR values became negative (hypointense) after injection of the 
contrast agent, and as for the micelles, the enhancement was more pronounced in the aged mice 
(figure 4C). 
figure 5 | Vessel wall chracteristics measured by Mri. A. Diameter of the aortic arch in mm measured at end-diastole 
and end-systole measured in CINE MRI images from 3 months and 12 months old ApoE-/- mice 
B. Stiffness β’-index of the aortic arch of both age groups. C. Distensibility of the aortic arch measured by 
the average maximal circumferential strain calculated for both age groups.
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Age related differences in vessel wall stiffness
A common consequence of atherosclerosis, observed both in humans and in animal models, is 
an increase in the stiffness of the aorta and major arteries, resulting in decreased vascular elasticity 
and compliance13, 27. Therefore we assessed whether we could determine the stiffness of the aortic 
arch based on the self-gated MRI data.
An increase in the diameter of the ascending aorta of the aged mice compared to the younger 
animals was observed both at end-systole and end-diastole (figure 5A). Based on the difference 
in diameter over the heart cycle, the aortic wall stiffness β’-index was calculated for both groups 
of mice (Figure 5B). Stiffness was increased by about 28% in the aged animals compared to the 
young animals. A significant decrease of 46% in average maximal circumferential strain values 
was observed between 3 and 12-month-old ApoE-/- mice (figure 5C).
effect of statin treatment on aortic plaque and vessel stiffness
We assessed whether the effects of statin therapy could be observed both on plaque level as well 
as the stiffness of the aortic arch in ApoE-/- mice.
In aged ApoE-/- mice treated for 12 weeks with a Western diet supplemented with atorvastatin 
plaques CNR changes were significantly smaller both in micelle injected mice as well as USPIO 
injected mice compared to age-matched untreated mice (figure 6A and 6B). 
Diameter of the aortic arch in mm was measured at end-diastole and end-systole measured in 
all 3 ApoE-/- treatment groups (figure 6C). The diameter at both end-diastole and end-systole was 
significantly decreased in the 12-months-old statin-treated mice compared to the untreated 
12-months-old animals, yet still significantly higher than in the young mice. The stiffness of the 
aortic arch in the statin-treated group was significantly lower than for the untreated age-matched 
group and was slightly higher, yet not significantly different from the young animals (figure 6D). 
The average maximal circumferential strain calculated during the cardiac cycle shows a decrease 
with age (figure 6E). A statistically significant lower decrease in strain was noted after statin 
treatment.
Correlation between Mri contrast enhancement, aortic stiffness and histological plaque area
The plaque area in the inner curvature of the aortic arch was independently determined using 
histology. The anatomical position of the plaques found on MR images corresponds to the areas 
observed by lipid staining with Oil Red O (figure 7A & 7B). The plaque lesion sizes for the different 
groups are shown in figure 7C. The plaque size was smallest for the young animals, largest for 
the aged animals. After statin treatment, the plaque size was reduced by 28.5 %, but still significantly 
larger than in young ApoE-/- mice. Using an anti-Gd-DTPA staining, the presence of micelles could 
be detected in distinct plaque areas: at the inner curvature of the aortic arch and in the intima of 
the vessel wall, in line with our MRI results. In contrast, the hypointense plaque regions due to 
iron-oxide accumulations mainly occurred in the plaque core, which was confirmed by Prussian 
Blue staining (figure 7D & 7E). Contrast enhancement on MRI for individual animals correlated 
very well (p<0.01) with the lesion size as determined with histology (figure 7F), also after statin 
treatment, with an R2 of 0.4203 and 0.7822 for the Gd-micelles and the USPIO respectively.
Both the aortic stiffness as well as the circumferential strain showed a linear correlation with 
plaque size, as determined by histology (figure 7G and 7H), with an R2 of 0.5359 (p<0.01) and 
0.6465 (p<0.01) respectively. Lastly, linear regression showed that both the aortic stiffness and 
circumferential strain were also correlated to the CNR after contrast agent administration (stiffness: 
figure 7I, R2 0.2792, p<0.05 and R2 0.4019, p<0.05; strain: figure 7J, R2 0.4133 p<0.05 and R2 0.3790, 
p<0.05). 
2012110 proefschrift Brigit den Adel_def.indd   51 22-01-13   21:49
chapter 3
52 |
figure 6 | the effect of atorvastatin treatment on atherosclerotic plaques. A. CNR and -CNR 
of atherosclerotic plaques on the inner curvature of the aortic arch of 3 months old 
as well as 12-14 months old ApoE-/- mice on a western diet with or without 
supplementation with atorvastatin after micelle injection. B. CNR and -CNR of 
atherosclerotic plaques on the inner curvature of the 3 treatment groups after USPIO 
injection. C. Diameter of the aortic arch in mm measured at end-diastole and end-
systole measured in CINE MRI images in all 3 ApoE-/- treatment groups. D. Stiffness 
β’-index of the aortic arch of the 3 treatment groups. E. Average maximum 
circumferential strain values of the 3 treatment groups.
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figure 7 | histological validation of atherosclerosis and Mri. A. Lipid depositions on the basis of the aortic arch and 
in the branches to the carotid and brachiocephalic arteries were shown by Oil Red O staining. B. Regions 
with atherosclerotic plaques corresponding to the regions in A are depicted in this MR image of the aortic 
arch. C. Plaque sizes of the 3 treatment groups in μm2 determined on histological slices. D. Gd-DTPA 
localized the micelles in atherosclerotic plaques. E. Iron deposits are visualized in blue in the wall of the 
aortic arch. F. Correlation CNR of atherosclerotic plaques on the inner curvature of the aortic arch with 
plaque sizes of the 3 groups determined on histological slices. G. Correlation of the aortic arch lesion area 
with the β’-index. H. Correlation of the aortic arch lesion area with the circumferential strain of the 3 
treatment groups. I. Correlation of the CNR of both micelles as well as USPIO with the β’-index J. Correlation 
of the CNR of both micelles as well as USPIO with the circumferential strain.
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DISCuSSIoN
self-gated cine Mri for atherosclerotic plaque detection
Atherosclerotic plaque formation typically originates in the aortic root and progresses to the 
ascending aorta, the aortic arch and onward through the aorta’s principal branches leading to 
progressive arterial stiffness4. These anatomical positions have one common theme; low and 
oscillatory (multi- or bidirectional) flow patterns, implying that plaque detection may be hampered 
by alterations in blood flow33. 
Proper visualization and quantification of atherosclerotic plaque components in both patients 
and animal models usually relies heavily on black-blood or bright-blood techniques with saturation 
slices or double inversion recovery methods34, 35. However, the required steady state blood 
saturation can be difficult to maintain in ECG-triggered sequences18 especially in animal models. 
In the aortic arch, the prime site of plaque development, and carotid arteries assessment of 
plaques and vessel wall area becomes even more difficult, because of its proximity to the beating 
heart which may cause large motion artifacts on top of flow artifacts. 
Classically, synchronization with the heart cycle, or prospective gating, is done using respiratory 
and ECG sensors to generate triggering signals36. In hemodynamically unstable animals, one needs 
to monitor the R-R interval closely, or choose this interval conservatively, which means that the 
total scan time will be longer and as a consequence the influence of the imaging session on 
animal welfare will be higher.
Therefore, the use of a retrospective-gated cine MRI sequence provides distinct advantages 
over a triggered cine or single-frame sequence. Firstly, the maintenance of steady state 
saturation of the retrospective-gated sequence helped to reduce in-flow artifacts. Secondly, 
the retrospective-gated cine sequence covered the full cardiac cycle without dead time at the 
end of the cardiac cycle waiting for the next ECG trigger. Using the retrospective-gated cine 
sequence in combination with contrast agents known to accumulate in atherosclerotic plaques, 
micelles as well as USPIO, allowed for a good discrimination of the atherosclerotic lesion on 
the inner curvature of the aortic arch9, 10. 
Plaque burden and aortic stiffness
The finding of age-related increases in aortic stiffness, vessel diameter and aortic atherosclerosis 
is consistent with prior studies37. Traditionally, the stiffness and compliance of conduit vessels 
is an estimate from the pulse wave velocity (PWV)38, 39. This is routinely done in the clinic using 
ultrasound or MRI, yet PWV measurements in mice are feasible as shown in the group of Jakob, 
but challenging due to the high heart rate and difficulties to measure flow velocities in vivo15, 15, 
16. Using the stiffness of the vessel wall can be a good alternative or additional tool to characterize 
vessel compliance. The correlation between aortic stiffness and plaque burden is particularly 
interesting because the elastic properties of the aortic wall play an important role in the 
pathogenesis of cardiovascular disease including atherosclerosis and hypertension, and is an 
independent risk factor for ventricular hypertrophy and stroke. Further pathophysiological 
studies may include longitudinal follow-up experiments to assess the temporal relationship 
between vascular compliance and plaque burden as well as the ageing related increase in vessel 
wall diameter. 
Our study showed that in a ApoE-/- mouse model the histological plaque burden was closely 
related to both contrast-enhancement on MRI and the aortic distensibility. This correlation was 
preserved over a large age range, also during statin treatment (figure 7G), indicating that in this 
mouse model, changes in aortic stiffness are dominated by the plaque burden. Moreover the 
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average circumferential strain decreases with age, whereas statin treatment slows down this 
decrease. Together with the observation of an increase in vessel wall diameter this points at a 
decrease in arterial elasticity and compliance with age and in relation to the extent of atherosclerosis 
progression.
Therefore, aortic compliance measurements may be an alternative approach in this animal model 
to monitor subtle changes of the arterial wall elasticity to actual plaque imaging, which is still 
difficult and time-consuming. Aortic stiffness measurements would provide a straight-forward 
method to study the response to various dietary and pharmacological manipulations both in this 
animal models and patients40, 41. One of the limitations in the current experimental setup is the 
lack of blood pressure measures due to the incompatibility with our MRI setup. The assumption 
of the blood pressure, although based on literature using animals of the same genetic background 
and anesthesia setup generate a bias point in our results. 
Though we found a very clear correlation between aortic stiffness and plaque burden in the 
ApoE-/- mouse, this is not necessarily the case in other mouse models, nor in patients. Arterial 
stiffness is an independent predictor of ventricular hypertrophy and stroke in patients, indicating 
that other mechanisms than plaque development may cause stiffening of the arteries. Assessing 
the temporal relationship between vascular compliance and plaque burden, may be particularly 
useful in different mouse models of atherosclerosis, including models of vascular dysfunction.
CoNCluSIoN
We have shown that retrospectively gated CINE MRI can be used to detect plaque burden and 
aortic distensibility simultaneously. Because the method can be used for both black-blood and 
bright-blood contrast, it is suitable for both gadolinium- and iron oxide based contrast agents. 
We have shown that in the ApoE-/- mouse there is a high correlation between aortic stiffness, and 
plaque load, and both measures can be used to assess atherosclerotic plaque progression and 
therapeutic interventions.
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SuPPlEMENtAl fIGuRES
supplemental figure 1 | A. Time course of Gd-micelle accumulation in the inner curvature of 
the aortic arch of ApoE-/- mice. Contrast to Noise Ratios (CNR) were 
determined at different time points after intravenous injection. B. CNR 
determined at different time points after USPIO injection in the inner 
curvature of the aortic arch
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supplemental figure 2 | Aortic arch diameter measurements at end-systole and end-diastole 
for 5, 8, 12, 15, 20 and 40  reconstructed cardiac movie frames 
compared to 10 movie frames. * P<0.05 compared to 10 movie 
frames.
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supplemental figure 3 | A. Position in the aortic where frames were taken 
orthogonal to the aortic arch. B. Schematical 
depiction of determination of the diameter of the 
aortic arch using circular cross-sections only.
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AbStRACt
The use of contrast-enhanced MRI to enable in vivo specific characterization of atherosclerotic 
plaques is increasing. In this study the intrinsic ability of two differently sized gadolinium-based 
contrast agents to enhance atherosclerotic plaques in ApoE-/- mice was evaluated with MRI. We 
obtained a kinetic profile for contrast enhancement, as the literature data on optimal imaging 
time points is scarce, and assessed the more long-term kinetics. Signal enhancement in the wall 
of the aortic arch, following intravenous injection of paramagnetic micelles and liposomes was 
followed for 1 week. In vivo T1-weighted MRI plaque enhancement characteristics were 
complemented by fluorescence microscopy of NIR664 incorporated in the contrast agents and 
quantification of tissue and blood Gd-DTPA. Both micelles and liposomes enhanced contrast in 
T1-weighted MR images of plaques in the aortic arch. The average contrast-to-noise ratio 
increased after liposome or micelle injection to 260% or 280%, respectively, at 24 hours after 
injection, compared to a pre-scan. A second wave of maximum contrast enhancement was 
observed around 60-72 hours after injection, which only slowly decreased towards the 1 week 
end-point. Confocal fluorescence microscopy and whole body fluorescence imaging confirmed 
MRI-findings of accumulation of micelles and liposomes. Plaque permeation of contrast agents 
was not strongly dependent on size in this mouse model. Our results show that intraplaque 
accumulation over time of both contrast agents leads to good plaque visualization for a long 
period. This inherent intraplaque accumulation might make it difficult to discriminate passive from 
targeted accumulation. This implicates that in the development of targeted contrast agents on a 
lipid-based backbone extensive timing studies are required.
INtRoDuCtIoN
Atherosclerotic disease remains the primary cause of mortality in industrialized countries, despite 
the clinical advances that have been made in the prevention and treatment of this disease over 
the past 20 years1. Studies have shown that more than two-third of acute coronary syndromes 
occur in patients who are classified as being at intermediate risk according to traditional 
Framingham Score risk-stratification methods. Based on these findings, it is clear that noninvasive 
diagnostic strategies are required to accurately assess the extent of cardiovascular disease in 
order to predict which patients most urgently need treatment.
High-resolution magnetic resonance imaging (MRI) has emerged as one of the most promising 
techniques for the direct and non-invasive evaluation of atherosclerotic plaques2-5. The natural 
differences in tissue structure between the healthy vessel wall and atherosclerotic lesions result 
in contrast differences on T1w, T2w and DW MRI scans6. However, particularly at the early stages 
discriminating intimal thickening and developing lesions from healthy vessels is not 
straightforward because of the limited sensitivity, partial volume effects and motion artifacts 
inherent to these scans. 
Apart from the afore mentioned ‘traditional’ MR imaging approaches, there is increasing interest 
in the use of MR contrast agents that enable a more refined characterization of atherosclerotic 
plaques7;8. Dynamic contrast-enhanced imaging using small gadolinium-based contrast agents 
such as gadofluorine9;10 and gadodiamide11 has been explored to investigate plaque neo-
vascularization and permeability. Although the above studies have demonstrated that imaging of 
plaques and even intraplaque processes is feasible in patients, these Gd chelates still have an 
inherently low relaxivity (r1 ~ 3.4 mmol-1 s-1 at 1T), resulting in only a modest signal enhancement. 
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A number of strategies have been developed to amplify the relaxivity and to deliver sufficient 
quantities of Gd in vivo in order to detect atherosclerotic lesions. One of these strategies is to use 
lipid-based nanoparticles like micelles or liposomes, carrying high payloads of amphipathic Gd 
chelates embedded in the outer lipid membrane. These particles may contain as many as 50,000 
Gd atoms, resulting in a relaxivity per particle that is magnitudes higher than of single Gd chelates12. 
Other previously explored approaches for contrast enhanced MRI of atherosclerotic plaque 
include perfluorcarbon nanoparticles13 and iron oxide particles14.
Lipid-based nanoparticles like micelles and liposomes accumulate in atherosclerotic plaques due 
to a leaky vasculature, ineffective lymphatic drainage, and enhanced endocytotic activity. This 
phenomenon provides a mechanism for passive targeting of nanoparticles to atherosclerotic 
sites15. The MR contrast agents used in this paper are polyethylene glycol2000 (PEG2000)-micelles 
and liposomes that include gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA)-based 
lipids16;17. This platform has been used to image macrophages in plaques and oxidized low-density 
lipoprotein (LDL). These nanoparticles have a longer half-life than regular micelles18;19 due to the 
protective “stealth” effect of the outer shell of PEG chains, which reduces recognition by opsonins 
and consequently clearance18, resulting in increased accumulation at inflamed sites20;21.
The pharmacokinetics of these nanoparticles and the resulting concentration gradient between 
blood and atherosclerotic lesion determines the wash-in and washout kinetics, and thereby the 
timing of maximum contrast enhancement of the plaque20;22. In practice, contrast-enhanced MRI 
using nanoparticles is typically performed at baseline and either followed for a short period of 
time (few hours) or measured at a single time point within 1 to 48 hours after contrast agent 
administration. Data on the optimal imaging time points are scarce23;24. Even though the 
pharmacokinetics of larger liposomes, iron oxides and perfluorcarbon nanoparticles has been 
extensively studied25-27, very little is known about the dynamics of contrast enhancement of 
micelles and liposomes in atherosclerotic plaque during longer periods of time. Longitudinal 
follow-up of plaque development and therapy response through imaging is highly desirable and 
for that purpose Gd-loaded micelles and liposomes are more and more applied. In this respect, 
detailed information on the accumulation and clearance kinetics of contrast agents is of major 
importance. 
In this study, we therefore aimed 1) to obtain a kinetic profile for contrast enhancement and 2) 
to assess the more long-term kinetics of Gd-loaded micelles and liposomes. We assessed the 
passive kinetic behavior of Gd-loaded micelles and liposomes in atherosclerotic plaques in the 
aortic arch of 1-year-old ApoE-/- mice over a period of 1 week using MRI and plasma profiles. 
Liposomes and micelles were labeled with a fluorescent marker for validation of the MRI finding 
using histology and for in vivo whole-body biodistribution measurements. 
MAtERIAlS AND MEtHoDS
hardware
All experiments were performed with a vertical 9.4 T magnet (Bruker, Ettlingen, Germany) supplied 
with an actively shielded Micro2.5 gradient system of 1 T/m and a 30 mm transmit/receive birdcage 
RF coil, using Paravision 4.0 software.
Contrast Agents
Micelles and liposomes were prepared by lipid film hydration as described previously28. A mixture 
of the appropriate amounts of lipids (typically 120 mol of total lipid) was dissolved in chloroform/
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methanol 3:1 (vol/vol) in a round-bottom flask. A lipid film was made under reduced pressure 
using rotary evaporation at 37 °C and dried under a stream of nitrogen. For micelles Gd-DTPA-
BSA (Gd-DTPA-bis(stearylamide) and PEG2000-DSPE (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]) were used at a molar ratio of 
1.5/1.35. For fluorescent detection, 0.1 mol% NIR664-DSPE (SyMO-CHEM B.V., Eindhoven, The 
Netherlands) was added. The lipid film was subsequently hydrated in HEPES buffered saline (HBS), 
containing 20 mM HEPES and 135 mM NaCl (pH 7.4) and vigorously stirred at 65 ºC for 45 min. 
For liposomes, Gd-DTPA-BSA (Gd-DTPA-bis(stearylamide), DSPC (1,2-distearoyl-sn-glycero-3-
phosphocholine), cholesterol, and PEG2000-DSPE were used at a molar ratio of 0.75/1.10/1/0.15 
and rehydrated in HBS as described for micelles. The resulting lipid dispersion was extruded 
sequentially four times through polycarbonate membrane filters (Nuclepore, Pleasanton, USA) 
with a pore diameter of 200 nm and subsequently 10 times through filters with a pore diameter 
of 100 nm using a Lipofast Extruder (Avestin, Canada). The temperature during extrusion was 
65°C. 
The size and size distribution of the contrast agents were determined by dynamic light scattering 
(DLS) at 25°C with a Malvern 4700 system (Malvern ZetaSizer Nano S, Malvern, UK). The micelles 
had a mean size of 16 nm and liposomes had a mean size of 100 nm. Both micelles and liposomes 
had a polydispersity index below 0.1, which indicates a narrow size distribution. The relaxivity was 
measured at 37°C and 9.4 T. The phospholipid content of the liposome preparations was 
determined by phosphate analysis according to Rouser after destruction with perchloric acid29. 
pH stability was assessed using DLS at different pH, ranging from 4.0 till 9.0.
In vivo experiments
All experiments were conducted in accordance with the Dutch guidelines for research animal 
care at our institution. A schematic overview of the experimental design and groups of mice 
(n=34) can be found in figure 1. Each block in this figure represents an experimental group. 
Thirty-four groups (n=5 per group) of aged (between 10 and 14 months old) male ApoE-/- mice 
on a C57BL/6/J background were fed a normal chow diet. For MRI and assessment of contrast 
agent distribution 30 groups were used: each mouse was scanned before administration of 
contrast agent and every 6 hours for 142 hours (6 days) after intravenous injection of the equivalent 
of 50 μmol Gd3+-DTPA lipid/kg bodyweight (i.e. 1.25 μmol Gd/25 g body weight) in 200 μl micelles 
or liposomes (figure 1). Mice were anesthetized during MRI with isoflurane (± 2% in oxygen and 
air). At every 6 hour time-point till 30 hours post injection a group of mice (n=5) was taken out 
of the experiment and sacrificed by transcardial perfusion for histological validation of MRI images. 
figure 1 |  A schematic overview of the in vivo experiments shows the distribution of different groups of animals 
over the experiments. Each block represents a group of 5 animals that is sacrificed at the end time indicated 
in the box.
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After 30 hours, groups of mice were taken out of the experiment every 12 hours. In total 16 groups 
of mice for both micelles and liposomes were used to monitor the in vivo behavior of these 
nanoparticles.
2 separate groups of mice were used to follow kinetics of the contrast agents in blood. Moreover 
for in vivo fluorescent imaging 2 groups of mice were used.
Mri protocols
In vivo
At the start of each examination, several 2D FLASH scout images were recorded in the transverse 
and axial planes through the heart to determine the orientation of the aortic arch. A modified 
FLASH sequence with a navigator echo (IntraGate) was used for retrospective CINE MRI with the 
following parameters: 
1)  Cross sections of the aortic arch: RF pulse 1 ms; flip angle 15°; TR 31.4 ms; TE 2.96 ms; navigator 
echo points 64; 10 cardiac frames; FOV 1.8*1.8 cm2; matrix 128*128; in-plane resolution 141*141 
mm2; 6 slices, slice thickness 0.4 mm; number of repetitions 400; total acquisition time 
approximately 20 min. 
2)  For a frontal view of the aortic arch the MR sequence was slightly adapted: TR 15.7 ms, TE 2.96 
ms, 3 slices, slice thickness 0.5 mm, total acquisition time approximately 10 min.
During the examination, the respiration rate was continuously monitored using a balloon pressure 
sensor connected to the ECG/respiratory unit. The isoflurane concentration was adjusted to keep 
the respiration rate between 50 and 90 respirations/min. 
Ex vivo
Blood samples were drawn from the tail vein from n=5 mice for both micelle and liposome 
injected mice every 6 hours for 78 hours. T1 values of plasma samples were determined using a 
saturation recovery protocol spin-echo sequence with the following parameters: TE 7 ms, TR 25, 
20, 15, 10, 8, 6, 5, 4, 3, 2, 1.6, 1.2, 1.0, 0.8, 0.6, 0.4, and 0.3 s, matrix 128*128, resolution 195*195 
μm2, 2 slices, slice thickness 1 mm. 
The T1 values of the various ROIs were determined using the 3-parameter fit function 
M(t) = M0 (1-exp[-t/t1]).       [eq1]
The change in longitudinal relaxation rate ΔR1 values of the blood over time were determined by
Δr1(t)  = (1/t1[gd(t)])- 1/t[0].      [eq2]
The ΔR1 values were fitted using a mono-exponential decay function 
Δr1(t)   = Ae-ln(2)t/t 
1/2
 ,       [eq3]
where A is the initial quantity of gadolinium, and t1/2 is the circulation half-life of gadolinium in 
the blood. 
Mri Analysis
Images were analyzed using ImageJ software. Black blood images in 3 to 4 adjacent slices of 
cross-sections through the aortic arch were analyzed. ROIs were drawn around the plaque region 
in the vessel wall (Iwall). A 2nd ROI was drawn in the surrounding muscle tissue of the shoulder girdle 
(Imuscle). Furthermore, an ROI was placed outside the animal to measure the noise level (stdevnoise) 
(Figure 2). 
The contrast–to-noise ratio was defined as
Cnr= (i
wall
 – i
muscle
)/stdev
noise
 ,      [eq4] 
which is a measure how well the lesioned wall can be discriminated from the surrounding tissue. 
CNR values are shown as mean ± standard deviation.
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optical imaging
Whole body distribution of NIR664 was followed for 7 days at 12 hour intervals using 700 nm 
laser excitation (IVIS spectrum). OptiView software was used to create both intensity and lifetime 
images and a pixel-to-pixel ROI comparison.
gd-DtPA elisA 
Gd-DTPA concentrations in tissue homogenates of liver, kidney, lungs and the aortic arch were 
determined using an enzyme immunoassay test kit (BioPAL Inc, Huissen, The Netherlands) with 
a sensitivity limit of 0.5 pg. Tissue samples (lungs, liver, kidney, spleen, heart, aortic arch) from 5 
mice per contrast agent per time point were harvested at 6, 12, 18, 24, 30, 48 and 60 hours after 
contrast agent injection. 
figure 2 | Contrast to noise ratios of atherosclerotic plaques were determined in black blood images of a cross-
section of the aortic arch by ROI 1, the signal intensity of the plaque in the vessel wall (Iwall) corrected on 
ROI 2, the signal intensity of surrounding muscle tissue (Imuscle) and ROI 3, the standard deviation of the 
noise (stdevnoise).
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histology
Aortic arches were frozen in Tissue Tek® (Sakura Finetek Europe, Zoetermeer, The Netherlands) 
and cut into serial 5 μm sections. Sections were stained with Oil Red O for lipid deposition and 
hematoxilin eosin for gross morphology, followed by bright-field microscopy.
To detect the presence of F4-80 positive macrophages sections were fixed in 10% isopropanol 
and incubated overnight at room temperature with a rat polyclonal primary antibody against F4-
80 (1:100, SantaCruz). Rabbit anti rat conjugate (1:200, DAKO) with normal rabbit serum diluted 
in PBS was incubated for 1 hour at room temperature as secondary antibody. Biotin labeling was 
followed by development using DAB (Vector Laboratories Inc., United Kingdom) and counterstain 
was performed with Mayer’s hematoxilin. Sections were analyzed using bright-field 
microscopy.
Imaging of micelle and liposome fluorescence was performed using a Leica TCS-SL confocal 
laser scanning microscope interfaced to a DM6000B microscope. NIR664 was excited with a 633 
nm HeNe laser, emission was filtered through a band-pass filter of 650-710 nm. Autofluorescence 
of elastic lamellae was detected at an emission wavelength of 450-500 nm. 
statistical analysis
Data are presented as the mean ± standard deviation. Statistical analysis was performed using 
SPSS 15.0 ANOVA for computations within and between groups. Results were considered 
statistically significant at p < 0.05. 
RESultS
nanoparticle characteristics
The manufactured nanoparticles were characterized using dynamic light scattering (DLS), showing 
that the micelles had a mean hydrodynamic diameter of approximately 16 nm with a polydispersity 
index of 0.1, indicating a narrow size distribution. Liposomes were approximately 5-6 fold larger 
than micelles, with a mean diameter of 100 ± 0.05 nm. Micelles had a higher r1 relaxivity per 
mmol Gd compared to liposomes (table 1), both at 1.41 T and 9.4 T at 37 oC and pH 7.3. For 
liposomes it was already known that they are stable within a physiological pH range (30). Micelles 
were tested for stability with changing pH; pH lowering did not compromise micelle stability. 
Lowering the pH to 4.0 results in only a very modest change in size distribution from 16 to 15.4 
nm. Increase in pH to 9.0, however, results in increased hydrodynamic diameter of micelles, which 
may be explained by hypertonicity of the solvent.
table 1. Characteristics of micelles and liposomes
hydrodynamic diameter (nm) r1 (s-1 mM-1)
ph 7.3 4.0 9.0 1.4 t, 37°C 9.4 t room temp
Micelles 16.1 ± 0.2 15.4 20.2 11.4 5.8
Liposomes 103 ± 0.4 101 ± 0.2 121 ± 0.9 6.5 2.5
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In vivo Mri study
In line with contrast agent concentrations applied in previous studies16;31, ApoE-/- mice were 
injected intravenously with a single dose of contrast agent at a concentration of 50 μmol Gd3+-
DTPA lipid per kg bodyweight. Axial and sagittal T1w images of the aortic arch were made before 
contrast agent injection, as well as directly after contrast agent administration. Scans were 
repeated at several times points after injection, for up to 24 hours. T1-weighted MRI images 
showed a strong bright blood effect after an intravenous bolus injection of liposomes or micelle. 
The blood enhancement gradually disappeared during the 24 hours after injection due to clearance 
of the particles from the blood stream. Contrast enhancement was analyzed by drawing regions 
of interest on plaque areas at the basis of the aortic arch in black blood images (figure 2). Average 
CNR increased gradually after liposome or micelle injection to 260% or 280% respectively at 24 
hours after micelle injection when compared to the pre-scan (figure 3A). However, the CNR had 
not reached a plateau at 24 hours post injection, which let us to postulate that micelles and 
liposomes were still circulating and entering atherosclerotic plaques after these time points.
Therefore, the fluctuations in CNR were monitored over time for a longer period of 1 week after 
injection, both for micelles and liposomes (figure 3B). One day after contrast agent injection, the 
signal intensities of both nanoparticles started to drop significantly. However, a second contrast 
enhancement peak was observed at around 60-72 hours after injection, which only slowly 
decreased towards the 1 week post injection end-point. The area in the vessel wall with clear 
contrast enhancement was larger at the 2nd peak contrast point than within the first 24 hours after 
administration (figure 3B). 
Plasma kinetics
Plasma T1 values were determined to assess the amount of circulating contrast agent, using blood 
samples obtained from the tail vein taken at regular intervals after contrast agent injection. Plasma 
T1 values showed an inverse relation to the fluctuations in CNR observed in atherosclerotic 
plaques (figure 4A). Shortly after contrast agent injection, a sharp decrease in plasma T1 was 
observed, which slowly increased to almost normal plasma T1 values between 10 to 30 hours 
after injection. Thereafter, a second decrease in T1 values was observed for both contrast agents, 
which was more prominent in the case of micelles. 
figure 3 | Contrast to noise ratios of atherosclerotic plaques were determined at different time points after micelle 
or liposome injection and plotted against time. Panel A shows CNR follow-up till 24 hours post injection, 
whereas panel B shows CNR follow-up for several days.
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Based on the ΔR1 values during the first 24 hours (before recirculation), the blood circulation 
half-life was calculated to be 8.1 hours for micelles (R2 =0.95) and 5.3 hours (R2 =0.96) for 
liposomes, assuming mono-exponential behavior (figure 4B).
In vivo detection of whole body biodistribution
To further assess the pharmacokinetics of the nanoparticles, we measured the biodistribution 
with in vivo fluorescence imaging using the NIR664 fluorochrome incorporated in the lipid layer 
of the respective nanoparticles. In line with the enhancement pattern observed with MRI, contrast 
agent accumulation was observed in the region of the aortic arch, with maximum accumulation 
around 40 and 60 hours after injection for micelles and liposomes respectively (figure 5). However, 
a biphasic pattern in fluorescence, like detected with MRI in the aortic arch region could not be 
observed. In the first 15 min after injection, both the renal and hepatic regions became positive, 
indicative for primary accumulation and/or elimination via that route. Steady, but slowly fading, 
accumulation in the neck region (maybe the carotid arteries) and axillary lymph nodes was 
observed over the entire measurement period of 7 days. Apart from the expected uptake and 
clearance routes, the paws of all animals that were injected with micelles and liposomes showed 
NIR664 fluorescence, possibly indicative of poor circulation in the paws of these aged mice. 
Excretion of the fluorescent dye was observed in the feces, confirming the involvement of the 
liver in the metabolism of the contrast agents.
Assessment of gadolinium content 
An enzyme-linked immunosorbent assay (ELISA), originally developed for the detection of Gd-
DTPA in serum and urine, was performed on tissue homogenates from internal organs harvested 
every 6 hours after contrast agent injection, i.e. directly after MRI at the respective time points. 
The ELISA was used to indirectly determine the biodistribution of micelles and liposomes via Gd-
DTPA in liver, lungs, kidney, spleen, aortic arch and heart. 6 hours after contrast agent injection. 
We observed Gd accumulation in the liver of about 4% and 7% of the injected dose (ID) and spleen 
of about 2% and 3% of ID for micelles and liposomes respectively. The lungs and kidney showed 
less accumulation, in the order of 0.5-1% of the ID after 6 hours (figure 5). In all these organs, Gd 
was cleared over the 60 hours of the experiment. In contrast, both the heart and the aortic arch 
showed an initial decrease in gadolinium content followed by a steady secondary increase in Gd 
during the second to third day after injection, consistent with the contrast increase observed on 
MRI (figure 6). 
figure 4 | 1/T1 values in panel A describes the inverted pattern of micelle and liposome blood circulation compared 
to the accumulation patterns observed in the aortic arch. In panel B the temporal changes in R1 values 
illustrate the blood circulation and circulation half-life was calculated over the first 24 hours.
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immunohistochemistry
To examine which components within atherosclerotic plaques are preferably targeted by micelles 
and liposomes, confocal laser scanning microscopy (CLSM) and light microscopy was performed 
on cryosections of the aortic arch. For CLSM, elastic lamellae were autofluorescent in the green 
spectrum; liposomes and micelles were already labeled with NIR664. 
Early after contrast agent injection, at 12 hours, presence of contrast agents within atherosclerotic 
plaques could be confirmed (figure 7). However, at this time no uptake of the nanoparticles in 
the macrophages or macrophage-derived foam cells could be observed. At later time points, 
starting 24 hours after injection, it was observed that liposomes were mainly found associated 
with elastic lamellae, whereas this was not the case for micelles (figure 7). Micelles were found 
in macrophage positive areas from 12 hours after injection onwards. Staining for smooth-muscle 
cells with α-actin did not show any micelle or liposome uptake in these cells (data not shown). 
figure 5 | Whole body fluorescence imaging of ApoE-/- mice 
after injection of liposomes or micelles respec-
tively shows the distribution patterns over time of 
the NIR664 fluorophore incorporated in the con-
trast agents.
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This suggests that liposomes remain restricted to the extracellular space of the atherosclerotic 
plaque and that there was no cellular uptake of the contrast agent, whereas micelle retention is 
linked to the presence of macrophages. Some colocalization was observed for the elastic lamellae 
and the micelles in the atherosclerotic plaque. Although in all sections micelles and liposomes 
were found throughout the entire aortic plaque, the contrast agents were heterogeneously 
distributed, with most micelles and liposomes present in the center of the plaque early after 
injection, but in the cap regions of the plaque at later time points. 
figure 6 | Gd-DTPA accumulation was determined at several time points by ELISA on tissue homogenates in liver 
(A), lungs (B), kidneys (C), spleen (D), heart (E) and aortic arch (F). An increase in Gd-DTPA can be observed 
in the hearts and aortic arch of animals injected with both micelles and liposomes starting around 30 hours 
post injection.
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DISCuSSIoN
Biphasic enhancement on Mri
In this study we determined the pharmacokinetics of untargeted lipid-based Gd-loaded micelles 
and liposomes in the ApoE-/- atherosclerotic mouse. ApoE-/- mice are characterized by the 
spontaneous and diet-induced occurrence of atherosclerosis in their arteries at sites with low 
and oscillatory flow patterns8. The occurrence of atherosclerotic plaques is preceded by damage 
to the endothelial layer, rendering the endothelium leaky. As a consequence molecules, but also 
nanoparticles like micelles and liposomes, can pass the endothelial lining and penetrate 
atherosclerotic plaques where they may be retained. 
Here we show that in the unaffected vessel wall no MR contrast enhancement occurred, whereas 
at the classical atherosclerosis-prone sites increased signal intensity was observed with peak 
contrast enhancement at two time points around 12 and around 60 hours after injection in 
ApoE-/- mice. Previous studies already mention peak contrast points shortly after injection (minutes) 
which can be attributed to a first passage effect and peak enhancements in the period of 12-24 
hours after contrast agent injection, with contrast agent follow-up ranging from 24 to 48 hours24;32. 
figure 7 | Histology of aortic arch after contrast agent injection. Lipid deposition in vessel wall is visualized with Oil 
Red O, gross morphology with HE. Presence of macrophages in the plaques is visualized via F4-80. NIR664 
in contrast agents is visualized in corresponding plaque regions on adjacent histological slices.
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The difference between the previous described and our recent observations may be attributed 
to imaging timing (much later time points than previously) and possibly also increased sensitivity 
to the detection of contrast enhancement by the use of cine MRI.
This biphasic kinetic pattern was present for both liposomes and micelles. For all time points, the 
areas of MRI contrast enhancement showed good agreement with the Gd-DTPA concentration 
in tissues and the presence of NIR664 on the histological sections, suggesting that the 
paramagnetic and fluorescent lipids remain co-localized for the entire observation period.
During the second wave of enhancement, we still observed co-localization of the fluorescence 
and Gd signal. When contrast agents are administered intravenously there may be some local 
extravasation encouraged by mass action, owing to particle size and loading dose. The second 
contrast wave may also be due to slow release of these particles from the liver or more likely from 
contrast agent loaded macrophages migrating out of the spleen in the days following contrast 
agent injection, as previously observed with 19F in the early days of RES imaging33. At this time 
point, the micelles and liposomes were probably no longer intact, but one could easily interpret 
the results differently because we did not observe differences in the time course or localization 
within the plaque of the fluorescent and Gd components based on the histological evaluation. 
Whether or not the particles were still intact, this second contrast wave should be considered for 
longitudinal experiments, as it will be a confounding factor in follow-up studies.
Passive accumulation in plaques: micelles versus liposomes
From the microscopic analysis, it became apparent that the uptake mechanism of micelles in 
atherosclerotic plaque was most likely related to passive diffusion of the micelles over the 
abnormal endothelial lining followed by uptake into phagocytic cells like monocytes and 
macrophages. Liposomes were also found inside the plaque, but mainly outside cells and close 
to the elastic laminae.
No significant liposome or micelle uptake was observed in normal vessel walls of ApoE-/- mice 
with MRI or histology. LSCM showed a predominant first uptake of the contrast agents into the 
extracellular space of the plaque on the laminar side of the lesion in ApoE-/- mice indicative for 
the enhanced permeability of the vessel wall. Furthermore, colocalization of the micelles with 
cell nuclei and F4-80 positive cells revealed that micelles were retained in the plaque by uptake 
in cells, whereas this was not the case for liposomes. We did not observe ingestion of the 
nanoparticles within circulating monocytes or macrophages in the first hours after injection, as 
determines by blood smears. This however does not rule out that ingestion does occur at a low 
percentage and that these cells then migrate into the plaque. 
Finally, maximum signal enhancement of the plaque occurred at relatively late time points 
suggestive for slow uptake and accumulation of both liposomes and micelles in the plaque. The 
difference in behavior inside the plaque of the particles may be due to the difference in size which 
makes it favorable to phagocytose micelles but not liposomes34
Clearance and distribution pathways
During the first phase after injection, contrast agents that were cleared from the blood accumulated 
in various organs, as shown by the in vivo whole body biodistribution studies, and the Gd- content 
in tissue homogenates. 
Both micelles and liposomes are metabolized through the liver and to a much lesser extent by 
the kidneys. The liver may serve as a reservoir for the nanoparticles as the fluorescence and Gd-
DTPA content remains high over time and clearance from this organ is slow. Compared to micelles, 
liposomes accumulated more in the spleen, liver and lungs of mice, possibly due to the fact that 
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liposomes are a magnitude larger than micelles and therefore get trapped in the capillary beds 
in these organs. At atherosclerotic areas this difference disappears as the damaged endothelial 
lining of atherosclerotic layer allows easier passage of particles. Both in micelle- as well as 
liposome-injected mice a steady decline in Gd content in the spleen was observed, which suggests 
involvement of the spleen in the redistribution of the Gd-lipids.
We did not observe a biphasic enhancement pattern for the aortic plaques in the in vivo 
fluorescence study. However, this does not imply it is not present. On MRI images we report 
differences in T1 in the plaque with high sensitivity and spatial accuracy, and thereby indirectly 
on the fluctuations in the amount of contrast agent internalized in the plaque. In contrast, specific 
quantification of the fluorescent signal in the aortic arch was not possible due to the low spatial 
resolution of in vivo fluorescence cameras and the relatively large amount of micelle and liposome 
uptake in the entire thoracic region (i.e. in the heart, lymph nodes and large arteries). As reported 
previously, liposomes and micelles did not produce a sufficient signal to visualize the plaques in 
its anatomical context in vivo, presumably because of insufficient tissue penetration of the exciting 
and emitted signals35. Ex vivo visualization of the aortic arch however showed increased 
fluorescence in the aortic tree and at the basis of the aortic arch in line with our histological 
findings. Overall we observed no real differences in tissue distribution between micelles and 
liposomes, which is in line with previous studies using other nanoparticles26;27;32;36. 
CoNCluSIoNS
The maximum enhancement for Gd-loaded micelles and liposomes was shown to be dependent 
on contrast agent size and blood circulation kinetics, which underscores that plaque enhancement 
by nontargeted and targeted contrast agents must be interpreted with care. Our results indicate 
that the timing of contrast-enhanced MRI is of utmost importance and will need to be optimized 
for every novel contrast agent and animal model.
2012110 proefschrift Brigit den Adel_def.indd   76 22-01-13   21:49
REFERENCES
| 77
REfERENCES
1 Sanz J, Moreno PR, Fuster V. The year in 
atherothrombosis. J Am Coll Cardiol 2008 Mar 
4;51(9):944-55.
2 Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular 
and functional imaging of atherothrombosis. Nat 
Rev Drug Discov 2004 Nov;3(11):913-25.
3 Itskovich VV, Samber DD, Mani V, Aguinaldo JG, 
Fallon JT, Tang CY, et al. Quantification of human 
atherosclerotic plaques using spatially enhanced 
cluster analysis of multicontrast-weighted magnetic 
resonance images. Magn Reson Med 2004 
Sep;52(3):515-23.
4 Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. 
Magnetic resonance imaging of atherosclerotic 
plaque with ultrasmall superparamagnetic particles 
of iron oxide in hyperlipidemic rabbits. Circulation 
2001 Jan 23;103(3):415-22.
5 Yuan C, Hatsukami TS, Cai J. MRI plaque tissue 
characterization and assessment of plaque stability. 
Stud Health Technol Inform 2005;113:55-74.
6 Sanz J, Fayad ZA. Imaging of atherosclerotic 
cardiovascular disease. Nature 2008 Feb 
21;451(7181):953-7.
7 Saraste A, Nekolla SG, Schwaiger M. Cardiovascular 
molecular imaging: an overview. Cardiovasc Res 
2009 Sep 1;83(4):643-52.
8 Van der Heiden K, Hierck BP, Krams R, de CR, Cheng 
C, Baiker M, et al. Endothelial primary cilia in areas 
of disturbed flow are at the base of atherosclerosis. 
Atherosclerosis 2008 Feb;196(2):542-50.
9 Barkhausen J, Ebert W, Heyer C, Debatin JF, 
Weinmann HJ. Detection of atherosclerotic plaque 
with Gadofluorine-enhanced magnetic resonance 
imaging. Circulation 2003 Aug 5;108(5):605-9.
10 Sirol M, Itskovich VV, Mani V, Aguinaldo JG, Fallon 
JT, Misselwitz B, et al. Lipid-rich atherosclerotic 
plaques detected by gadofluorine-enhanced in vivo 
magnetic resonance imaging. Circulation 2004 Jun 
15;109(23):2890-6.
11 Kerwin WS, O’Brien KD, Ferguson MS, Polissar N, 
Hatsukami TS, Yuan C. Inflammation in carotid 
atherosclerotic plaque: a dynamic contrast-
enhanced MR imaging study. Radiology 2006 
Nov;241(2):459-68.
12 Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen 
AW, Nicolay K. Lipid-based nanoparticles for 
contrast-enhanced MRI and molecular imaging. 
NMR Biomed 2006 Feb;19(1):142-64.
13 Tran TD, Caruthers SD, Hughes M, Marsh JN, Cyrus 
T, Winter PM, et al. Clinical applications of 
perfluorocarbon nanoparticles for molecular 
imaging and targeted therapeutics. Int J 
Nanomedicine 2007;2(4):515-26.
14 Burtea C, Laurent S, Mahieu I, Larbanoix L, Roch A, 
Port M, et al. In vitro biomedical applications of 
functionalized iron oxide nanoparticles, including 
those not related to magnetic properties. Contrast 
Media Mol Imaging 2010 Dec 29.
15 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, 
Langer R. Nanocarriers as an emerging platform for 
cancer therapy. Nat Nanotechnol 2007 
Dec;2(12):751-60.
16 Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, 
Aguinaldo JG, Vucic E, et al. Molecular imaging of 
macrophages in atherosclerotic plaques using 
bimodal PEG-micelles. Magn Reson Med 2007 
Dec;58(6):1164-70.
17 Mulder WJ, Griffioen AW, Strijkers GJ, Cormode DP, 
Nicolay K, Fayad ZA. Magnetic and fluorescent 
nanoparticles for multimodality imaging. 
Nanomedicine (Lond) 2007 Jun;2(3):307-24.
18 Lukyanov AN, Torchilin VP. Micelles from lipid 
derivatives of water-soluble polymers as delivery 
systems for poorly soluble drugs. Adv Drug Deliv Rev 
2004 May 7;56(9):1273-89.
19 Torchilin VP. Structure and design of polymeric 
surfactant-based drug delivery systems. J Control 
Release 2001 Jun 15;73(2-3):137-72.
20 Chono S, Tauchi Y, Deguchi Y, Morimoto K. Efficient 
drug delivery to atherosclerotic lesions and the 
antiatherosclerotic effect by dexamethasone 
incorporated into liposomes in atherogenic mice. J 
Drug Target 2005 May;13(4):267-76.
21 Metselaar JM, Storm G. Liposomes in the treatment 
of inflammatory disorders. Expert Opin Drug Deliv 
2005 May;2(3):465-76.
22 Neubauer AM, Sim H, Winter PM, Caruthers SD, 
Williams TA, Robertson JD, et al. Nanoparticle 
pharmacokinetic profiling in vivo using magnetic 
resonance imaging. Magn Reson Med 2008 
Dec;60(6):1353-61.
23 Klink A, Lancelot E, Ballet S, Vucic E, Fabre JE, 
Gonzalez W, et al. Magnetic resonance molecular 
imaging of thrombosis in an arachidonic acid mouse 
model using an activated platelet targeted probe. 
Arterioscler Thromb Vasc Biol 2010 Mar;30(3):403-
10.
24 Beilvert A, Cormode DP, Chaubet F, Briley-Saebo KC, 
Mani V, Mulder WJ, et al. Tyrosine polyethylene 
glycol (PEG)-micelle magnetic resonance contrast 
agent for the detection of lipid rich areas in 
atherosclerotic plaque. Magn Reson Med 2009 
Nov;62(5):1195-201.
25 McGoron AJ, Pratt R, Zhang J, Shiferaw Y, Thomas 
S, Millard R. Perfluorocarbon distribution to liver, 
lung and spleen of emulsions of 
perfluorotributylamine (FTBA) in pigs and rats and 
perfluorooctyl bromide (PFOB) in rats and dogs by 
19F NMR spectroscopy. Artif Cells Blood Substit 
Immobil Biotechnol 1994;22(4):1243-50.
26 Waters EA, Chen J, Yang X, Zhang H, Neumann R, 
Santeford A, et al. Detection of targeted 
perfluorocarbon nanoparticle binding using 19F 
diffusion weighted MR spectroscopy. Magn Reson 
Med 2008 Nov;60(5):1232-6.
27 Waters EA, Chen J, Allen JS, Zhang H, Lanza GM, 
Wickline SA. Detection and quantification of 
angiogenesis in experimental valve disease with 
integrin-targeted nanoparticles and 19-fluorine MRI/
MRS. J Cardiovasc Magn Reson 2008;10:43.
28 Mulder WJ, Strijkers GJ, Griffioen AW, van BL, 
Molema G, Storm G, et al. A liposomal system for 
2012110 proefschrift Brigit den Adel_def.indd   77 22-01-13   21:49
78 |
chapter 4
contrast-enhanced magnetic resonance imaging of 
molecular targets. Bioconjug Chem 2004 
Jul;15(4):799-806.
29 Rouser G, Fkeischer S, Yamamoto A. Two dimensional 
then layer chromatographic separation of polar 
lipids and determination of phospholipids by 
phosphorus analysis of spots. Lipids 1970 
May;5(5):494-6.
30 Sabin J, Prieto G, Ruso JM, Hidalgo-Alvarez R, 
Sarmiento F. Size and stability of liposomes: a 
possible role of hydration and osmotic forces. Eur 
Phys J E Soft Matter 2006 Aug;20(4):401-8.
31 Briley-Saebo KC, Amirbekian V, Mani V, Aguinaldo 
JG, Vucic E, Carpenter D, et al. Gadolinium mixed-
micelles: effect of the amphiphile on in vitro and in 
vivo efficacy in apolipoprotein E knockout mouse 
models of atherosclerosis. Magn Reson Med 2006 
Dec;56(6):1336-46.
32 van Bochove GS, Paulis LE, Segers D, Mulder WJ, 
Krams R, Nicolay K, et al. Contrast enhancement by 
differently sized paramagnetic MRI contrast agents 
in mice with two phenotypes of atherosclerotic 
plaque. Contrast Media Mol Imaging 2011 
Jan;6(1):35-45.
33 Ratner AV, Hurd R, Muller HH, Bradley-Simpson B, 
Pitts W, Shibata D, et al. 19F magnetic resonance 
imaging of the reticuloendothelial system. Magn 
Reson Med 1987 Dec;5(6):548-54.
34 Roerdink F, Wassef NM, Richardson EC, Alving CR. 
Effects of negatively charged lipids on phagocytosis 
of liposomes opsonized by complement. Biochim 
Biophys Acta 1983 Sep 21;734(1):33-9.
35 Peters D, Kastantin M, Kotamraju VR, Karmali PP, 
Gujraty K, Tirrell M, et al. Targeting atherosclerosis 
by using modular, multifunctional micelles. Proc 
Natl Acad Sci U S A 2009 Jun 16;106(24):9815-9.
36 Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, 
Aguinaldo JG, Vucic E, et al. Molecular imaging of 
macrophages in atherosclerotic plaques using 
bimodal PEG-micelles. Magn Reson Med 2007 
Dec;58(6):1164-70.
2012110 proefschrift Brigit den Adel_def.indd   78 22-01-13   21:49
| 79
2012110 proefschrift Brigit den Adel_def.indd   79 22-01-13   21:49
2012110 proefschrift Brigit den Adel_def.indd   80 22-01-13   21:49
Under revision
Filip M.E. Segers, Brigit den Adel, Ilze Bot, Linda M. van der Graaf, Walter Gonzalez, 
Isabelle Raynal, Menno de Winther, Robert E. Poelmann, Theo J.C. van Berkel, 
Louise van der Weerd and Erik A.L. Biessen
Scavenger receptor-AI targeted iron oxide 
nanoparticles for in vivo MRI detection of 
atherosclerotic lesions
Chapter 5
2012110 proefschrift Brigit den Adel_def.indd   81 22-01-13   21:49
chapter 5
82 |
AbStRACt
rationale
Several MRI studies have shown atherosclerosis can be detected both in humans and animal 
models. Uptake of non-targeted contrast agents (CA) in the leaky endothelium of atherosclerotic 
plaque gives good plaque enhancement yet without discrimination of the different plaque 
components. 
objective
In search of molecular imaging modalities for specific detection of inflammatory atherosclerotic 
plaques, we explored the potential of targeting scavenger receptor-AI (SR-AI), which is highly 
expressed by lesional macrophages and linked to an effective internalization machinery.
Methods and results
Ultrasmall Superparamagnetic Iron Oxide (USPIO) particles were conjugated to a peptidic SR-AI 
ligand (0.371mol Fe/L and 0.018mol PP1/L). In vitro incubation of human or murine macrophages 
with SR-AI targeted USPIO led to significantly higher iron uptake in vitro than with non-targeted 
USPIO, as judged from quantitative atomic absorption spectroscopy and Perl’s staining. Incremental 
uptake was strictly mediated by scavenger receptors. SR-AI targeted USPIO displayed accelerated 
plasma decay, and a 3.5 fold increase (p=0.01) in atherosclerotic plaque accumulation upon i.v. 
injection into ApoE-/- mice, as compared to non-targeted USPIO. In keeping,  atherosclerotic 
humanized LDLr-/- chimeras with leukocyte expression of human SR-AI showed a significant 
improvement in contrast-to-noise ratio (2.7-fold; p=0.003) in the atherosclerotic aortic arch 
plaques 24h after injection of SR-AI targeted USPIO compared to chimeras with leukocyte SR-AI 
deficiency.
Conclusion
Collectively, our data  provides several lines of evidence that SR-AI targeted molecular imaging 
of USPIO based contrast agents holds great promise for in situ detection of inflammatory plaques 
in manifest atherosclerosis.
 
AbbREVIAtIoNS
T-USPIO – Targeted Ultrasmall Superparamagnetic Iron Oxide particles
hSR-AI ki – human Scavenger Receptor-AI knock in
ROI – Region of Interest
 
INtRoDuCtIoN
Despite recent advancement in our understanding of the pathogenesis of acute cardiovascular 
syndromes (ACS), the current imaging diagnostic modalities are primarily appropriate for detecting 
the degree of stenosis, but lack the desired specificity to identify those atherosclerotic plaques 
that are at risk of becoming clinically symptomatic. Non-invasive detection methods, such as 
magnetic resonance imaging (MRI), have shown to enable early tracking of subclinical lesions, 
characterization of plaque composition, and accurate discrimination between stable and unstable 
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lesions. To augment the inherent low sensitivity of MRI, superparamagnetic contrast agents 
have been developed and are to date widely used as contrast agents for molecular and cellular 
imaging1. An example of such an agent is Ferumoxtran-10, an ultrasmall superparamagnetic 
iron-oxide nanoparticle (USPIO). USPIOs have already been applied for detection of metastases2, 
3, multiple sclerosis lesions4, 5, inflammatory foci in the central nervous system6 and atherosclerotic 
plaques7, 8. USPIO particles are only slowly cleared from the bloodstream, potentially via nonspecific 
receptor mediated endocytosis9 by macrophages, and as a result of this long circulation time end 
up in lymph node macrophages and peripheral tissue macrophages10, 11. Nevertheless, plaque 
uptake is rather inefficient, possibly due to USPIO’s inherent low affinity for the major elimination 
receptors. The dextran coating is progressively degraded and almost exclusively eliminated via 
the urinary system, whereas iron is assimilated in the body’s iron pool, progressively incorporated 
in red blood cells (haemoglobin) and finally eliminated via faeces with a half-life of 84 days1. While 
advantageous for some imaging purposes, a prolonged biological half-life may be accompanied 
by cytotoxic effects on the long run12. USPIO were reported to reside in the lysosomal compartment 
for up to 7 days in vitro13 before complete degradation.
A hallmark in the pathogenesis of atherosclerosis is monocyte infiltration, their differentiation 
into macrophages and foam cells, and subsequent activation in the arterial intima14. Plaque 
macrophages highly express class A scavenger receptors (SR-A), which have been suggested 
to play a crucial role in atherosclerotic lesion development15-18. Scavenger-receptor-mediated 
uptake of modified lipoproteins is deemed instrumental in foam cell formation and activation, 
promoting a pro-inflammatory phenotype of lesional macrophages19. Abundant scavenger 
receptor expression was found in lesion-specific foam cells and vascular smooth muscle cells 
but not in the healthy vessel wall20, 21. Relevant to vulnerable plaque detection, abundant SR-AI 
expression was shown in macrophage enriched inflammatory foci in the advanced, 
atherosclerotic lesion. Combined with efficient receptor-mediated endocytosis of bound 
substrates this qualifies SR-AI as promising target for plaque-directed molecular imaging and 
drug delivery approaches. Due to the complex chemical nature of known macromolecular 
SR-AI substrates, attempts in ligand design for this receptor have so far been rather unsuccessful. 
We recently identified a 15-mer peptide PP1 by phage display library screening, which shows 
high in vitro and in vivo affinity and specificity for both human and murine macrophage 
scavenger receptor class A22.
In the current study we report the development and validation of SR-AI targeted USPIO 
functionalized with the aforementioned SR-A specific peptide. The targeted USPIO was not only 
tested in vitro on mouse and human macrophages but also in vivo in an established mouse model 
for atherosclerosis (aged chow fed ApoE-/- mice), as well as in a humanized model of atherosclerosis 
(western type diet fed LDLr-/- chimera with leukocyte expression of human SR-A1).
MAtERIAlS AND MEtHoDS
Cell culture
RAW264.7 murine macrophage cells and human THP-1 monocyte cells (gift from Guerbet Group, 
France) were grown at 37°C in a humidified atmosphere (5% CO2) in Dulbecco’s Modified Eagle’s 
Medium (DMEM) and RPMI 1640 medium, respectively, supplemented with 10% Fetal Bovine 
Serum (FBS) (Heat-inactivated, 30min 56°C), 2mmol/L L-glutamine, 100 U/ml Penicillin and 
100μg/ml streptomycin (all from PAA, Cölbe, Germany). THP-1 monocytes were differentiated 
into macrophages by incubation with phorbol 12-myristate, 13-acetate (PMA, 100nM, o.n.) 
2012110 proefschrift Brigit den Adel_def.indd   83 22-01-13   21:49
chapter 5
84 |
(Sigma, Zwijndrecht, The Netherlands). Fucoidan (Sigma, Zwijndrecht, The Netherlands) was 
used as an inhibitor for SR-AI.
Animals
All animal work was conducted in compliance with the Dutch government guidelines. ApoE-/- (1-
year old) and female LDLr-/- mice (aged 8-12 weeks) were obtained from the local animal breeding 
facility. SR-A1-/- mice were from Jacksons Laboratory (Bar Harbor, Maine, USA) and transgenic 
mice with human SR-A overexpression on a SR-AI deficient background were obtained from Dr. 
Menno de Winther, Maastricht University Medical Center, the Netherlands. All mice were kept 
under standard laboratory conditions. Diet and water were provided ad libitum throughout the 
experiment.
Bone Marrow transplantation and induction of hypercholesterolemia
Female LDLr–/– mice were lethally irradiated by a single dose of 9 Gy (0.19 Gy/min, 200 kV, 4 mA) 
total body irradiation, using an Andrex Smart 225 Röntgen source (YXLON Int, Copenhagen, 
Denmark) equipped with a 6-mm aluminium filter. Donor bone marrow was isolated by flushing 
femurs and tibias with phosphate-buffered saline (PBS). Single-cell suspensions were prepared 
by passing the cells through a 30-μm nylon gauze. Irradiated recipients received 0.5x107 bone 
marrow cells by intravenous injection into the tail vein. After a recovery of 6 weeks animals 
received a semisynthetic high-cholesterol diet containing 15% (w/w) fat and 0.25% (w/w) 
cholesterol (Diet W; Abdiets, Woerden, The Netherlands) for 12-18 weeks. Drinking water was 
supplemented with antibiotics (83 mg/L ciprofloxacin and 67 mg/L polymyxin B sulfate) and 6.5 
g/L sucrose. Mouse health and weight was monitored during the experiment and blood samples 
were collected by tail bleeding every 2-3 weeks for assessment of plasma cholesterol levels. Total 
cholesterol levels were quantified spectrophotometrically using an enzymatic procedure (Roche 
Diagnostics, Germany). Precipath standardized serum (Boehringer, Germany) was used as an 
internal standard.
Preparation of functionalized usPio
The PP1 peptide was synthetized as previously described22. PP1 peptide was conjugated to USPIO 
through their amino-terminal groups (5%; 0.018mol PP1/L and 0.371mol Fe/L)  by Guerbet (Aulnay-
sous-Bois, France). PEG-NH2 (Mw =750 g/mol; Sigma) was conjugated to the free carboxyl groups 
exposed by the particles and the pH was finally adjusted to 7.6. In order to remove the free non-
conjugated molecules, the solution was exhaustively dialyzed.
The physico-chemical characterization was carried out as previously described23. Briefly, the mean 
diameter of coated USPIO-PP1 (T-USPIO) was about 22nm measured by photon correlation 
spectroscopy (PCS) on a Malvern system (Zêtasizer nanoseries ZEN 3600). USPIO were of 
comparable size, namely 24.1nm. Iron concentration was determined by ICP-AES after 
mineralization in acidic conditions (HNO3,  80°C). 
relaxivity
The relaxivities (r1, r2) were measured in water at 60 and 20 MHz at 37°C on a Bruker Minispec 
(respectively mq60 and mq20) by Guerbet (Aulnay-sous-Bois, France). Before the in vivo 
experiments, the transverse r2 relaxivity was determined from the slope of a linear regression 
curve of T2 measurements of several contrast agent concentrations on the in vivo MRI system 
(9.4T) at 37°C. 
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In vivo Mri
All experiments were performed on a 9.4T (400 MHz) vertical 89-mm bore MR magnet interfaced 
to a Bruker AVANCE (Bruker BioSpin MRI GmbH, Ettlingen, Germany) MR imaging console equipped 
with ParaVision 5.0 software, with an actively shielded Micro2.5 gradient system (1 T/m). Mice 
were scanned in a transmit/receive birdcage radiofrequency coil with an inner diameter of 3.0 
cm (Bruker BioSpin MRI GmbH, Ettlingen, Germany).
In vivo MRI was performed on the animals described above (ApoE-/- and bone marrow transplanted 
LDLr-/- mice). For in vivo imaging mice were anesthetized with isoflurane (2% in air). During the 
examination, the respiration rate was continuously measured with a balloon pressure sensor using 
a respiration cushion under the mouse chest connected to the ECG/respiratory unit (SA 
Instruments, Inc., Stony Brook, NY). The isoflurane concentration was adjusted to keep the 
respiration rate between 50 and 80 respirations/min. The mice were randomly divided into two 
groups injected with targeted (T-USPIO) or non-targeted contrast agent (USPIO).
To determine the optimal imaging time point 2 groups (n=5 per group) of aged ApoE-/- mice were 
injected with 250 μmol Fe/kg bodyweight SR-A1 targeted or control USPIO. Animals were imaged 
with 30 minutes intervals for the first 3 hours and thereafter every 2.5 hours to find the optimal 
imaging time point. The optimal imaging time point is defined as the moment where the highest 
difference in blooming effect was observed between the 2 contrast agents. At 24 hours after 
injection contrast enhancement was largest using the T-USPIOs (supplemental figure 1).
At the start of each examination, several 2D FLASH scout images were recorded in the transverse 
and axial plane of the heart to determine the orientation of the aortic arch. The following 
parameters were used for the shout scans: Hermite-shaped RF pulse 1.000 ms; flip angle (FA) 10; 
repetition time (TR) 14.7 ms; echo time (TE) 1.8 ms; sample rate 40 kHz; echo position 30%; field 
of view (FOV) 1.8*1.8 cm2 ; matrix 128*128; in-plane resolution 0.141 mm; slice thickness 0.4 mm; 
number of repetitions 64; total acquisition time approximately 2 min.
A modified FLASH sequence with a navigator echo (IntraGate) was used for retrospective CINE 
MRI with the following parameters:
Hermite-shaped RF pulse 1.000 ms; FA 15˚; TR 15.7 ms; TE 2.96 ms; sample rate 40 kHz; echo 
position 30%; navigator echo points 64; 10 cardiac frames; FOV 2.56*2.56 cm2; matrix 128*128; 
in-plane resolution 0.2 mm; slice thickness 0.5 mm; number of repetitions 400; total acquisition 
time approximately 14 min.
image Analysis
For each time point, bright blood images were selected and 3 to 4 adjacent slices of cross-sections 
of the aortic arch were manually analyzed using ImageJ software. Regions of Interest (ROIs) were 
drawn around the vessel wall (Iwall). A 2nd ROI was drawn in the muscle tissue of the shoulder 
region (Imuscle). Furthermore, an ROI was placed outside the animal to measure the noise level 
(stdevnoise) (Supplemental Figure 1). 
The contrast to noise ratio was defined as: 
Cnr= (i(wall) – i(muscle))/stdev(noise      [eq1] 
histology and Morphometry
Cryostat sections (10μm) were prepared of the aortic valve area and lipid deposits were stained 
with Oil Red O. Mean lesion area was calculated from 8-10 consecutive Oil Red O (ORO) stained 
sections. Lesional macrophage content was determined after immunohistochemical staining with 
a macrophage specific antigen antibody (MoMa-2, monoclonal rat IgGb2, dilution 1:50; Serotec, 
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Oxford, UK). Secondary antibody goat-anti- rat IgG-AP (1:100; Sigma, St-Louis, MO) and enzyme 
substrate Nitro Blue Tetrazolium – 5-Bromo-4-Chloro-3-Idolyl Phosphate (NBT-BCIP) (Dako, 
Glostrup, Denmark) were used. Iron deposits were visualized by hemosiderin staining according 
to the Perl’s method.
Morphometric analysis on Oil Red O and MoMa-2 stained sections was performed using Leica 
Qwin image analysis software and a Leica-DM-RE microscope (Leica imaging systems, Cambridge, 
UK). Perl’s positive cells were counted manually in a blinded manner.
Quantitative analysis of iron dosages in plasma and organs
Blood samples were collected by tail vein puncture and plasma was isolated. Upon sacrifice, mice 
were anesthetized and underwent in situ PBS perfusion via the left cardiac ventricle. Organs of 
interest were isolated and stored at -80˚C until further analysis. Iron content of cell cultures and 
tissue was determined by inductively coupled plasma atomic emission spectroscopy (ICP-AES) 
(Optima 3300 RL, Perkin Elmer, Courtaboeuf, France).
RESultS
relaxivity analysis
The contrast agent relaxivities were measured at 37˚C at 20, 60 and 400 MHz respectively 
(Table 1). The transverse relaxivities of the SR-A1 and control particle did not differ significantly 
nor did the longitudinal relaxivity. 
increased uptake of scavenger receptor targeted usPio by macrophages in vitro
The kinetics of basal uptake, processing and detection of USPIO in vitro and in vivo by macrophages 
have been subject of numerous studies9. Here we sought to investigate whether USPIO uptake 
by (plaque associated) macrophages could be augmented by conjugation to a newly devised 
peptide ligand for SR-AI22, a receptor previously shown to be highly expressed by this leukocyte 
subset in inflammatory foci within the plaque24. As a measure of USPIO uptake by RAW264.7 cells 
(300μg Fe/ml) cell-associated iron was assessed using quantitative atomic absorption spectroscopy 
analysis. SR-AI targeted USPIO (T-USPIO) showed a markedly increased uptake by macrophages 
than non-targeted USPIO (1729 ± 152 versus 805 ± 111ng Fe/g cell pellet, p<0.001, figure 1.A). In 
vitro uptake studies in human THP-1 macrophages revealed a comparable increase in cellular 
uptake of T-USPIO (600 ± 35) over USPIO (343 ± 48 ng Fe/g cell pellet, p=0.01). T-USPIO uptake 
could be blocked to a large extend by pre-incubation of the cells with fucoidan, an established 
table 1. relaxivity analysis (r1 and r2) for usPio and targeted usPio (t-usPio) particles
20 Mhz water 37°C 60 Mhz water 37°C 400 Mhz saline 37°C
usPio t-usPio usPio t-usPio usPio t-usPio
R1 mM-1.s-1 34.1 40.0 16.1 17.0 0.47*102 0.5*102
R2 mM-1.s-1 91.3 82.0 90.7 78.7 5.0*102 5.3*102
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inhibitor of SR-AI/II25. Fucoidan also diminished the uptake of non-targeted USPIO, which is 
consistent with the previously suggested role of scavenger receptors in USPIO phagocytosis. 
(figure 1.B). Of note, the targeted USPIO uptake remains significantly higher than the uptake of 
its untargeted counterpart.
The increased T-USPIO accumulation by THP-1 cells translated in a decreased T2 relaxation time 
(65.4 ± 0.6 msec; p=0.01) compared to cells incubated with USPIO (72.5 ±1.4msec) (Figure 1.C). 
Again, incubation with fucoidan neutralized the decrease in T2 relaxation of T-USPIO, albeit to a 
lesser extent also of USPIO-incubated macrophages. In fact, T2 relaxation times after fucoidan 
treatment were comparable to that of the control samples. 
In keeping with these in vitro MRI data, Perl’s staining of THP-1 macrophages confirmed the more 
abundant presence of iron deposits in T-USPIO incubated macrophages (figure 1.D-E). Our results 
thus indicate that peptide targeted USPIO display significantly increased, SR-AI dependent uptake 
by macrophages in vitro.
figure 1 | scavenger receptor targeted usPio display improved uptake by macrophages in vitro compared to 
untargeted usPio. Cellular uptake of targeted (T-USPIO; 300μg Fe/ml; A right) and non-targeted USPIO 
(USPIO, 300μg Fe/ml; A left) was assessed in different in vitro macrophage cell cultures. (B) RAW264.7 
macrophages were incubated with T-USPIO or USPIO for 24h. Cells without contrast agents served as 
control. Cell pellets were collected and quantitatively analyzed by inductively coupled plasma atomic 
emission spectroscopy (ICP-AES). (C) THP-1 macrophages with () or without () inhibitor (Fucoidan; 
0.5mg/ml) were incubated for 24h with USPIO and T-USPIO. Uptake of (T-)USPIO was determined by 
ICP-AES based iron analysis of cell lysates and corrected for protein content. (D) T2 relaxation times from 
cell pellets were analyzed by MRI. Iron uptake was reflected by signal loss in T2-weighted MRI analysis of 
cell pellets. THP-1 incubated with USPIO (E) and T-USPIO (F) were stained for iron with Perl’s staining to 
visualize intracellular iron deposition. Data are shown as mean ± SEM. (*p<0.05, **p<0.01 and 
***p<0.001)
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increased plasma clearance and increased signal in vivo upon targeted delivery of usPio in 
Apoe-/- mice
As a next step, we investigated the optimal imaging window and the fate of plaque accumulation 
of the SR-AI targeted T-USPIO in vivo in aged (1y) ApoE-/- mice (N=14) with established advanced 
atherosclerotic lesions. Mice were imaged every 30 minutes for the first 3 hours after contrast 
agent injection and thereafter followed every 2.5 hours until 48 hours after injection. Gradually 
increasing uptake in the plaque on the inner curvature of the aortic arch was observed until a 
significant difference in uptake between the T-USPIO and USPIO was observed 24 hours after 
injection. 
A subset of mice received a single intravenous injection with T-USPIO (250μmol Fe/kg, N=6) while 
the control group received plain USPIO (250μmol Fe/kg, N=6). The remaining mice were used 
to determine endogenous tissue iron content. Kinetic analysis of plasma iron levels by inductively 
coupled plasma atomic emission spectroscopy (ICP-AES) (figure 2.A) pointed to an increased 
plasma clearance of T-USPIO (T1/2 = 1.7h) compared to USPIO (T1/2 = 2.9h; P<0.05). Plasma iron 
levels declined to baseline within 24h after administration of T-USPIO or USPIO. Analysis of 
macrophage-rich organs such as liver, spleen and lungs, as well as kidney 24h after injection 
(figure 2.B), showed increased iron accumulation in liver, the primary eleminating organ, in USPIO 
(3.1 ± 0.3μmol Fe/g; NS) and even more so in T-USPIO treated mice (3.4 ± 0.4μmol Fe/g tissue; 
p<0.05) compared to the endogenous tissue iron concentrations (1.6 ± 0.3μmol Fe/g). In vivo 
MRI of the aortic arch 24 hours after injection of contrast agent revealed increased accumulation 
of T-USPIO compared to non-targeted USPIO in atherosclerotic plaques on the basis of the 
innercurvature of the aortic arch (T-USPIO Contrast-to-Noise Ratio (CNR) -14.0 ± 1.7, USPIO -9.8 
figure 2 |  targeted usPio show faster kinetics 
in blood and improved accumulation 
in macrophage-rich organs. Aged 
ApoE-/- (1-year old) mice received 
USPIO (N=6; white bars) or targeted 
USPIO (T-USPIO; N=6; black bars) by 
intravenous injection. Mock injected 
mice served as control and were used 
to determine endogenous tissue iron 
concentrations (gray bars). (A) Plasma 
samples were subjected to ICP-AES 
atomic absorption spectroscopy and 
iron content in mice treated with 
T-USPIO () and untargeted USPIO 
() was determined. (B) At 24h after 
administration, organs of interest were 
harvested and analyzed for iron uptake 
by ICP-AES. Data are shown as 
mean±SEM. (*p<0.05)
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± 0.7, p<0.05) (figure 3.A-C). Except for liver, biodistribution profiles of T-USPIO and USPIO were 
essentially similar and did not significantly differ from that of untreated controls (figure 2.B). Lesion 
prone artery segments (aortic valve area, figure 3) were also analyzed ex vivo for lesion size, 
monocyte/macrophage content and iron accumulation. As expected, no differences were 
observed in lesion size (figure 3.J-K) and monocyte/macrophage content (figure 3.G-I). However, 
in line with the aforementioned results obtained by MRI, visualization of iron uptake by Perl’s 
staining (figure 3.D-F) revealed a significant, 3.3-fold increase in Perl’s positive cells in lesions of 
T-USPIO injected mice compared to those injected with USPIO (P=0.01). Our data thus 
demonstrate that targeted contrast agents combine accelerated plasma clearance with increased 
accumulation in advanced atherosclerotic lesions.
t-usPio show superior accumulation in plaques in a humanized mouse model of 
atherosclerosis
In initial studies we already showed that the SR-AI targeting peptide PP1 had higher affinity for 
human derived THP-1 macrophages than for murine macrophages, suggesting that PP1 may be, 
at least, equally effective in a human setting22. To address its potential for human plaque imaging 
we generated LDLr-/- chimeras with hematopoietic human SR-AI (hSR-AI) expression by bone 
marrow transplantation (>90% bone marrow reconstitution after 6 weeks). Chimeras with 
hematopoietic SR-AI deficiency (SR-AI-/-) and wild type bone marrow transplanted LDLr-/- mice 
served as control. After a recovery period of 6 weeks, atherogenesis was induced by high 
cholesterol diet feeding. After 3 months of diet exposure, all groups of mice received a single 
intravenous dose of PP1-targeted contrast agent (T-USPIO; 250μmol Fe/kg). After 24h, mice were 
anesthetized and subjected to in vivo magnetic resonance imaging at 9.4T. In keeping with previous 
findings26, 27 morphometric analysis did not reveal any differences in plaque size between SR-AI-/- 
and hSR-AI mice (figure 4.G; representative pictures of the Oil-Red-O staining in online supplement 
figure 2) Importantly, plaque monocyte/macrophage content of the atherosclerotic lesions did 
also not differ (figure 4.D-F). In vivo MRI analysis of the aortic arch revealed a significantly decreased 
contrast-to-noise ratio in mice overexpressing human SR-AI (-17.4 ± 2.3) compared to SR-A-/- 
controls (-6.4 ± 0.5; p=0.004) and control BM animals (figure 4A-D). Moreover the signal voids 
in MR images pointed to augmented iron uptake in hSR-AI overexpressing mice. These results 
clearly illustrate the improved capacity of SR-AI targeted contrast agents to accumulate in 
atherosclerotic lesions in a SR-AI dependent manner.
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figure 3 | sr-Ai targeting of contrast agents results in increased uptake in advanced atherosclerotic plaques in 
Apoe-/- mice. Aged ApoE-/- (1-year old) mice received an intravenous injection of non-targeted (USPIO; 
white) or targeted USPIO (T-USPIO; black). After 24h mice underwent in vivo MRI analysis (A-C) and were 
sacrificed and sections were made of the atherosclerotic lesion prone aortic root. These sections were 
subsequently stained for Perl’s (D-F), MoMa-2 (G-H) and Oil-Red-O (J-L). Perl’s staining was analyzed in 
a blinded manner and Perl’s+ cells were individually scored (data presented as # Perl’s+ cells/plaque area). 
Data are shown as mean±SEM.(* p<0.05)
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DISCuSSIoN
The data of the current study show that conjugation of PP1 to USPIO particles could provide a 
useful molecular imaging tool for noninvasive imaging of atherosclerotic plaques. We not only 
show induced delivery of this PP1 conjugated USPIO to macrophages in vitro and in vivo, but also 
enhanced MRI image contrast in macrophage rich atherosclerotic plaques in a humanized model 
of atherosclerosis.
Ultrasmall superparamagnetic iron oxide particles (USPIO) have been used in non-invasive 
clinical imaging to enhance image contrast in detection of malignancies28, inflammatory multiple 
sclerosis lesions, CNS pathologies and atherosclerotic lesions7. One of the major challenges in 
cardiovascular imaging is the clinically relevant distinction between stable and unstable rupture-
prone lesions. The abundant presence of macrophages is a hallmark feature of the latter 
plaques29. This renders macrophages primary targets in diagnostic strategies for vulnerable 
plaque detection. The current study provides several lines of evidence for effective scavenger 
receptor A1 directed targeting of plaque macrophages. Firstly USPIO particles equipped with 
the SR-AI specific peptide ligand PP1, T-USPIO, show preferential  and SR-AI dependent uptake 
by murine and human macrophages in vitro. Secondly T-USPIO had accelerated plasma decay 
and augmented accumulation by atherosclerotic plaques in aged ApoE-/- mice and in western 
type diet fed LDLR-/- with human SR-AI. Thirdly, T-USPIO was capable of visualizing inflammatory 
aortic arch plaques by MRI in vivo. 
The marked expression of SR-AI in macrophage enriched sites of inflammation and the fact 
that this receptor mediates efficient endocytosis of its substrates  renders it an interesting 
figure 4 | in vivo Magnetic resonance imaging of the aortic arch reveals increased lesional uptake of targeted 
usPio in hsr-A overexpressing lDlr-/- chimeras. After bone marrow transplantation, LDLr-/- chimeras 
were fed a high cholesterol diet to induce atherosclerotic plaque formation. SR-A-/-, hSR-A overexpressing 
and WT (control) bone marrow recipients received a single administration with targeted USPIO. At 24h 
after injection, mice were subjected to in vivo magnetic resonance imaging and subsequently sacrificed. 
Contrast-to-Noise Ratio (CNR) was determined by computer assisted analysis of MRI images (A-C). For 
each mouse three images were analyzed and mean CNR was determined (D). Cryosections were made 
from the atherosclerotic lesion prone aortic root and subsequently stained (F-G) and analyzed for MoMa-
2 (E) and for atherosclerotic plaque size (G). Data are shown as mean ± SEM. (**p<0.01)
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candidate for targeted delivery to inflammatory plaques15, 30, 31. Recently, our group successfully 
identified a small 15-mer peptide (PP1) with high specificity and affinity for scavenger receptor 
class AI, which is better fit as homing device for contrast agents22. Concordant with our previous 
study, PP1 conjugated USPIO are preferentially taken up by macrophages in a scavenger-
receptor dependent manner as fucoidan coincubation blunted the incremental uptake. 
Macrophage uptake of conventional USPIO was partly inhibited as well, fueling the notion that 
SR-A can also mediate untargeted USPIO uptake to some extent9. Further support for SR-AI 
specificity was derived from the sharply diminished accumulation of T-USPIO in LDLr-/- chimeras 
deficient in leukocyte SR-AI26. 
Another important issue is whether the effective macrophage targeting observed in our study is 
reflective of its effectiveness in a human context. Our data in a humanized model of atherosclerosis, 
i.e. LDLr-/- mice with macrophage-specific overexpression of the human macrophage scavenger 
receptor class A27, 32, 33 clearly corroborate the plaque macrophage imaging potential of PP1 
equipped USPIO for humans. From histological plaque analysis we can exclude differences in 
lesion size or plaque characteristics between the different groups, confirming that the increased 
image contrast is attributable to increased T-USPIO ingestion by SR-AI expressing plaque 
macrophages.
Although the targeting efficacy of T-USPIO in hSR-AI->LDLr-/- chimeras and ApoE-/- was largely 
the same, we did notice minor differences. These may well relate to issues other than species 
differences in SR-AI receptor binding, such as progression stage of lesions (higher in ApoE-/-), the 
level of neovascularisation (higher in ApoE-/-)34, plaque inflammation and cap fibrosis, all of which 
potentially affecting the penetration of T-USPIO particles into the plaque 35. 
The biodistribution profile of T-USPIO was consistent with that of [125I]-labeled PP122. The faster 
plasma decay of T-USPIO and increased hepatic uptake relative to USPIO, likely due to accelerated 
elimination by SR-A1 on liver cells and endothelial cells36 will have beneficial and adverse effects 
on plaque imaging. On the one hand it may constrain the penetration of T-USPIO into the plaque, 
and may enhance USPIO deposition in cells of the reticulo-endothelial system for metabolization, 
with the associated risk of toxicity12. On the other hand it may be accompanied by even faster 
normalization of blood signal intensity, and will reduce nonspecific USPIO accumulation by 
surrounding tissue, which both will augment contrast-to-noise ratio in the vessel wall. With 
regard to the latter, it will be of great interest for future studies to optimize the circulation time 
of the particles for maximum specificity and minimum toxicity, e.g. by using larger iron oxide 
particles37.
Several reports have been published so far on targeted imaging of inflammation and of vulnerable 
atherosclerotic plaques. Macrophages remain an important target for imaging as they are key 
effectors in atherosclerosis29 and their high abundance in plaque was associated with a high risk 
of clinical complications38-40. Currently two major approaches exist for imaging intraplaque 
macrophage density. Macrophages have been targeted in a passive manner, be it after penetration 
of USPIO into the plaque and ingestion in situ, or via circulating USPIO laden monocytes which 
after plaque invasion differentiate into macrophages41. Alternatively, for molecular imaging of 
inflammatory plaques the potential of active targeting of plaque leukocyte subsets (detailed review 
see42) have been explored, often using scavenger receptors as route of entry43,44. 
Synthetic PP1 may contrast favourably to the homing devices used in the latter studies. It shows 
a similar to even higher in vivo accumulation ratio than macrophage targeted immunomicelles45, 
MDA246, OxLDL targeted46 and tyrosine PEG-micelles47 and HDL based contrast agent48. While at 
least equally effective and synthetically flexible, these peptide based homing vehicles display 
higher receptor specificity (compared to PEG micelles, HDL-based contrast agents), are less 
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immunogenic (vs MDA2 micelles, synthetic HDL), or do not give rise to cell activation (vs 
liposomes)49. PP1 equipped contrast agents (PET or MRI) may thus represent effective screening 
tools to detect macrophage-rich atherosclerotic lesions in the patient at risk, and, in more general 
sense, inflammatory foci, precisely mapping location and extent of inflammation. How scavenger 
receptor directed imaging of inflammatory atherosclerotic plaques compares to that the imaging 
of other vulnerable plaque components or processes such as apoptosis, necrosis, 
neovascularization, extracellular matrix and MMP’s (for a review see 50) remains to be investigated 
yet the plaque macrophage specificity of SR-A1 gives this contrast agent an important advantage 
over the imaging of other more general biological processes .
In conclusion, we here show the successful development of an SR-AI targeted iron-oxide-based 
MRI contrast agent that shows increased and SR-AI dependent uptake by macrophages in vitro 
as well as in vivo in an established atherosclerotic mouse model. The SR-AI targeted USPIO 
combines rapid blood decay with effective SR-AI dependent plaque macrophage uptake, due to 
its high affinity for SR-AI. Importantly it displays a favorable contrast-to-noise ratio in MRI aided 
detection of atherosclerotic plaques in a humanized model of atherosclerosis. With these features, 
PP1 targeted USPIO constitutes a promising new platform for the non-invasive detection of 
macrophage-rich foci in chronic inflammatory diseases such as the atherosclerotic plaque and 
might even allow selective discrimination of unstable plaques.
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SuPPlEMENtAl fIGuRES
supplemental figure 1 | A) Schematic overview of the ROI’s used for MRI Image analysis. (B) Contrast enhancement 
measurements before and at regular time intervals after intravenous injection of USPIO and 
T-USPIO in 1y-old ApoE-/- mice.
supplemental figure 2 |  Oil Red O staining of the aortic root of SRA1-/- and h SR-A1 ki bone marrow transplanted 
LDLr-/- mice.
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AbStRACt
rationale
Non-invasive determination of atherosclerotic plaque composition is essential for diagnosis, 
monitoring and treatment of atherosclerosis. We and others have observed that Vascular Cell 
Adhesion Molecule-1 (VCAM-1) is weakly expressed in healthy vessels but rapidly induced on 
vascular endothelium in early atherosclerotic plaques. In later plaque stages VCAM-1 is expressed 
on vascular smooth muscle cells and macrophages. The aim of this study was to image selective 
enhancement of VCAM-1 positive atherosclerotic plaque using VCAM-1 targeted USPIO. Secondly, 
we hypothesized that endothelial and intraplaque VCAM-1 expression could be distinguished 
based on the biokinetics of VCAM-1-USPIO.
Methods and results
First, targeting of VCAM-1-UPSIO versus a non-targeted control USPIO was assessed in aortic 
arch plaques of aged ApoE-/- mice. VCAM-1-USPIO contrast on MRI was significantly increased 
when compared to control particles, and colocalized with VCAM-1 expression. Secondly, plaque 
progression was imaged at 3, 6 and 9 weeks after placement of a carotid artery collar to induce 
plaque formation in young ApoE-/- mice. VCAM-1 targeted USPIO enhancement at 1.5 hours after 
i.v. injection showed enhanced uptake of the contrast agent (CA) in the vessel wall of all mice. 6 
hours after injection, intraplaque binding of the CA was apparent in mice with more advanced 
lesions. The CNR ratio between early (1.5 hr) and late (6 hrs) imaging time points allowed us to 
discriminate reliably between different plaque stages. To test the potential of VCAM-1-USPIO to 
monitor therapy response, ApoE-/-mice were exposed to a western diet with or without atorvastatin. 
A clear correlation was observed between the therapy response and intraplaque VCAM-1-USPIO 
accumulation.
Conclusion
VCAM-1 targeted USPIO holds great promise for in vivo non-invasive determination of 
atherosclerotic plaque composition and stage. Ultimately this technology might be an effective 
tool for diagnosis and monitoring of disease progression in patients.
INtRoDuCtIoN
Clinically as well as pre-clinically, it is of great interest to identify and characterize vulnerable 
atherosclerotic lesions timely, since early diagnosis may prevent progression towards vascular 
events, including myocardial infarction (MI) or ischemic stroke. Current non-invasive clinical 
imaging technologies largely focus on luminal narrowing1 and do not provide information on 
plaque composition. However, more and more studies show that the anatomical severity of 
stenosis is a poor predictor for plaque rupture, and thereby for the risk of vascular events2. More 
sophisticated molecular imaging techniques are now rapidly evolving, providing direct information 
on plaque composition and the biological processes involved in plaque progression and plaque 
vulnerability1, 3, 4. 
To achieve this, targeted contrast agents are needed that can identify molecules of interest with 
high specificity, while conveying sufficient contrast to be easily distinguished from unenhanced 
tissue. MRI is a promising imaging modality as it is non-invasive and provides excellent soft tissue 
contrast, high spatial resolution and structural definition. The sensitivity for contrast agent 
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detection using MRI is inherently low compared to other molecular imaging modalities such as 
positron emission tomography (PET). Nevertheless, for indications such as atherosclerotic plaques, 
with highly abundant targets that are readily accessible, MRI using targeted contrast agents has 
been shown to be a viable imaging technique5-7.
In atherosclerotic plaques, numerous potential molecular imaging targets are expressed either 
by endothelial cells and / or by cells within the wall of the artery. Ideally, a molecule of interest is 
differentially expressed from early lesion formation to advanced plaques5, 8.  
Early markers of atherogenesis include endothelial cell adhesion molecules, such as P- and 
E-selectin (CD62-E), and vascular cell adhesion molecule-1 (VCAM-1: CD106), which facilitate 
mononuclear leukocyte recruitment to activated endothelium and subsequent transmigration 
into the subendothelial space9, 10. VCAM-1 expression particularly plays a cardinal role in 
atherosclerotic plaque progression11-13. The adhesion molecule is present on the endothelium at 
atherosclerosis-prone sites even before macroscopic disease is apparent. As the lesion advances, 
VCAM-1 expression persists, but shifts from the endothelium to intraplaque sites, i.e. lesional 
macrophages and smooth muscle cells11-13. 
We14-16 and others17-22 have already successfully demonstrated that VCAM-1 targeted nanoparticles 
can detect atherosclerotic plaques and other inflammatory processes using MRI or nuclear 
techniques. Using VCAM-1-targeted ultrasmall superparamagnetic iron oxide (USPIO), robust 
contrast enhancement could be demonstrated in aortic plaque in the ApoE-/- mouse model16, 18. 
However, the feasibility to distinguish intraplaque and endothelial VCAM-1 expression by in vivo 
MRI, has not yet been investigated, nor the relation between these expression sites and plaque 
progression and therapy response.
The aim of this study was to test whether it is feasible to differentiate early and advanced plaques 
using VCAM-1 targeted USPIOs. To that extend, we compared the VCAM-1-targeted contrast 
enhancement at different time points after injection. We hypothesized that early imaging time 
points favor the enhancement of endothelial VCAM-1 expression, whereas imaging at later time 
points visualizes USPIO binding both at the endothelial layer and inside the plaque, thus providing 
a method to differentiate between early and advanced plaque. In addition, we hypothesized that 
this method could be used to monitor atherosclerotic plaque progression over time and the effect 
of an anti-atherosclerotic therapy in the ApoE-/- mouse model.
MAtERIAlS AND MEtHoDS
Contrast agents
USPIO were prepared as previously described15, 16. In short, a VCAM-1-targeted cyclic heptapeptide 
was conjugated to USPIO (USPIO-R832 hereafter called VCAM-1 USPIO), and VCAM-1 binding 
was first confirmed on human umbilical vein endothelial cells (HUVEC) stimulated with TNF-alpha. 
The control imaging probe was represented by USPIO vectorized by a non-specific peptide 
(USPIO-NSP, called control USPIO). The size of functionalized USPIO was ~30 nm. Further 
characterization of these particles can be found in16.
Mri hardware
All experiments were performed on a vertical 89-mm bore 9.4T magnet (Bruker, Ettlingen, 
Germany) with an actively shielded Micro2.5 gradient system of 1T/m and a 30 mm transmit/
receive birdcage RF coil, using Paravision 5.0 software. 
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Animal experiments
All experiments were conducted in accordance with the Dutch guidelines for research animal 
care. In total 12 groups of n=5 (with the exception of 2 groups of n=8) male ApoE-/- mice on a 
C57BL/6/Jico background were used for the experiments. Supplemental figure 1 gives and 
overview of the experimental groups. All mice were housed in groups and allowed ad libitum 
access to food and water. The given diet was either chow or a Western diet, depending on the 
experiments, as described below. 
Contrast enhancement over time
Optimal time points for plaque accumulation of both the VCAM-1-targeted as well as the 
untargeted USPIO were determined in a pilot time-course study in 2 groups (group A, supplemental 
figure 1) of 12-14 months old male ApoE-/- mice in which contrast agent accumulation and wash-
out was followed over time for 48 hours. Each mouse was scanned before administration of 
USPIO and at several time points after intravenous injection of 0.05 mmol Fe/kg bodyweight in 
200 μl dextrose solution. From 0-4 hours after USPIO injection mice were scanned every 30 
minutes, thereafter every 2 hours from 4-12 hours after injection and every 6 hours from 12-48 
hours after injection. Mice were anesthetized during MRI with isoflurane (± 2% in oxygen and air). 
During the examination, the respiration rate was continuously monitored using a balloon pressure 
sensor connected to the ECG/respiratory unit. The isoflurane concentration was adjusted to keep 
the respiration rate between 50 and 90 respirations/min. 
The optimal time point was defined as the time at which the largest contrast-to-noise ratio (see 
below) difference was observed.
In vivo toxicity was assessed after injection of the USPIO in these latter mice. Acute adverse effects 
were assessed by monitoring changes in heart rate and respiration after injection. Animals were 
sacrificed 48 hours after contrast agent injection. In each group organs were harvested and 
inspected for gross abnormalities by a trained animal pathologist (heart, aorta, liver, lungs, spleen 
and kidneys). No signs of toxicity were observed during this observation period (data not 
shown).
supplemental figure 1. overview of the experimental groups of Apoe-/- mice that were included in 
the study.
group Age
optimal imaging time 
point
A (n=5 VCAM USPIO,  
n=5 control USPIO)
12-14 months old ApoE-/- mice
Plaque imaging at  
1.5 & 6 hrs
B (n=5 VCAM USPIO,  
n=5 control USPIO)
12-14 months old ApoE-/- mice
Collar model plaque 
stages
C1 (n=5 per age group,  
3, 6 &9 wks) MRI
12 wks old ApoE-/- mice
C2 (n=3 per age group,  
3, 6 & 9 wks) Western blotting
12 wks old ApoE-/- mice
Atorvastatin therapy D (n=5 per age groups,  
3, 6 & 9 weeks)
12 wks old ApoE-/- mice
Plasma half-time e (n=5 VCAM USPIO,  
n=5 control USPIO)
12-14 months old ApoE-/- mice
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Plaque imaging in aged ApoE-/- mice
2 groups (n=5 per group, group B) of 12-to-14-month-old male ApoE-/- mice were fed a normal 
chow diet. Each mouse was scanned before administration of contrast agent to visualize the 
aortic arch without contrast enhancement. The groups were injected with either VCAM-1 or 
untargeted USPIO and scanned at two time points after injection: 1.5 hours and 6 hours. These 
time points had been determined from the pilot time course experiment to be the optimal time 
points for endothelial enhancement and intraplaque enhancement respectively. 
Imaging of plaque stage in ApoE-/- mice with carotid cuff 
3 groups (n=8) of 12-week-old male ApoE-/- mice were exposed to a Western diet (1% Cholesterol, 
Ab-diets, The Netherlands). Four weeks later, at the age of 16 weeks, a restrictive collar was placed 
around the left carotid artery, to mechanically induce the formation of atherosclerotic plaques 
around the collar. Mice were randomized for 3, 6 or 9 week follow-up of plaque formation, 
corresponding to early, intermediate and advanced plaque formation stages respectively. At each 
time point a group of 5 mice (group C1) was scanned before contrast agent injection and 1.5 and 
6 hours thereafter. The remaining mice (n=3, group C2) were sacrificed and the left carotid artery 
was dissected for western blot analysis. 
imaging of the effect of atorvastatin therapy on plaque development
Finally, 3 groups (n=5, group D) of 12-week-old male ApoE-/- mice were exposed to a Western 
diet with or without the addition of 0.01% wt/wt atorvastatin (Lipitor, Pfizer) (=0.1g statin / kg 
bodyweight) for a period of 4 weeks. After 4 weeks, at the age of 16 weeks, the restrictive collar 
was placed around the left carotid artery. Mice were randomized for 3, 6 or 9 week follow-up of 
plaque formation, subsequently mice were scanned 1.5 and 6 hours after i.v. injection of VCAM-
1 targeted USPIO.
Mri protocols
At the start of each in vivo examination, several 2D Fast Low Angle Shot (FLASH) scout images 
were recorded in the transverse and axial plane of the heart to determine the orientation of the 
aortic arch. 
A modified 2D FLASH sequence with a navigator echo (IntraGate, Bruker) was used for retrospective 
CINE MRI with the following parameters: 
T1 weighted images: hermite-shaped RF pulse 1 ms; FA 15°; TR 31.4 ms; TE 2.96 ms; navigator 
echo points 64; 10 cardiac frames; FOV 1.8*1.8 cm2 ; matrix 128*128; in-plane resolution 141 
μm; slice thickness 0.4 mm; number of repetitions 400.
T2* weighted images: hermite-shaped RF pulse 1 ms; FA 10°, TR 34 ms, TE 6 ms, navigator echo 
points 64; 10 cardiac frames; FOV 1.8*1.8 cm2 ; matrix 256*256; in-plane resolution 70 μm; slice 
thickness 0.4 mm; number of repetitions 400.
image Analysis
Images were analyzed using ImageJ software. Bright blood images were analyzed in 3 to 4 
adjacent cross-sectional slices through the aortic arch as described previously ((23)in press). ROIs 
were semi-automatically drawn around the vessel wall (Iwall) in all 10 movie frames. A 2nd ROI was 
drawn in the surrounding muscle tissue of the shoulder girdle (Imuscle). Furthermore, an ROI was 
placed outside the animal to measure the noise level (SDnoise). 
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The contrast–to-noise ratio was defined in the 3 to 4 adjacent bright-blood movie frames as 
following:
Cnr= (iwall – imuscle) / sDnoise       [eq1] 
which is a measure to what extend the lesioned wall can be discriminated from the surrounding 
tissue. 
histology
Mouse Tissue
After MRI, mice were terminally anesthetized with a intraperitoneal injection of 5 mg/kg midazolam 
(dormicum®, Roche), 0.5 mg/kg medetomidine (domitor®, Orion corporation, Finland) and 0.05 
mg/kg fentanyl (Janssen-Cilag, Belgium) followed by transcardial perfusion with saline; arteries 
were taken out for histological validation. Aortic arches and carotid arteries were frozen in Tissue 
Tek® (Sakura Finetek Europe, Zoetermeer, The Netherlands) and cut into serial 5 μm sections. 
Sections were stained with Oil Red O for lipid deposition and counterstained with hematoxilin, 
followed by bright-field microscopy. Iron deposits were visualized using Perl’s Prussian blue 
method with DAB enhancement as described previously24. Slides were first incubated with fresh 
2% potassium ferrocyanide (Sigma Aldrich) in water, mixed with equal volumes of 2% hydrochloric 
acid for up to 20 minutes at room temperature. Slides were washed, incubated in methanol/H2O2 
and subsequently the iron staining was enhanced using 3,3’-diaminobenzidine (DAB) (Sigma-
Aldrich). Slides were counterstained with nuclear fast red (Vector Laboratories, Burlingame, USA), 
and mounted in Vectashield (Vector laboratories).
VCAM-1 was visualized by incubating the sections overnight with rabbit-anti-mouse VCAM-1 
(Santa Cruz, H276). Slides were subsequently incubated with biotinylated goat-anti-rabbit (Vector 
laboratories Inc, United Kingdom) in 1.5% goat serum (Vector Laboratories Inc., United Kingdom). 
Biotin labelling was followed by development using red alkaline phosphatase substrate (Vector 
Laboratories Inc., United Kingdom) according to the manufacturer’s instructions, and as described 
in ((25) in press). Counterstaining was performed with Mayer’s hematoxylin.
Human coronary artery
Human left anterior descending (LAD) coronary artery was obtained post-mortem. Approval was 
given by the Institutional Review Board of the Erasmus MC, and informed consent was obtained. 
The LAD was frozen in Tissue Tek® and cut into serial 5 μm sections. Oil Red O and 
immunohistochemical staining for CD31/CD34 (clone Jc/70A, Abcam and QBEND-10, Sanbio) 
as well as CD68 (clone KP1, Abcam) was performed, followed by light microscopical analysis. 
Furthermore, slices were incubated for 30 minutes with 5 μM VCAM-1 or control USPIO, followed 
by Prussian blue iron staining as described above.
Western immunoblotting for VCAM-1
Left carotid arteries from group C2 were cleaned and homogenized in cold lysis buffer (100 
mmol/L K2HPO4, 1 mmol/L phenylmethylsulfonyl fluoride, and 0.2% Triton X-100). Protein 
concentration was determined by the bicinchoninic acid (BCA) protein assay (Pierce) using bovine 
serum albumin (2 mg/ml, Pierce, USA) as a standard. Equal amount of protein preparations (10 
μg in 25μL buffer) were run on SDS–PAGE, using NuPage 12% Bis-Tris gels (Invitrogen), electro-
transferred overnight to polyvinylidene difluoride filter (PVDF) membrane (Hybond-P, GE 
Healthcare, the Netherlands). To reduce non-specific binding, the PVDF membrane was blocked 
for 1 h at room temperature with blocking buffer (ECL Advance blocking agent, GE Healthcare) 
in TBST solution composed of 10 mmol/l Tris-HCl, 0.05% Tween-20, 150 mmol/l NaCl, pH 8.0. 
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Thereafter, the PVDF membrane was incubated with primary antibodies diluted 1:50,000 in 
blocking buffer at room temperature for 60 min, washed four times in TBST solution, and incubated 
with horseradish peroxidase- conjugated secondary antibodies diluted 1:35,000 in blocking buffer 
at room temperature for 60 min. Bands were visualized with the enhanced chemiluminescence 
detection system (ECL Advance western blotting detection kit, GE Healthcare), exposed to X-ray 
film (GE Healthcare).
Molecular band intensity (arbitrary units relative to β-actin) was determined by densitometry using 
ImageJ. Primary antibodies used were: rabbit-anti-mouse VCAM-1 (Santa Cruz, H276) and rabbit- 
anti-mouse β-actin (Santa Cruz). Secondary antibody used was goat anti-rabbit IgG conjugated 
to HRP (Santa Cruz Biotechnology).
Blood half life
Blood circulation half-lives were determined for both USPIO using 2 groups of n=5 (group E) 
12-14 months old ApoE-/- mice. Blood samples from the tail vein were collected in heparin-coated 
vials at regular intervals before and up to 48 hours after contrast agent administration (0h, 15, 30, 
45 min, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 32h, 40h, 48h). T1 values of plasma samples and 
USPIO were determined using a saturation recovery protocol (multi slice multi echo (msme) 
sequence) with the following parameters: TE 7 ms, TR: 25-20-15-10-8-6-5-4-3-2-1.6-1.2-1.0-
0.8-0.6-0.4-0.3 s, excitation hermite 1 ms, ref hermite 0.75 ms, band width 100kHz, matrix 
128*128, resolution (195)2 μm, 2*1mm slices. 
The T1 values of the various ROIs were determined using a 3-parameter fit function: 
M(t) = M0 (1-exp (-t/t1)) [eq2]
T2 was measured using a MSME sequence with TR 2000 ms, TE 9-300 ms in 32 steps. hermite-
shaped RF pulse 1 ms, ref hermite 0.75 ms, BW 100kHz, matrix 128*128, resolution (195)2 μm, 
2*1mm slices. The T2 values of the various ROIs were determined using
M[t]=M0*exp(-t/t2) [eq3]
The change in the relaxation rate (ΔR2) of the blood over time was determined by:
Δr2,blood(t)  = (1/t2,blood(t)- 1/t2,blood(0) [eq4]
The ΔR2 change over time was fitted using a mono-exponential decay function: 
Δr2,blood(t)   = Ae-ln(2)t/t1/2 [eq5]
where A is the initial R2 change upon USPIO injection, and t1/2 is the circulation half-life of USPIO 
in the blood. 
soluble VCAM-1 measurements 
At baseline and after 2 and 4 weeks, serum concentrations of sVCAM-1 from all mice at a Western 
diet with or without the addition of atorvastatin (group C1 and D) were determined with an ELISA 
kit from R&D Systems (Minneapolis, MN, USA) according to the manufacturer’s protocol.
statistical analysis
Data are presented as the mean ± standard deviation. Statistical analysis was performed using 
SPSS 15.0 ANOVA for computations within and between groups. Results were considered 
statistically significant at p < 0.05.
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RESultS
VCAM-1 expression in atherosclerotic plaques
Understanding the spatial and temporal expression patterns of atherosclerosis markers may result 
in identification of novel diagnostic cues to tailor atherosclerosis therapy. The extracellular adhesion 
molecule VCAM-1 is reported to be present at atherosclerosis-prone sites in humans even before 
macroscopic disease is apparent, with persistent expression in more advanced lesions11-13. 
To assess whether the VCAM-1 expression patterns observed in human plaques can be recapitulated 
in a mice model suitable for longitudinal MRI studies we placed a constrictive collar around the 
left carotid artery in hypercholesterolemic ApoE-/- mice (figure 1A). In these mice plaque 
development around the collar is progressive over the course of several weeks and well 
characterized26. Histological H&E stained sections of typical plaques proximal to the collar are 
shown in figure 1B, corresponding histological measurement of plaque area is shown in figure 
1C. In early plaques, the presence of VCAM-1 was confined to the luminal area (endothelium) 
(figure 1D). As the atherosclerotic lesion progressed, VCAM-1 positive areas were visible inside 
the plaque (figure 1E&F). This mouse model thus allows for a controlled induction of early and 
advanced lesions together with a changing VCAM-1 pattern. Western blot analysis of carotid artery 
homogenates confirmed our histological finding that total VCAM-1 protein expression increases 
significantly during collar-induced plaque development (figure 1G).
figure 1 | VCAM-1 expression in atherosclerosic lesions. A1. Schematical depiction of the left carotid artery with a 
collar. The areas with stimulated plaque development are indicated in red. The grey arrow (corresponding 
to the green arrow in panel A3) points at the region we used for planning the MRI imaging plane as well 
as the histological sections. A2. Photo of a collar in situ in an ApoE-/- mouse directly after placement. A3. 
Angiogram of the arterial tree after placement of a collar. B. H&E stainings of sections of the left carotid 
artery of ApoE-/- mice 3, 6 and 9 weeks after collar placement. C. Histological measurement of the plaque 
size. D, E and F. VCAM-1 immunohistochemical staining of the left carotid artery of ApoE-/- mice 3, 6 and 
9 weeks after collar placement respectively. G1. Western blot for VCAM-1 and β-actin of an undiseased 
carotid artery and the left carotid artery of ApoE-/- mice 3, 6 and 9 weeks after collar placement. G2. 
Quantification in arbitrary units of the VCAM-1 Western blot shown in panel G1.
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We14-16 and others17-21 have already successfully demonstrated that VCAM-1 targeted nanoparticles 
can detect atherosclerotic plaques and other inflammatory processes using MRI or nuclear 
techniques. Here, we attempt to take VCAM-1 imaging to the next level by assessing the feasibility 
of in vivo intraplaque and endothelial VCAM-1 imaging, and its relation to plaque development 
and therapy response.
Relaxivity of USPIO at 9.4T
Relaxivity measurements yield information on the strength of the contrast agent at a given MRI 
field strength. The r1 and r2 relaxivity were calculated based on relaxation time measurements at 
9.4T. VCAM-1 USPIO r1 relaxivity was 0.850 s-1 mM-1 and r2 121.8. s-1 mM-1 versus r1 of 0.948 s-1 
mM-1 and r2 of 131.46. s-1 mM-1 for control USPIO at 37˚C respectively (Table1). The r2/r1 ratio 
was 141.95 and 138.6 for VCAM-1 USPIO and control USPIO respectively, indicating that these 
particles will result mainly in T2 and T2* contrast. 
Blood half-life in aged ApoE-/- mice
Next, we assessed the in vivo properties of the VCAM-1 and control USPIO in aged ApoE-/- mice. 
Blood samples obtained at different time points after intravenous injection were used to measure 
the blood circulation half-life of VCAM-1 and control USPIO. Relaxation rates (R2) of the different 
blood samples were measured and T1/2 was calculated accordingly. Control USPIO had a blood 
circulation half-life of ~7.5 ± 0.8 hours. VCAM-1 USPIOs had a slightly shorter blood circulation 
half-life of 5.9 ± 1.3 hours (Table 1). 
Atherosclerotic plaque detection in aged Apoe-/- mice 
Having established the compound kinetics, we assessed the in vivo targeting of plaques in the 
aortic arch of 12-14 months old ApoE-/- mice. Before USPIO injection, the contrast to noise 
ratio (CNR) of atherosclerotic plaques in the aortic arch to surrounding muscle was -2.75 ± 
0.85, and plaques were not easily discernible on T1 or T2* weighted images (figure 2A T1 
weighted image). As early as 0.5 hours after injection, VCAM-1 USPIO caused a marked MRI 
contrast effect in the inner curvature of the aortic arch, evident as focal hypointense areas on 
T2*-weighted self-gated images of the aortic arch (figure 2B). The contrast enhancement 
persisted for over 24 hours and was observed in atheroprone areas, as confirmed by post-
mortem Oil Red O stainings of the same animals (figure 2C and 2D). At the earliest time points, 
however, the blood plasma levels were too high to clearly visualize the vessel wall (figure 2B). 
The largest difference in contrast enhancement of VCAM-1 USPIOs compared to control 
USPIOs was observed at 1.5 hours after intravenous injection (figure 2E). 
table 1. Ex vivo relaxivity measurements, in vivo circulation half-time and peak contrast enhance-
ment of VCAM-1 and control usPio at 9.4t.
VCAM-1 usPio Control usPio
r1 (s-1 mM-1) 0.858 0.948
r2 (s-1 mM-1) 121.816 131.46
T1/2 (hours) 5.9 ± 1.3 7.5 ± 0.8 
Peak contrast in vivo (hours) 1.5
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At this time point the USPIO accumulation could mainly be observed at the endothelium, as 
illustrated by the iron staining of the aortic arch (figure 2F). Note that USPIO binding is only 
observed in the areas with atherosclerotic lesions, not on the contralateral side of the artery. 
As it takes time for USPIOs to infiltrate a plaque, we postulated that imaging later after injection 
would favor imaging of intraplaque binding. Imaging 6 hours after injection unveiled higher 
VCAM-1 USPIO uptake inside the plaque as illustrated by iron staining of the aortic arch harvested 
immediately after MRI at the 6 hour time point (figure 2G). 24 hours after injection, the CNR in 
the lesional areas is still high, but did not differ significantly anymore between control and VCAM-
1 USPIO injected ApoE-/- mice, indicating that passive USPIO accumulation is dominating the 
enhancement at this stage. 
Plaque staging - endothelial versus intraplaque VCAM-1 imaging
We used the hypercholesterolemic ApoE-/- mouse model with a constrictive collar to assess whether 
it is possible to differentiate early from more advanced lesions using VCAM-1 targeted USPIO.
CNR was determined on T2*-weighted MRI 1.5 and 6 hours after VCAM-1 USPIO injection at 3, 
6 or 9 weeks after collar placement in different groups to assess early, intermediate or late plaque 
stages respectively (figure 3A). Highest decrease in CNR on 1.5 hour post-injection MR images 
(early) was observed 3 weeks after collar placement, i.e. in an early plaque stage. The CNR change 
became smaller with plaque progression. 9 weeks after collar placement the CNR shows an 
figure 2 | Atherosclerotic plaque detection in Apoe-/- mice with VCAM-1 usPio. A. T1 weighted MRI of the aortic 
arch of a 12-14 months old ApoE-/- mouse without injection of USPIO. B. T2* weighted MRI of the same 
aortic arch as in panel A, 30 minutes after VCAM-1 USPIO injection. C. Contrast enhancement on the 
innercurvature of the aortic arch 24 hours after VCAM-1 USPIO injection. The green arrow points at a 
plaque region. D. Corresponding Oil Red O staining of the aortic arch and descending aorta of a 12-14 
months old ApoE-/- mouse. E. Iron staining of an atherosclerotic lesion in the aortic arch 1.5 hours after 
VCAM-1 USPIO injection. F. Kinetics in Contrast to Noise Ratio(CNR) after injection of either control or 
VCAM-1 targeted USPIO. A zoom of a selection of time points is shown for clarity. In red are the optimal 
imaging time points 
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opposite trend, with advanced plaques, having a larger CNR change than early lesions at 6 hours 
after injection. The ratio of the late (6h) over early (1.5h) CNR is indicative for the plaque stage in 
this model (figure 3B). In the collar-induced plaque model an early plaque was characterized by 
a late/early ratio <1, whereas advanced plaques had a ratio > 1.5.  
Immediately after MRI, the left carotid arteries were harvested for immunohistochemical 
assessment of VCAM-1 USPIO distribution and VCAM-1 distribution. Areas with positive staining 
for VCAM-1 were shown to be associated with areas where VCAM-1-USPIO was present (figure 
3C). We found a significant correlation (R2 = 0.6945, p<0.001) between the in vivo VCAM-1 USPIO 
enhancement (CNR ratio on T2*w-MRI) and ex vivo VCAM-1 density in the plaque respectively 
(figure 3D) 
Atorvastatin therapy
To assess the potential of VCAM-1 targeted molecular imaging for therapy follow-up, ApoE-/- mice 
were fed a Western diet supplemented with atorvastatin. The mice were injected with VCAM-1 
targeted USPIO at 3, 6 or 9 weeks after collar placement, and as before MRI was performed 1.5 
and 6 hours after contrast agent injection.
Statin treatment significantly decreased the CNR change of VCAM-1 USPIO at 1.5 hours after 
injection (figure 4A), indicating reduced VCAM-1 USPIO binding to the endothelial layer in the left 
carotid artery in all plaque stages. The effect of statin therapy on the CNR at 6 hours after injection 
was even more pronounced, with CNR changes becoming significantly smaller over time, 
indicating reduced intraplaque targeting (figure 4A). The late/early CNR ratio after therapy was 
figure 3 | VCAM-1 targeted imaging of different stages of atherosclerosis. A. CNR measured 1.5 and 6 hours after 
VCAM-1 USPIO injection in carotid arteries of ApoE-/- mouse with a collar around the left carotid artery at 
3, 6 and 9 weeks after placement. B. Ratio of late versus early imaging time points CNR in carotid arteries 
of ApoE-/- mouse with a collar around the left carotid artery at 3, 6 and 9 weeks after placement. C. 
Immunohistochemical assessment of VCAM-1 (in red) and VCAM-1 USPIO (in brown) staining in the carotid 
artery of ApoE-/- mice. D. Correlation between the in vivo VCAM-1 USPIO enhancement signal and the ex 
vivo VCAM-1 density in the plaque.
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figure 4 | VCAM-1 targeted imaging for atorvastatin therapy follow-up. A. CNR measured 1.5 and 6 hours after 
VCAM-1 USPIO injection in carotid arteries of ApoE-/- mouse with a collar around the left carotid artery at 
3, 6 and 9 weeks after placement. Mice were either fed a Western diet (dotted bars) or a Western diet 
supplemented with atorvastatin (striped bars). B. Late/early imaging ratio to assess the plaque phenotype 
in mice with a collar around the left carotid artery. Mice were either fed a Western diet (white bars) or a 
Western diet supplemented with atorvastatin (grey bars). C. Immunohistochemical measurement of the 
plaque area in plaques in the carotid artery at 3, 6 and 9 weeks after collar placement, with (grey bars) or 
without (white bars) atorvastatin treatment respectively. D. VCAM-1 staining in an atherosclerotic lesion 
after atorvastatin treatment. E. Circulating sVCAM-1 levels determined by ELISA in plasma samples taken 
at baseline, 4, 7, 10 and 13 weeks of diet exposure.
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around 1 during all time points, indicating a less advanced plaque phenotype (figure 4B). 
Immunohistochemical assessment of plaque area showed that plaque growth was reduced (figure 
4C). Also VCAM-1 expression was less prominent in the atorvastatin-treated mice compared to 
the control mice, with the largest effect inside the plaque (figure 4D). 
Atorvastatin potentially could affect the amount of VCAM-1 shedding into the blood stream, 
thereby influencing the kinetics and binding potential of VCAM-1 USPIO. Therefore, we assessed 
soluble VCAM-1 levels in plasma samples taken at 4, 7, 10 and 13 weeks of Western diet exposure, 
but no significant differences in circulating VCAM-1 were observed between treated and non-
treated animals (figure 4E).
Confirmation of VCAM-1 imaging of atherosclerotic lesions in humans
As initial evidence of the potential for VCAM-1-USPIO imaging in humans, we incubated human 
obduction material of a LAD with both USPIO. Typical USPIO binding could be observed on the 
surface of an atherosclerotic plaque after incubation with VCAM-1 USPIO (figure 5A) in areas 
where VCAM-1 could be detected by immunohistochemistry (figure 5B) but not after incubation 
with control USPIO (figure 5C). Plaque morphology was further illustrated using Oil Red O (figure 
5D), macrophage content by CD68 staining (figure 5E), and endothelium by CD31 staining 
(figure 5F).
 
figure 5 | VCAM-1 usPio imaging on human vessels. A. Prussian blue staining of VCAM-1 USPIO that were incubated 
on a human LAD. Arrows point at DAB positive areas with clusters of USPIO. B. VCAM-1 immunostaining 
on human LAD. C. Prussian blue staining of control USPIO that were incubated on a human LAD. Arrows 
point at DAB positive areas with clusters of USPIO. Plaque morphology was further illustrated using D. Oil 
Red O E. CD68 staining and F. CD31 staining (figure 5E).
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DISCuSSIoN
feasibility of VCAM-1-targeted molecular imaging 
In the current study we successfully demonstrated the feasibility of endothelial and intraplaque 
VCAM-1 MR imaging in an ApoE-/- mouse model of atherosclerosis using VCAM-1 USPIO. The 
biodistribution of VCAM-1 USPIO proved favorable: VCAM-1 was specifically visualized at the area 
of atherosclerotic plaques, whereas contrast enhancement in undiseased vessels and the blood 
pool (at the optimal imaging time points) signal were low. VCAM-1 USPIO selectively targeted 
areas of atherosclerotic plaque with high VCAM-1 expression, as confirmed by histology. 
Early stage atherosclerotic plaques showed the largest contrast change at 1.5 hours after VCAM-
1 USPIO injection. The reverse was true for advanced lesions: the largest contrast change was 
observed at 6 hours after injection of VCAM-1 USPIO. The ratio between early and late 
enhancement provides a reliable measure of plaque progression.
Atorvastatin treatment, known to reduce VCAM-1 expression27, diminished VCAM-1 USPIO 
accumulation in vivo. 
The dose of USPIO administered in our study was 0.05 mmol Fe/kg body weight (corresponding 
to 2.8 mg/kg body weight), which is similar to that used clinically for non-targeted iron contrast 
agents in oncological imaging (2.6 mg/kg)28 and significantly lower than some ultrasmall 
particles of iron oxide doses used experimentally for imaging animal models such as rabbits 
(11–56 mg/kg)29. 
role of VCAM-1 in atherosclerosis
The recognition that inflammation drives the development and complication of atherosclerosis 
offers several potential imaging targets; vascular cell adhesion molecule-1 (VCAM-1) has gained 
considerable attention in this regard. Furthermore, like many other diseases, atherosclerosis is 
most amenable to treatment at an early stage. Efforts are underway to create novel therapies 
aimed at interrupting the inflammatory events that initiate plaque formation. If treatment is to be 
initiated years to decades before atherosclerosis becomes clinically evident, then a method for 
accurately detecting vascular inflammation is a critical asset.
Lipid lowering (LDL) with statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) 
is an established therapy in the primary and secondary prevention of atherosclerotic disease30. 
Although the LDL lowering does not occur in ApoE-/- mice31, 32 statins also have beneficial effect 
on the inflammatory process involved in atherosclerosis plaque formation and progression both 
in mice and men33. As VCAM-1 is one of these markers of inflammation, we used this well-known 
clinical drug, atorvastatin, to assess treatment response in ApoE-/- mice with different plaque 
stages.
Previous studies on VCAM-1 imaging have used several different molecules like affinity ligands 
detected by ultrasound (coupled to microbubbles)34, 35, by MRI (attached to iron oxides16, 18, 20, 36 or 
using F-1937), or by nuclear imaging (derivatized with F-1821). This earlier work provided evidence 
for the feasibility in several imaging modalities, addressed the imaging of therapeutic efficiency, 
and explored a variety of applications. Our work is unique in the sense that we apply a VCAM-1 
targeted USPIO to differentiate early from advanced atherosclerotic lesions by tuning the imaging 
timing to detect different origins of contrast enhancement. 
endothelial and intraplaque VCAM-1 expression 
Understanding the spatial and temporal expression patterns of atherosclerosis markers may result 
in identification of novel diagnostic cues to tailor atherosclerosis therapy. The extracellular 
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adhesion molecule VCAM-1 is present at atherosclerosis-prone sites in humans even before 
macroscopic disease is apparent, with persistent expression in more advanced lesions11-13. In later 
plaque stages, VCAM-1 expression shifts from the endothelial layer to lesional macrophages and 
smooth muscle cells. The collar model used in this study results in VCAM-1 expression patterns 
that closely resemble the expression during human plaque development.
The early induction, confinement of expression to atherosclerotic lesions, and accessible position 
in proximity to the blood pool render VCAM-1 an attractive imaging biomarker for early stage 
plaque identification. Moreover, the presence of the adhesion molecule on lesional macrophages 
and smooth muscle cells in later plaque stages make VCAM-1 an attractive candidate to image 
advanced atherosclerotic plaques. 
While the role of VCAM-1 as mediator of monocyte chemotaxis is rather well understood9, 13, 
the role of VCAM-1 expression inside the plaque in advanced lesions remains speculative. 
VCAM-1 expressed by vascular smooth muscle cells (SMCs) may facilitate the accumulation 
of transmigrated leukocytes within the vascular wall13. Indeed, in advanced human plaques, 
VCAM-1 expression is not often observed on the endothelial cells in the arterial lumen, but it 
is prevalent at the base of plaques38, 39. VCAM-1 expression on SMCs in the intima and media 
is most prominent in fibrous plaques and advanced atherosclerotic lesions40. Macrophages on 
the other hand are known to express VCAM-1 in lipid-containing plaques41, implying that no 
clear VCAM-1 expression pattern is associated with either stable or unstable atherosclerotic 
lesions. 
Despite the lack of knowledge of the exact role of intraplaque VCAM-1, response to therapy 
can be evaluated using this VCAM-1 specific contrast agent. VCAM-1 USPIO could theoretically 
be useful in patients in which atherosclerotic lesions already have been identified with 
conventional imaging techniques. In these patients, VCAM-1 USPIO could serve as a tool for in 
vivo differentiation between early lesions and more advanced potentially “unstable” 
atherosclerotic lesions. In our study, we started atorvastatin therapy at an early plaque stage, 
thereby preventing plaque growth and reducing the pro-inflammatory status. Clinically, it would 
be of interest to study the effect of statins on the inflammatory response in more advanced 
plaques, to be able to follow longitudinally whether a reduction in VCAM-1 expression is (directly) 
associated with a reduced risk for vascular events.
Comparison to other VCAM-1 targeting imaging agents
One of the most successful applications of VCAM-1 contrast agents thus far has been the 
development of 18F-4V, a hybrid PET-CT tracer, by Nahrendorf et al21. While PET has higher 
detection sensitivity (picomolar range) than MRI, and better tissue penetration than ultrasound 
or OCT, the disadvantages of PET are its limited spatial resolution, logistics of isotope provision, 
substantial radiation exposure and costs. Similar to our findings, endothelial targeting of 18F-4V 
is optimal between 60-120 minutes after injection. However, because of the short blood half-
life of 18F-4V and the fast decay of the radio isotope, intraplaque targeting is not feasible with 
this compound. 
For molecular MR imaging of endovascular VCAM-1, large iron oxide particles (MPIO) have proven 
to be very useful42. The relatively large size of MPIO makes them less susceptible to non-specific 
uptake than smaller particles43, thus retaining specificity for endothelial molecular targets. However, 
this is at the same time the major disadvantage for plaque staging with these particles, as they 
are not taken up into the plaque. Their use thus remains restricted to the detection of early pro-
inflammatory plaques. 
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Study limitations
The exact role of VCAM-1 in the development and progression of atherosclerotic plaques in 
ApoE-/- mice has not been fully elucidated. Whether the expression of VCAM-1 on vascular smooth 
muscle cells and macrophages in advanced lesions represents a marker of stability, instability or 
only of lesion stage is a matter of ongoing research. 
While the current preclinical findings are encouraging, a number of hurdles must be overcome 
before agents such as VCAM-1 USPIO can be used clinically; perhaps the most important will be 
the development of fully biodegradable USPIO, together with full toxicological testing of the 
humanized and biodegradable agent
CoNCluSIoN
This study demonstrated that molecular MRI using VCAM-1 USPIO allows selective imaging and 
quantification of endothelial and intraplaque VCAM-1 expression in ApoE-/- mice. VCAM-1 targeted 
imaging may therefore be a useful approach for in vivo detection and staging of atherosclerotic 
lesions, as well as for monitoring of a therapeutic response.
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AbStRACt
rationale
Molecular imaging using specific markers for atherosclerotic plaque stage may substantially 
improve the diagnosis, monitoring and treatment of atherosclerosis. E-selectin is weakly expressed 
in healthy vessels but rapidly induced on vascular endothelium in early atherosclerotic plaques 
with increasing expression during plaque progression. We hypothesized that E-selectin targeted 
ultrasmall particles of iron oxide (E-selectin USPIO) would be a suitable candidate for molecular 
MRI of atherosclerotic plaque composition and stage.
Methods and results
We assessed E-selectin USPIO uptake in aortic arch plaques of aged ApoE-/- mice, and in collar-
induced plaques in carotid arteries of young ApoE-/- mice. MRI performed 1.5 hours after i.v. 
injection of E-selectin USPIO showed enhanced uptake of the contrast agent (CA) on the vessel 
wall in aged mice. Uptake of E-selectin USPIO 1.5 h after injection was significantly increased in 
mice 3 weeks post collar placement. At later stages after collar placement we observed a higher 
change in CNR. Passive USPIO uptake imaged 24 hours after USPIO injection gradually increased 
with increasing plaque size. To test the potential of E-selectin USPIO to monitor therapy response, 
ApoE-/-mice were exposed to a western diet with or without atorvastatin or fenofibrate. Mice on 
western diet had large, advanced plaques with a high E-selectin expression. Atorvastatin therapy 
reduced both plaque burden as well as E-selectin expression on the endothelium. Mice treated 
with fenofibrate had a smaller change in E-selectin CNR at 1.5 hours after USPIO injection but 
not less late CA uptake.
Conclusion
E-selectin targeted USPIO holds great promise for in vivo non-invasive determination of 
atherosclerotic plaque composition, progression and stage. Ultimately this technology might be 
an effective tool for diagnosis and monitoring of disease progression in patients.
 
INtRoDuCtIoN
Atherosclerosis is a complex arterial disease that affects the large and medium-sized arteries. 
Cholesterol deposition, oxidative stress, degradation of the extracellular matrix, chronic 
inflammation, and thrombus formation all play major roles in progression towards clinical events1. 
The disease is quickly becoming the leading cause of mortality worldwide, accounting for a fifth 
of all deaths2, 3. Disease progression is usually slow and remains asymptomatic until stenosis occurs 
and thereby reduced blood supply, or a plaque rupture occurs precipitating clinical events resulting 
in myocardial infarction or stroke. 
Today’s clinical imaging technologies focus on the severity of luminal narrowing, yet do not 
provide information on plaque composition4. However, the anatomical severity of stenosis is not 
sufficient to predict the risk of vascular events5. A priori detection of vulnerable or advanced 
lesions is an increasing clinical need, requiring molecular imaging techniques that provide 
information on plaque composition and the biological processes associated with progression 
and destabilization. Because of its high anatomical details, magnetic resonance imaging (MRI) 
has emerged as a promising technique for both the direct assessment of plaque burden and the 
evaluation of plaque composition6, 7.
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In atherosclerosis, a vast range of molecular targets is expressed both at the endothelial surface 
and within the vessel wall with a differential expression from early lesions to advanced and 
vulnerable plaques. One of these markers is E-selectin (CD-62E), an endothelial cell adhesion 
molecule expressed on activated endothelium involved in the recruitment of leukocytes8. 
E-selectin is expressed in the endothelium of human atherosclerotic lesions, particularly when 
lesions are associated with subendothelial leukocytic infiltrates9, 10. An et al. have described that 
Gr1+/Ly6Chigh “pro-inflammatory” monocytes preferentially accumulate at sites of endothelial 
activation and thrombosis11, leading to the accumulation of lipid-laden macrophages in apoE-
deficient (ApoE-/-) mice12. The extent of E-selectin expression is related to atherosclerosis 
development. Soluble E-selectin levels, like other inflammatory markers, is of prognostic value 
for cardiovascular risk prediction13. Also within the plaque, inflammation, particularly monocyte 
and macrophage infiltration at plaque rupture-sensitive sites (i.e. fibrous cap and areas of erosion) 
has been shown to be associated with plaque vulnerability14-16. 
Previously, we and others have provided proof-of-concept for E-selectin targeted MRI contrast 
agents to image endothelial activation in inflammation17-20. Here we tested the ability of the 
E-selectin targeted USPIOs to detect progression of atherosclerotic lesions. We assessed active 
targeting of E-selectin using sialyl Lewis X (sLeX) USPIO and control particles by imaging 1.5 hours 
after USPIO injection. Secondly, we hypothesized that these particles are being engulfed by 
macrophages whether they are targeted or not. We therefore also imaged the same animals at 
24 hours, to assess the macrophage pool21, 22. Lastly, we treated groups of ApoE-/- mice with 
atarvostatin or fenofibrate, hypothetizing these therapies differentially influence the macrophage 
pool of atherosclerotic lesions, and assessed the potential of E-selectin targeted molecular 
imaging to monitor anti-atherosclerotic therapy. 
MAtERIAlS AND MEtHoDS
Contrast agents
USPIO-PEG750-sLeX was prepared as described previously by Radermacher et al.19 Briefly, 
nanoparticles with carboxylated groups on their surface were modified in 2 steps. Briefly, 
nanoparticles with carboxylated groups on their surface were first coupled to sLeX mimetic and 
then to AminoPEG750 by using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
as an activator reagent. After each step of conjugation, the mixture was ultrafiltered on a 30 kD 
membrane to remove low-molecular weight material. The control imaging probe was a USPIO 
vectorized with a non-specific peptide (USPIO-NSP). 
Mri hardware
All experiments were performed with a vertical 89-mm bore 9.4T magnet (Bruker, Ettlingen, 
Germany) supplied with an actively shielded Micro2.5 gradient system of 1T/m and a 30 mm 
transmit/receive birdcage RF coil, using Paravision 5.0 software. 
Animal experiments
The experiments were conducted in accordance with the Dutch guidelines for research animal 
care. Protocols were approved by the Dier Experimentele commissie (Committee for laboratory 
animal use) at the Leiden University Medical Center under DEC protocol number 10136. In total 
17 groups of n=5 male ApoE-/- mice were used for the experiments (see Table 1).
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Blood half life
Blood circulation half-lives were determined for the different USPIO using 2 groups (n=5) 12-14 
months old ApoE-/- mice (group A). Blood samples from the tail vein were collected in heparin-
coated vials at regular intervals before and up to 48 hours after contrast agent administration (0h, 
15, 30, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 32h, 40h, 48h). 
The change in longitudinal relaxation rate ΔR2  of the blood over time was determined by:
Δr2(t)  = 1/t2(t)- 1/t2(0)       [eq1]
The ΔR2 change over time was fitted using a mono-exponential decay function: 
Δr2(t)   = Ae-ln(2)t/t1/2       [eq2]
where A is the initial R2 change upon USPIO injection, and t1/2 is the circulation half-life of USPIO 
in the blood. 
Contrast enhancement over time
Optimal time points for plaque accumulation of both the E-selectin USPIO as well as the control 
USPIO were determined in 2 groups of n=5 (group B) 12-14 months old ApoE-/- mice in a pilot 
time-course study in which contrast agent accumulation was followed for 48 hours. Each mouse 
was scanned before administration of USPIOs and at several time points after intravenous injection 
of 0.05 mmol Fe/kg bodyweight in 200 μl dextrose solution. From 0-4 hours after USPIO injection 
mice were scanned every 30 minutes, and thereafter every 4 hours from 4-48 hours after injection. 
Mice were anesthetized during MRI with isoflurane (± 2% in oxygen and air). During the examination, 
the respiration rate was continuously monitored using a balloon pressure sensor connected to 
the ECG/respiratory unit (SA Instruments, New York). The isoflurane concentration was adjusted 
to keep the respiration rate between 50 and 90 respirations/min. 
table 1. overview of the experimental groups of Apoe-/- mice that were included in the study
experiment group nanoparticle time points Age Diet
Plasma half-time A1 (n=5)
A2 (n=5)
E-selectin USPIO 
control USPIO
16 
from 0-48h
12-14 
months 
Chow
Optimal imaging 
time point
B1 (n=5) 
B2 (n=5)
E-selectin USPIO
control USPIO
16 from 0-48h 12-14 
months 
Chow
Plaque imaging at 
1.5 & 24 hrs
C1 (n=5)
C2 (n=5)
C3 (n=5)
C4 (n=5) 
E-selectin USPIO
control USPIO
E-selectin USPIO
control USPIO
1.5h 
      
1.5h, 24h      
12-14 
months 
Chow
experiment group nanoparticle time after cuff Age start
Collar model 
plaque stages:  
MRI & histology
D1 (n=5) 
D2 (n=5) 
D3 (n=5) 
E-selectin USPIO
E-selectin USPIO
E-selectin USPIO
3 weeks
6 weeks
9 weeks
12 wks Western
Collar model 
plaque stages: 
western blotting
D4 (n=3) 
D5 (n=3) 
D6 (n=3) 
3 weeks
6 weeks
9 weeks
12 wks Western
experiment group nanoparticle treatment Age
Atorvastatin / 
Fenofibrate 
therapy
E1 (n=5) 
E2 (n=5) 
E3 (n=5) 
E-selectin USPIO
E-selectin USPIO
E-selectin USPIO
None
Atorvastatin
Fenofibrate
12-14 
months 
Western
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The optimal time point was defined as the time at which the highest contrast-to-noise ratio (see 
below) was observed.
Plaque imaging in aged ApoE-/- mice
4 groups (n=5 per group, group C) of 12-to-14-month-old male ApoE-/- mice on a C57BL/6/Jico 
background were fed a normal chow diet. Each mouse was scanned before administration of 
contrast agent to visualize the aortic arch without contrast enhancement. Two of these groups 
were injected with either E-selectin USPIO or control USPIO and scanned at the optimal time 
point for endothelial binding, 1.5 hours after contrast agent injection. The other 2 groups were 
also injected with E-selectin USPIO or control USPIO, but these animals were scanned at both 
1.5 hours and 24 hours after contrast agent injection.
Imaging of plaque stage in ApoE-/- mice with carotid collar
3 groups (n=8, group D) of 12-week-old male ApoE-/- mice were exposed to a Western diet (1% 
Cholesterol, Ab-diets, Woerden, The Netherlands). Four weeks later, at the age of 16 weeks, a 
restrictive collar was placed around the left carotid artery to mechanically induce the formation 
of atherosclerotic plaques around the collar. Mice were randomized for 3, 6 or 9 week follow-up 
of plaque formation, corresponding to early, intermediate and advanced plaque formation stages 
respectively. At each time point a group of 5 mice (group D1-D3) was scanned before contrast 
agent injection and at 1.5 hours and 24 hours thereafter. The remaining mice (n=3 per group, 
group D4-D6) were sacrificed and the left carotid artery was dissected for western blot 
analysis. 
Imaging the effect of atorvastatin or fenofibrate therapy on plaque inflammation
Finally 3 groups (group E) of 12-14 months old male ApoE-/- mice were exposed to a Western diet 
for 4 weeks. After a 4-hour fasting period, body weight was determined and EDTA plasma (Sarstedt, 
Nümbrecht, Germany) was collected via the tail vein. Total plasma cholesterol and triglyceride 
levels were measured (Roche Diagnostics, Almere, The Netherlands). Mice were randomized to 
3 treatment groups based on the cholesterol and lipid levels. Mice were subsequently exposed 
to E1: 4 weeks of Western diet, E2: Western diet with the addition of 0.01% wt/wt atorvastatin 
(=0.1g / kg bodyweight, Lipitor, Pfizer) or E3: Western diet with 0.05% w/w fenofibrate (= 0.1g / 
kg bodyweight, Abbott Laboratories) for a period of 4 weeks. After 4 weeks of treatment, body 
weight was determined and EDTA plasma was collected via the tail vein. The mice were scanned 
with the same MRI protocol and timing as described above after i.v. injection of E-selectin targeted 
USPIOs.
After the final MRI scan all mice were terminally anesthetized with a mixture of midazolam 
(dormicum®, Roche), medetomidine (domitor®, Orion corporation, Espoo, Finland) and fentanyl 
(Janssen-Cilag, Beerse, Belgium) followed by transcardial perfusion; arteries were taken out for 
histological validation.
Mri protocols
At the start of each in vivo examination, several 2D Fast Low Angle Shot (FLASH) scout images 
were recorded in the transverse and axial plane of the heart to determine the orientation of the 
aortic arch. 
A modified FLASH sequence with a navigator echo (IntraGate, Bruker) was used for retrospective 
CINE MRI with the following parameters: 
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T1 weighted images: hermite-shaped RF pulse 1 ms; FA 15°; TR 31.4 ms; TE 2.96 ms; navigator 
echo points 64; 10 cardiac frames; FOV 1.8*1.8 cm2 ; matrix 128*128; in-plane resolution 141 μm; 
slice thickness 0.4 mm; number of repetitions 400.
T2* weighted images: hermite-shaped RF pulse 1 ms; FA 10°, TR 34 ms, TE 6 ms, navigator echo 
points 64; 10 cardiac frames; FOV 1.8*1.8 cm2 ; matrix 256*256; in-plane resolution 70 μm; slice 
thickness 0.4 mm; number of repetitions 400.
relaxivity measurements
T1 measurements
T1 values of plasma samples and USPIO were determined using a saturation recovery protocol 
(multi slice multi echo (MSME) sequence) with the following parameters: TE 7 ms, TR: 25-20-15-
10-8-6-5-4-3-2-1.6-1.2-1.0-0.8-0.6-0.4-0.3 s, excitation hermite 1 ms, ref hermite 0.75 ms, band 
width 100kHz, matrix 128*128, resolution (195)2 μm, 2*1mm slices. 
The T1 values of the various ROIs were determined using a 3-parameter fit function: 
M(t) = M0 (1-exp (-t/t1)) [eq3]
T2 measurements
MSME sequence with TR 2000 ms, TE 9-300 ms in 32 steps. hermite-shaped RF pulse 1 ms, ref 
hermite 0.75 ms, BW 100kHz, matrix 128*128, resolution (195)2 μm, 2*1mm slices. The T2 values 
of the various ROIs were determined using
M[t]=M0*exp(-t/t2) [eq4]
image Analysis
Images were analyzed using ImageJ software. Bright blood images of 3 to 4 adjacent cross-
sectional slices through the aortic arch were analyzed. ROIs were semi-automatically drawn 
around the vessel wall (Iwall) in all 10 movie frames. A 2nd ROI was drawn in the surrounding muscle 
tissue of the shoulder girdle (Imuscle). Furthermore, an ROI was placed outside the animal to measure 
the noise level (SDnoise) (Figure 1). 
The contrast–to-noise ratio was defined in the 3 to 4 adjacent movie frames with the lowest 
signal intensity inside the vessel as following:
Cnr= (iwall – imuscle) / sDnoise  [eq5] 
which is a measure of how well the lesioned wall can be discriminated from the surrounding 
tissue. CNR are shown as mean ± standard deviation.
histology
Aortic arches and carotid arteries were frozen in Tissue Tek® (Sakura Finetek Europe, Zoetermeer, 
The Netherlands) and cut into serial 5 μm sections. Sections were stained with Oil Red O for lipid 
deposition, counterstained with hematoxilin and assessed by bright-field microscopy.
USPIO were visualized using the Perl’s Prussian blue method with DAB enhancement as described 
previously23. Slides were first incubated with fresh 2% potassium ferrocyanide (Sigma Aldrich, St 
Louis, MO, USA) in water mixed with equal volumes of 2% hydrochloric acid for up to 20 minutes 
at room temperature. Slides were washed, incubated in methanol/H2O2 and subsequently the 
iron staining was enhanced using 3,3’-diaminobenzidine (DAB) (Sigma-Aldrich). Slides were 
counterstained with nuclear fast red (Vector Laboratories, Burlingame, USA), and mounted.
For E-selectin staining slides were incubated overnight with rat-anti-mouse E-selectin (Pharmingen, 
San Diego, CA, USA), for macrophage staining slides were incubated with rat-anti-mouse F4-80 
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(clone A3-1, Serotec, Düsseldorf, Germany). Subsequently slides were incubated with horse radish 
peroxidase (HRP) -labelled or biotinylated goat-anti-rat (Vector laboratories Inc, Peterborough 
United Kingdom) in 1.5% goat serum (Vector Laboratories Inc.). Biotin labelling was followed by 
development using red alkaline phosphatase substrate (Vector Laboratories Inc.) according to 
the manufacturer’s protocol, and as described in den Adel et al24. HRP labeling was followed by 
3,3’-diaminobenzidine development. Counterstaining was performed with Mayer’s 
hematoxylin.
figure 1 | e-selectin expression in atherosclerotic lesions. A. E-selectin (red alkaline phosphatase) 
immunohistochemical staining of the aortic arch of a 12-14 months old ApoE-/- mouse, 40x magnification 
B Oil Red O staining of the aortic arch and descending aorta of a 12-14 months old ApoE-/- mouse depicting 
lesion areas in red. 2x magnification C-F. E-selectin DAB immunohistochemical staining of the left carotid 
artery of ApoE-/- mice before (C), 3 (D), 6 (E) and 9 (F) weeks after collar placement respectively. 40x 
magnifications. G. Western blot for E-selectin and β-actin of an undiseased carotid artery and the left 
carotid artery of ApoE-/- mice 3, 6 and 9 weeks after collar placement. Quantification in arbitrary units of 
the VCAM-1 Western blot is shown in the right-sided panel. * p< 0.05.
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Human coronary artery
Human left anterior descending (LAD) coronary artery was obtained post-mortem. Approval was 
given by the Institutional Review Board of the Erasmus MC, and informed consent was obtained. 
The LAD was frozen in Tissue Tek® and cut into serial 5 μm sections. Oil Red O, HE, RF and 
immunohistochemical staining for E-selectin and CD68 (clone KP1, Abcam) was performed, 
followed by light microscopical analysis. Furthermore, slices were incubated for 30 minutes with 
5 μM E-selectin or control USPIO, followed by Prussian blue iron staining as described above.
e-selectin Western blotting
Left carotid arteries from group D4-D6 were cleaned and homogenized in cold lysis buffer (100 
mmol/L K2HPO4, 1 mmol/L phenylmethylsulfonyl fluoride, and 0.2% Triton X-100). Protein 
concentration was determined by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, 
IL, USA) using bovine serum albumin (2 mg/ml, Pierce) as a standard. Equal amount of protein 
preparations (10 μg in 25μL buffer) were run on SDS–PAGE, using NuPage 12% Bis-Tris gels 
(Invitrogen, Carlsbad, CA), electro-transferred overnight to polyvinylidene difluoride filter (PVDF) 
membrane (Hybond-P, GE HealthcareDiegem, Belgium). To reduce non-specific binding, the 
PVDF membrane was blocked for 1 h at room temperature with blocking buffer (ECL Advance 
blocking agent, GE Healthcare) in TBST solution. Thereafter, the PVDF membrane was incubated 
with primary antibodies diluted 1:50,000 in blocking buffer at room temperature for 60 min, 
washed four times in TBST solution, and incubated with horseradish peroxidase- conjugated 
secondary antibodies diluted 1:35,000 in blocking buffer at room temperature for 60 min. Bands 
were visualized with the enhanced chemiluminescence detection system (ECL Advance western 
blotting detection kit, GE Healthcare), exposed to X-ray film (GE Healthcare).
Molecular band intensity (arbitrary units relative to β-actin) was determined by densitometry using 
ImageJ. Primary antibodies used were: rat-anti-mouse E-selectin (Pharmingen) and rabbit- anti-
mouse β-actin (Santa Cruz Biotechnology, Heidelberg, Germany). Secondary antibody used were 
goat anti-rat IgG and goat anti-rabbit IgG conjugated to HRP (Santa Cruz Biotechnology).
statistical analysis
Data are presented as the mean ± standard deviation. Statistical analysis was performed
using SPSS 15.0 ANOVA for computations within and between groups. Results were considered 
statistically significant at p < 0.05. 
 
RESultS
e-selectin expression on atherosclerotic plaques
The extracellular adhesion molecule E-selectin is reported to be present at atherosclerosis-prone 
sites in humans even before overt disease is apparent, with persistent expression concomitant 
with macrophage accumulation in more advanced lesions. We first assessed whether the E-selectin 
expression patterns observed in human plaques can be recapitulated in the ApoE-/- mice model 
often used for longitudinal MRI studies in atherosclerosis. Histological sections of the aortic arch 
confirmed the presence of E-selectin positive areas on the luminal side of the atherosclerotic 
lesion on the inner curvature of the aortic arch (figure 1A). Corresponding Oil Red O staining 
shows the lesional area on the inner curvature (figure 1B). In hypercholesterolemic ApoE-/- mice 
with a constrictive collar around the left carotid artery, plaque development around the collar is 
progressive over the course of several weeks and well characterized25. In control mice before 
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exposure to a Western diet no E-selectin was observed in the endothelium (figure 1C). In early 
plaques (3 weeks after collar placement), E-selectin was observed in the endothelium (figure 1D). 
As the atherosclerotic lesions developed and became larger, E-selectin positive areas were clearly 
visible in the endothelium and at the latest plaque stage also inside the plaque (figure 1E and 1F). 
Western blot analysis of aortic arch and carotid artery homogenates confirmed our histological 
findings that during plaque development, both spontaneous as well as after collar placement, 
total E-selectin protein expression increased significantly (figure 1G). This distinction in E-selectin 
expression allowed us to use the ApoE-/- mouse model to assess the feasibility of in vivo E-selectin 
imaging, and its relation to plaque development and therapy response.
Characterization of e-selectin usPio at 9.4t
Relaxivities were calculated from T1 and T2 relaxation time measurements to characterize the 
E-selectin and control USPIO at 400 MHz. E-selectin USPIO r1 relaxivity was 1.170 s-1.mM-1 and 
r2 212.78 s-1.mM-1 versus r1 of 0.948 s-1.mM-1 and r2 of 131.46 s-1.mM-1 for control USPIO at 37˚C 
respectively (Table 2). These values were well within expected ranges.
Blood half life
Next we assessed the in vivo properties of the E-selectin and control USPIO in ApoE-/- mice. Blood 
samples obtained at different time points after intravenous injection were used to measure the 
blood pool half-life of E-selectin and control USPIO. Relaxation rates (R2) of the different blood 
samples were measured and T1/2 was calculated according to equation 1 and 2. Control USPIO 
had a blood circulation half-life of ~7.2 ± 0.7 hours. The half-life of E-selectin USPIOs was similar 
at 6.63 ± 1.1 hours after intravenous administration in aged ApoE-/- mice (Table 2). 
imaging of e-selectin in aged Apoe-/- mice
We next addressed the potential of the E-selectin-USPIO to detect atherosclerotic lesions in aged 
male ApoE-/- mice. Before USPIO injection, the contrast to noise ratio (CNR) in the inner curvature 
of the aortic arch of 12 to 14-month-old ApoE-/- mice was low, and atherosclerotic plaques were 
not readily discernible from the surrounding tissue (figure 2A T1 weighted image). Shortly after 
USPIO injection, the CNR decreases and plaques can be discriminated from the surrounding tissue 
as focal hypointense areas. We followed the CNR of E-selectin USPIO to control USPIO over time 
to determine the optimal imaging window (figure 2B). The largest difference in contrast 
enhancement of E-selectin USPIO compared to control USPIO was observed between 1 and 2 
hours after intravenous injection (arrow in figure 2B). This time point is optimal for endothelial 
binding, as illustrated by the iron staining of the aortic arch 1.5 hours after injection (figure 2C). 
table 2. 
e-selectin usPio Control usPio
r1 (s-1 mM-1) 1.170 0.948
r2 (s-1 mM-1) 212.78 131.46
T1/2 (hours) 6.63 ± 1.1 7.2 ± 0.7 
Peak contrast in vivo (hours) 1.5-2 hours 24 hours
Ex vivo relaxivity measurements, in vivo circulation half-time and peak contrast enhancement of 
E-selectin and control USPIO at 9.4T. None of the values were significantly different between the 
two contrast agents.
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USPIO binding was not observed in non-diseased areas of the artery. The contrast enhancement 
in the plaques persisted for over 24 hours and was observed in areas where atherosclerotic lesions 
were detectable on Oil Red O staining (figure 2D and 1B). However, at 24 hours after injection, 
the CNR did not differ significantly anymore between control and E-selectin USPIO injected 
ApoE-/- mice (figure 2B), indicating that passive USPIO accumulation due to particle engulfment 
by macrophages inside the plaque is dominating the enhancement at this stage (figure 2E). We 
therefore chose this time point to image the plaque macrophage content.
Plaque staging
To assess the possibility to differentiate early from more advanced lesions using E-selectin 
targeted USPIOs we used the model of hypercholesterolemic ApoE-/- mice with a constrictive 
collar around the left carotid artery. CNR was determined on T2*-weighted MRI of the carotids 
at 1.5 and 24 hours after E-selectin USPIO injection, and at 3, 6 and 9 weeks after collar placement 
cross-sectionally to assess early, intermediate or late plaque stages respectively (figure 3A). 
We observed the highest CNR decrease at 9 weeks after collar placement for both the 1.5 hour 
scan and the 24 hour scan after E-selectin USPIO injection, indicating a progressive increase in 
both E-selectin expression on the endothelium and macrophage content in the plaque. 
figure 2 | Atherosclerotic plaque detection in Apoe-/- mice with e-selectin usPio. A. T1 weighted MRI of the aortic 
arch of a 12-14 months old ApoE-/- mouse without injection of USPIO. Arrow points at a plaque region in 
the inner curvature of the aortic arch.  A= aortic arch, L = lungs, * aortic valves, H=heart.  B. Kinetics of 
Contrast to Noise Ratio (CNR) after injection of either control or E-selectin targeted USPIO. The arrow 
represents the time point with highest CNR difference between control and E-selectin USPIO. C. DAB 
enhanced Iron staining (brown) of an atherosclerotic lesion in the aortic arch 1.5 hours after E-selectin 
USPIO injection, 40 x magnification. Arrows point at DAB positive areas D. Contrast enhancement on the 
inner curvature of the aortic arch 24 hours after E-selectin USPIO injection. The green arrow points at a 
plaque region with contrast enhancement in the inner curvature of the aortic arch. A= aortic arch, L = lungs, 
* aortic valves, H=heart.  E DAB enhanced Iron staining (brown) of an atherosclerotic lesion in the aortic 
arch 24 hours after E-selectin USPIO injection, 40 x magnification. Arrows point at DAB positive areas.
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Corresponding histological measurements of the plaque area proximal to the collar are shown 
in figure 3B, confirming the progressive increase in plaque development. This steady increase in 
CNR change was not observed in the contralateral right-sided carotid artery, where plaques also 
develop due to the Western diet, but slower and less predictable (figure 3C). Plaque size does not 
increase progressively in the right carorid artery, in line with the observation CNR change is not 
figure 3 | e-selectin targeted imaging of different stages of atherosclerosis. A. CNR measured 1.5 and 24 hours 
after E-selectin USPIO injection in carotid arteries of ApoE-/- mouse with a collar around the left carotid 
artery at 3, 6 and 9 weeks after placement. B. Histological measurement of the plaque size. C. CNR 
measured 1.5 and 24 hours after E-selectin USPIO injection in right collateral carotid arteries of ApoE-/- 
mouse (thus without a collar around the left carotid artery) at 3, 6 and 9 weeks after surgery. D. Histological 
measurement of the plaque size of the right carotid artery at 3, 6 and 9 weeks after surgery. E.Ratio of early 
versus late imaging time points CNR in carotid arteries of ApoE-/- mouse with a collar around the left 
carotid artery at 3, 6 and 9 weeks after placement. F. Immunohistochemical staining of the left carotid 
artery 24 hours after E-selectin USPIO injection, 9 weeks after collar placement.E-selectin in red (alkaline 
phosphatase, indicated by the arrow), and iron staining in brown (DAB, indicated with an asterisk).* p < 
0.05, ** p < 0.01 
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progressive with plaque progression (figure 3D). To generate a single measure of plaque stage, 
we calculated the ratio of early contrast enhancement over late enhancement, hypothesizing 
that late enhancement would be dominating as plaque stage progresses due to the mere bulk of 
the macrophage pool (figure 3E, histology in figure 3F). The calculated ratio indeed increased 
with progressing plaque stage. 
figure 4 | e-selectin targeted imaging of therapy follow-up. A. CNR was measured 1.5 and 24 hours after E-selectin 
USPIO injection in the inner curvature of the aortic arch of ApoE-/- mouse. Mice were either fed a Western 
diet (transparent bars) or a Western diet supplemented with fenofibrate (dotted bars) or a Western diet 
supplemented with atorvastatin (striped bars). B. Histological measurement of the plaque size after diet 
exposure. C. Oil Red O staining of the aortic arch and descending aorta of ApoE-/- mice exposed to a 
Western diet, a Western diet supplemented with atorvastatin, or a Western diet supplemented with 
fenofibrate. D. Plot depicting the relation between the plaque size of ApoE-/- mice after diet exposure on 
the innercurvature of the aortic arch and the histologically determined E-selectin density in the plaque. 
E. Percentage of F4-80 positive macrophages in the lesion area in the inner curvature of the aortic arch. 
F. DAB staining of F4-80 of a fenofibrate treated ApoE-/- mouse. * p < 0.05, ** p < 0.01
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Anti-atherosclerotic therapy
To assess the potential of E-selectin targeted molecular imaging for therapy follow-up, mice were 
exposed to two commonly prescribed anti-atherosclerotic drugs with a different mechanism of 
action. Aged male ApoE-/- mice were fed a Western diet for 4 weeks. After 4 weeks plasma lipids 
were measured (table 3) and mice were randomized into 3 groups that received another 4 weeks 
of Western diet, Western diet supplemented with atorvastatin or Western diet supplemented with 
fenofibrate.
Atorvastatin treatment significantly reduced both the early E-selectin-USPIO induced contrast 
enhancement as well as the late USPIO enhancement (figure 4A). In mice treated with fenofibrate, 
the early E-selectin USPIO induced CNR change 1.5 hours after contrast agent injection was also 
significantly reduced compared to untreated animals. However, the measurement 24 hours after 
E-selectin USPIO injection did not show a significant difference compared to untreated mice, 
suggesting that plaque size or macrophage content did not change after fenofibrate treatment 
(figure 4A). Immunohistochemical assessment of plaque area (Oil Red O) and E-selectin distribution 
confirmed the MRI results. After atorvastatin therapy, the lesion area was significantly reduced in 
mice exposed to a Western diet supplemented with atorvastatin compared to untreated mice 
(figure 4B). In contrast, lesion area in fenofibrate treated mice was not significantly reduced, 
although the lipid content was decreased (figure 4C). Presence of E-selectin on the endothelium 
was reduced in both atorvastatin and fenofibrate treated mice compared to the untreated mice 
(figure 4D). Macrophage content was significantly decreased in mice treated with atorvastatin, 
whereas the percentage of F4-80+ cells did not change with fenofibrate treatment compared to 
untreated Western diet fed mice (figure 4E and 4F). As expected, neither treatment resulted in a 
significant decrease of plasma lipids (Table 3).
table 3. Body weight and plasma lipids
Western diet Atorvastatin fenofibrate
At randomization
Body weight  (gram) 34.2 ± 1.8 33.9 ± 1.9 34.5 ± 2.1
Cholesterol    (mg/dL) 914 ± 24 923 ± 22 917 ± 27
Triglycerides  (mg/dL) 148 ± 12 147 ± 14 150 ± 16
At sacrifice
Body weight  (gram) 38.7 ± 2.1 * 31.4 ± 2.2 * 31.8 ± 1.9 *
Cholesterol    (mg/dL) 1094 ± 38 931 ± 27 925 ± 25
Triglycerides  (mg/dL) 179 ± 15 146 ± 14 144 ± 17
Body weight and plasma lipids of ApoE-/- mice were measured after 4 weeks of Western diet exposure, 
at randomization into 3 treatment groups, and 4 weeks later, at sacrifice. Atorvastatin treatment and 
fenofibrate treatment did not significantly influence plasma cholesterol or triglycerides. Body weight 
decreased significantly (*, p< 0.05) upon atorvastatin treatment as well as fenofibrate treatment, 
whereas Western diet exposure significantly increased the body weight compared to at 
randomization.
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Confirmation of e-selectin imaging potential  of atherosclerotic lesions in humans
As initial evidence of the potential for E-selectin USPIO imaging in humans, we exposed a human 
LAD tissue slice to E-selectin and control USPIO. Typical USPIO-induced dots were observed on 
the surface of atherosclerotic plaques after incubation with E-selectin USPIO (figure 5A) in contrast 
to control USPIO (figure 5B). E-selectin expression on the endothelium (figure 5C) was confirmed 
by immunohistochemistry and the anatomical setting was described using HE, RF, CD 68 and Oil 
Red O stainings (figure 5D - G)
DISCuSSIoN
feasibility of e-selectin-targeted molecular imaging 
In the current study we successfully demonstrated the feasibility of endothelial E-selectin and 
plaque macrophage MR imaging in an ApoE-/- mouse model of atherosclerosis using a combination 
of two imaging time points after contrast agent injection. The biodistribution of E-selectin USPIO 
proved favorable for early time points after injection (1.5 hours), as it was specifically visualized 
at the endothelium of atherosclerotic plaques. Contrast enhancement in undiseased vessel wall 
(as can be seen in part of figure 2D) and the blood pool (at the optimal imaging time points) were 
low. E-selectin USPIO selectively targeted areas of atherosclerotic plaque with high E-selectin 
expression, showing a quantitative correlation with histology of atherosclerotic plaques on excised 
carotids and aortic arches. At later imaging time points (24 h) after injection, non-specific USPIO 
uptake by macrophages is dominating the contrast.
figure 5 | e-selectin usPio imaging on human vessels. A. Prussian blue staining of E-selectin USPIO that were 
incubated on a human LAD. Arrows point at DAB positive areas with clusters of USPIO. 20x, zoom 400x. 
B. Prussian blue staining of control USPIO that were incubated on a human LAD. Arrows point at DAB 
positive areas with clusters of USPIO. C. Confirmation of E-selectin expression on the endothelium by 
immunohistochemistry. Plaque morphology was further illustrated using D. Oil Red O, E, Haematoxillin 
Eosin, F. CD68 staining and G. RF staining.
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Both statin and fenofibrate treatment are known to reduce E-selectin expression25, and indeed 
diminished in vivo E-selectin USPIO accumulation at 1.5 hours after contrast agent injection. 
However, only statins reduced the actual plaque size and macrophage pool, corresponding to a 
reduced CNR change at 24 hours. Fenofibrate treatment did not significantly alter the plaque size, 
which was also observed as unchanged contrast enhancement at 24 hours. 
role of e-selectin in atherosclerosis
The recognition that inflammation drives the development and complication of atherosclerosis 
paved the way to assess several early inflammatory markers of atherosclerosis. E-selectin is such 
an early marker of atherosclerosis expressed in the endothelium of human atherosclerotic lesions, 
particularly when lesions are associated with subendothelial leukocytic infiltrates9, 10. The extent 
of E-selectin expression is related to atherosclerosis development and soluble E-selectin levels 
are of prognostic value for cardiovascular risk prediction13. Therefore, imaging its presence on 
individual plaques would allow a risk prediction for individual lesions, and could thus complement 
serological tests. Here we present proof-of-concept of how E-selectin guided imaging offers 
insight in plaque progression.
imaging therapy response
Lipid (LDL) lowering with statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) 
has been established as an important therapy in the primary and secondary prevention of 
atherosclerotic disease26. LDL lowering does not occur in ApoE-/- mice (Table 3), although beneficial 
effect on the inflammatory process involved in atherosclerosis plaque formation and progression 
both in mice and men have been reported, including a reduction of the macrophage pool27, 28.
Peroxisome Proliferator-Activated Receptor-α (PPARα) agonists like fenofibrate also affects lipid 
metabolism and inflammation, modulating pathophysiological pathways implicated in fatty liver 
disease and atherosclerosis. As is the case for statins, ApoE-/- mice treated with fibrates do not 
respond to PPARα agonists as humans, displaying no change29 or even an increase30 in plasma 
lipids upon fibrate treatment (Table 3). The pleiotropic anti-inflammatory effects such as the effect 
on the E-selectin expression remains conserved. Recently, it became apparent that despite the 
beneficial effects of fibrates on atherosclerosis, lesion size does not decrease, a phenomenon 
also observed in our study. As current diagnostic imaging mainly focusses on lesion size, it is of 
importance to keep in mind that therapy response may exist without a significant decrease in 
lesional area. As demonstrated in this study, imaging the endothelium activation status and/or 
plaques macrophage content may then provide mechanistic insights. 
role of macrophages in the plaque 
Inflammation plays a pivotal role in all stages of atherosclerosis. E-selectin targeted early imaging 
allows to visualize the inflammatory status of the endothelium. The response to therapy is currently 
assessed by imaging the atherosclerotic lesion size or the luminal narrowing. Our current findings 
indicate that imaging the macrophage pool in a plaque gives complementary information on 
therapy response.
Both in murine and human atherosclerotic lesions different macrophage phenotypes co-exist31. 
Macrophage phenotypic polarization is thought to play a role in the fate of an atherosclerotic 
lesion. Classically activated macrophages (or M1) and alternatively activated macrophages (or M2) 
are two extremes representing inflammatory and reparative macrophage phenotypes32, 33. Several 
recent studies have suggested that pharmacological treatments may skew macrophage polarization 
toward the M2 phenotype, thereby stabilizing atherosclerotic lesions even without reducing the 
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macrophage pool32, 36. We hypothesize that the difference in macrophage content between 
animals on Western diet, atorvastatin or fenofibrate is not only related to a simple reduction in 
the number of macrophages, but also to a change in macrophage phenotype. Of course, this 
mode of action is still speculative and requires further thorough investigation of the exact effects 
of different pharmacological treatments on macrophage polarization in the context of 
atherosclerosis. In this context it would be very interesting to use contrast agents that are targeted 
specifically towards either M1 or M2 macrophages. Using our strategy of early imaging to visualize 
active M1 or M2 targeting combined with late imaging of the passive engulfment of USPIO in the 
plaque macrophage pool would in theory allow an assessment of the M1/M2 balance in vivo.
Comparison to other e-selectin targeting imaging agents
The imaging field has provided several proof-of-concept studies for E-selectin imaging in 
(experimental) atherosclerosis in the past decade. Molecular MRI of E-selectin was performed to 
image neuro-inflammation to visualize the upregulation of the endothelial leukocyte adhesion 
molecules P- and E-selectin37. The paramagnetic contrast agent Gd-DTPA (Magnevist ®) was 
functionalized with a mimetic of sialyl Lewis X (sLe X) that binds to P- or E-selectin. Changes in 
longitudinal MR relaxation time T1 were modest, but MRI revealed specific binding of Gd-DTPA-
(sLe X ). 
Kang et al. have functionalized cross-linked iron oxide (CLIO) nanoparticles with anti human 
E-selectin antibody fragments38. Boutry et al. targeted E-selectin with a synthetic mimetic of sialyl 
Lewis(x) (sLe(x)), a natural ligand of E-selectin expressed on leukocytes, conjugated to Gd-DTPA 
or to USPIO17-19. This last approach has been used in the current work. Following in vivo injection 
of these targeted USPIOs, significant hypointensities on T2* -weighted MR images were observed 
at sites of injury during hepatitis17.
Our work is unique as we apply an E-selectin USPIO to detect atherosclerosis and thereby 
differentiate early from advanced atherosclerotic lesions by tuning the imaging timing detecting 
both active E-selectin targeting and passive targeting of the macrophage load.
study limitations
The exact role of E-selectin in the development, progression and regression of atherosclerotic 
plaques in ApoE-/- mice has not been fully elucidated. Whether the expression of E-selectin on 
the endothelium in advanced lesions represents a marker of stabily or instability by its role in the 
attraction of inflammatory cells is a matter of ongoing research. As P-selectin also plays a pivotal 
role in leukocyte tethering during plaque development, dual targeting of both selectins could 
have been of interest in the current application of the USPIO, although the expression of P-selectin 
is broader, potentially limiting the imaging specificity.
While the current preclinical findings are encouraging, a number of hurdles must be overcome 
before agents such as E-selectin USPIO can be used clinically; perhaps the most important will 
be the development of fully biodegradable USPIO, together with full toxicological testing of the 
humanized and biodegradable agent. Nevertheless, to date we have observed no toxicological 
effects of the E-selectin USPIO used in mice
CoNCluSIoN
In conclusion, this study demonstrated that molecular MRI using E-selectin USPIO allows selective 
imaging and quantification of endothelial E-selectin on the aortic arch as well as the carotid 
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arteries in ApoE-/- mice. E-selectin imaging combined with macrophage imaging in the plaque 
represents a tool to monitor plaque progression, regression and treatment response in vivo. 
E-selectin targeted imaging may therefore be a useful marker for in vivo detection and staging 
of atherosclerotic lesions.
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AbStRACt
Atherosclerosis is an inflammatory disease causing considerable morbidity and mortality in the 
Western world. Rosiglitazone is an effective anti-diabetic drug that also has anti-atherosclerotic 
potential, but is controversial because of reported cardiac side effects. Therefore, a nanomedicinal 
micelle formulation of this drug was developed to improve targeted delivery. Micelle-mediated 
delivery of rosiglitazone was validated in vitro and in vivo in ApoE-/- and ApoE-/--eNOS-/- mice. 
The PPAR-γ activating potential of rosiglitazone micelles was assessed by a firefly luciferase 
expression assay responsive to activation of the PPAR-γ pathway. Contrast-enhanced magnetic 
resonance imaging was applied to assess micelle targeting and determine the therapeutic efficacy 
longitudinally. Significant anti-atherosclerotic effects and reduction in mortality were observed 
upon treatment with rosiglitazone micelles and rosiglitazone. However, micelle-mediated delivery 
resulted in less side effects (weight gain, plasma cholesterol increase) than conventional 
rosiglitazone. No significant changes were found for untreated animals or mice treated with 
control micelles. These findings were corroborated by immunohistochemical analysis of lesion 
size. In conclusion, this study evaluates a powerful strategy for efficient treatment of atherosclerosis 
that includes nanomedical therapy of atherosclerotic plaques and the application of noninvasive 
and clinically approved imaging techniques to monitor delivery and therapeutic responses. We 
demonstrate anti-atherosclerotic effects in atherosclerotic lesions after micelle-mediated 
rosiglitazone therapy, while reducing common side effects associated with rosiglitazone.
INtRoDuCtIoN
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the Western world 
leading to clinical events such as myocardial infarction, stroke or aortic aneurysm rupture 1. 
Atherosclerosis is considered as the single most important contributor to CVD, characterized by 
a chronic inflammation of the arterial wall with concomitant accumulation of lipids, fibrous 
components and debris in the vessel wall 2,3. Both pre-clinical and clinical studies have reported 
that the insulin sensitizers thiozolidinediones (TZD), which exert their action mainly through 
binding to peroxisome proliferator–activated receptor γ receptors, inhibit the development and 
progression of atherosclerosis in vivo 4-8. These anti-atherosclerotic effects are thought to occur 
independent of their metabolic effects 5,6. Moreover, TZD have a marked effect on both aneurysm 
development and rupture 9.
Despite its proven success in the treatment of diabetes, TZD therapy is hampered by its undesirable 
(cardiac) side effects. Rosiglitazone, a TZD, was recently even put under selling restrictions in the 
US and withdrawn from the market in Europe due to an increased risk of cardiovascular events. 
Therefore, TZDs have not been seriously considered for clinical treatment of atherosclerosis, 
probably because they exhibit a poor pharmacokinetic profile, resulting in relatively low drug 
concentrations at sites of intended action.
More efficient delivery of rosiglitazone to the atherosclerotic lesions may improve its biodistribution 
and allow lowering of the therapeutic dose, thus producing an anti-atherosclerotic effect while 
reducing the side effects of this drug. Nanoparticle delivery has been shown to be a viable method 
to improve therapeutic efficacy, with liposomal doxorubicin as key example of a successful 
nanoparticles that received clinical approval 10. Lipid-soluble drugs, such as rosiglitazone 
phosphate, can be encapsulated in micelles, coated with poly(ethylene) glycol (PEG) to enhance 
their circulation half-life, thereby increasing their accumulation at sites where the endothelium 
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is leaky (EPR effect) such as atherosclerotic lesions 11. This approach is particularly attractive, as 
micellar nanoparticles may be used not only for drug delivery to the atherosclerotic plaque, but 
also as an imaging platform by adding MRI-sensitive moieties such as gadolinium-DTPA, allowing 
a theragnostic approach to vascular disease11.
In the present study, micelle-mediated rosiglitazone delivery is explored as a tool towards 
theragnostic imaging and treatment of atherosclerotic lesions. Two mouse models were used: 
hyperlipidemic ApoE-/- mice, which develop extensive atherosclerotic lesions, and ApoE-/- 
-eNOS-/- mice 12, which develop both plaques and aneurysms. The objectives of this study were: 
(1) to assess whether micelle-encapsulated rosiglitazone could be delivered preferentially to 
sites of atherosclerotic plaques, (2) to assess whether plaque progression could be inhibited by 
micelle-mediated rosiglitazone therapy and (3) to assess whether the gadolinium-labelled 
micelles allowed a noninvasive follow-up assessment of the effect of rosiglitazone delivery on 
plaque progression.
MAtERIAlS AND MEtHoDS
Preparation of rosiglitazone micelles
Preparation of rosiglitazone micelles was performed by modification of a conventional lipid film 
hydration method 11.
A mixture of the appropriate amounts of lipids (typically 120 mol of total lipid) was dissolved in 
chloroform/methanol 3:1 (vol/vol) in a round-bottom flask. A lipid film was made under reduced 
pressure using rotary evaporation at 37 °C and dried under a stream of nitrogen. Gd-DTPA-BSA 
(Gd-DTPA-bis(stearylamide) and PEG2000-DSPE (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]) were used at a molar ratio of 
1.5/1.35. For fluorescent detection, 0.1 mol% NIR664-DSPE (SyMO-CHEM B.V., Eindhoven, The 
Netherlands) was added. 0.02 mmol rosiglitazone (Cayman Chemicals) was incorporated. The 
lipid film was subsequently hydrated in 135 mM NaCl (pH 7.4) and vigorously stirred at 65 °C for 
45 min. 
The size and size distribution of the contrast agents were determined by dynamic light scattering 
(DLS) at 25 °C with a Malvern 4700 system (Malvern ZetaSizer Nano S, Malvern, UK). The micelles 
had a mean size of 16 nm and a polydispersity index below 0.1, which indicates a narrow size 
distribution. The relaxivity was measured at 37 °C and 9.4T. 
The emission spectra of the probes were recorded using a fluorescence spectrophotometer 
(Fluorolog FII A Spectrofluorimeter, Spex Inc., NJ, USA) to confirm integration of rosiglitazone in 
the micelles as described previously 13.
In vitro PPAr-γ activation measurements
Rosiglitazone activity and incorporation into micelles was confirmed by in vitro cell culture 
experiments. An osteoblast cell line, U02S, without PPAR-γ expression, was seeded into 12-wells 
plates. When the cells had a confluence of 70% they were transfected with the PPARγ-reporter, 
containing a dual luciferase (Cignal PPAR Reporter (luc) kit, SABiosciences. Transfection results 
in continuous expression of Renilla luciferase, with firefly luciferase co-expression after activation 
of the PPAR-γ pathway. Rosiglitazone was used as a positive control. Control micelles, rosiglitazone 
micelles (containing 2.5 μM rosiglitazone), rosiglitazone (2.8 μM) were incubated for 24 hours 
after which the cells were lysed and luciferase expression was measured. Data was expressed as 
the ratio between Renilla and Firefly luciferase. All experiments were performed in duplo.
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in vitro monocyte activation measurements
Monocyte activation was determined by flow cytometry (FC500, Beckman Coulter, Fullerton, CA, 
USA) following incubation of human whole blood from healthy donors with rosiglitazone (2.8 
μM), rosiglitazone micelles (with 2.5 μM rosiglitazone), control micelles, or PBS. At different 
timepoints (30-240 minutes) blood samples were incubated with FACS antibodies for 30 minutes, 
red blood cells were lysed and FACS analysis was performed. CD14-PC5 (mouse anti-human 
IgG2a, A07765, Beckman-Coulter) was used for monocyte selection; CD11b-PE-Cy7 (mouse 
anti-human IgG1, 22-0118-42, eBioscience) and CD62L-ECD (L-selectin, mouse anti-human 
IgG1, IM2713U, Beckman-Coulter) were used to determine cell activation. CD14 positive cells 
were used and the percentage of the cells positive for CD11b and negative for CD62L were used 
to determine monocyte activation. 
Animal experiments
Animal experiments were conducted in accordance with the Dutch guidelines for research animal 
care. The experiments have been approved by the institutional Animal Ethics Committee (DEC) 
at the Leiden University Medical Center, permit number 11180. In total 6 groups of male ApoE-/- 
and 6 groups of male ApoE-/-eNOS-/- mice on a C57Bl6Jico background were included in this 
study (table 1). Mice were housed in isolator cages and given free access to food unless stated 
otherwise and acidified drinking water.  All knockout mice were backcrossed for 10 generations 
to the C57Bl/6J genetic background. To generate ApoE-/--eNOS-/- mice, eNOS-/- mice and ApoE-
/- mice (Jackson laboratories, Bar Harbor, ME, USA) were crossed. These double heterozygous 
mice were subsequently crossed and the offspring genotyped for eNOS and ApoE by polymerase 
chain reaction to select ApoE-/--eNOS-/- mice. 
In vivo passive targeting of micelles to atherosclerotic lesions 
To test the potential of rosiglitazone and control micelles to passively target atherosclerotic 
plaques, 2 groups (A) of 12-14 months old ApoE-/- and 2 groups (B) of 10-12 months old ApoE-/-
eNOS-/-  were exposed to a Western diet (Ab-diets, The Netherlands) for 4 weeks. Each mouse 
was subsequently scanned before administration of rosiglitazone micelles or control micelles and 
24 hours after intravenous injection of micelles (50 μmol Gd3+-DTPA lipid/kg bodyweight in 200 
table 1. overview of the experimental groups of mice that were included in the analysis of the 
study
Apoe-/- Apoe-/-- enos-/-
Plaque imaging potential A ( n=5 rosiglitazone micelles, 
n=5 control micelles)
B ( n=5 rosiglitazone micelles, 
n=5 control micelles)
4 weeks Western diet followed by
6 weeks Western diet C (n=5) D (n=5)
6 weeks Western diet with 
rosiglitazone
e (n=5) f (n=5)
6 weeks Western diet with 
control micelles
g (n=5) h (n=5)
6 weeks Western diet with 
rosiglitazone micelles
i (n=5) J (n=5)
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μl dextrose solution). The 24 hour time-point was determined in previous work as the optimal 
time point for passive targeting of micelles to the plaques 14.
Effect of rosiglitazone therapy on plaque inflammation and aneurysm formation
To assess the therapeutic potential of rosiglitazone micelles 4 groups of ApoE-/- and 4 groups 
of ApoE-/--eNOS-/- mice were exposed to a Western diet for 4 weeks. After a 4-hour fasting 
period, body weight was determined and EDTA plasma (Sarstedt, Germany) was collected via 
the tail vein. Total plasma cholesterol and triglyceride levels were measured (Roche Diagnostics). 
The ApoE-/- and ApoE-/--eNOS-/- mice were subsequently randomized according to their body 
weight and plasma lipid levels (table 2). One group of animals for each genotype was fed for 
another 6 weeks a Western diet (C, D), one group was exposed to a Western diet supplemented 
with rosiglitazone (Ab diets, 0.018% w/w rosiglitazone, ~10 mg/kg bw/day (GSK, Zeist, The 
Netherlands) (E, F), the third and fourth group of mice was fed a Western diet for 6 weeks and 
received micelles through mini-osmotic pumps (Alzet, USA). Animals had an osmotic pump 
inserted subcutaneously in the interscapular region that released either control micelles (G, H) 
or rosiglitazone micelles (~10 mg/kg bw/day) (I, J). As significant mortality was expected, 15 
mice were included per treatment group. Of the surviving animals, 5 mice per group were 
randomly selected for analysis after the treatment period.
table 2. overview of the plasma cholesterol and lipid values, as well as the body weight of the 
experimental groups of mice included in the study. 
Western diet
Western diet & 
rosiglitazone
Western diet & 
control micelles
Western diet & 
rosiglitazone 
micelles
Apoe-/- mice
At randomization
Body weight  (gram) 33.8 ± 1.8 33.1 ± 2.4 33.5 ± 2.8 34.5 ± 2.1
Cholesterol    (mg/dL) 934 ± 24 923 ± 22 932 ± 21 917 ± 27
Triglycerides  (mg/dL) 148 ± 12 147 ± 14 151 ± 9 150 ± 16
6 weeks treatment
Body weight  (gram) 36.7 ± 2.1 * 42.4 ± 3.2 * 37.0 ± 3.0 * 37.8 ± 1.9 *
Cholesterol    (mg/dL) 1014 ± 38 1092 ± 29 * 1000 ± 23 994 ± 25
Triglycerides  (mg/dL) 171 ± 14 196 ± 15 173 ± 13 174 ± 17
Apoe-/--enos-/- mice
At randomization
Body weight  (gram) 29.4 ± 1.6 28.7 ± 1.3 29.2 ± 2.0 28.9 ± 1.8
Cholesterol    (mg/dL) 984 ± 48 978 ± 45 982 ± 39 987 ±26
Triglycerides  (mg/dL) 124 ± 11 135 ± 16 128 ± 15 132 ± 14
6 weeks treatment
Body weight  (gram) 32.6 ± 1.2 41.7 ± 2.8 33.4 ± 1.9 34.8 ± 2.4
Cholesterol    (mg/dL) 1008 ± 35 1123 ± 25 * 1007 ± 41 1058 ± 37
Triglycerides  (mg/dL) 182 ± 9 211 ± 14 175 ± 7 187 ± 16
Body weight, total cholesterol and triglycerides significantly increased compared to mice in other 
groups with rosiglitazone treatment. * p< 0.05
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imaging hardware
All MRI experiments were performed with a vertical 9.4 T magnet (Bruker, Ettlingen, Germany) 
supplied with an actively shielded Micro2.5 gradient system of 1 T/m and a 30 mm transmit/
receive birdcage RF coil, using Paravision 5.0 software.
Mri protocols
In vivo
At the start of each examination, several 2D FLASH scout images were recorded in the transverse 
and axial planes through the heart to determine the orientation of the aortic arch. A modified 
FLASH sequence with a navigator echo (IntraGate) was used for retrospective CINE MRI with the 
following parameters: 
1)  Cross sections of the aortic arch:  
RF pulse 1 ms; flip angle 15°; TR 31.4 ms; TE 2.96 ms; navigator echo points 64; 10 cardiac 
frames; FOV 1.8*1.8 cm2; matrix 128*128; in-plane resolution 141*141 μm2; 6 slices, slice 
thickness 0.4 mm; number of repetitions 400; total acquisition time approximately 20 min. 
2)  For a frontal view of the aortic arch the MR sequence was slightly adapted:  
TR 15.7 ms, TE 2.96 ms, 3 slices, slice thickness 0.5 mm, total acquisition time approxima-
tely 10 min.
During the examination, the respiration rate was continuously monitored using a balloon pressure 
sensor connected to the ECG/respiratory unit (SA instruments, Stony Brook, NY, USA). The isoflurane 
concentration was adjusted to keep the respiration rate between 50 and 90 respirations/min. 
After the final MRI scan all mice were terminally anesthetized with a mixture of midazolam 
(dormicum®, Roche), medetomidine (domitor®, Orion corporation, Finland) and fentanyl 
(Janssen-Cilag, Belgium) followed by transcardial perfusion; arteries were taken out for 
histological validation.
Ex vivo
Relaxivity measurements:
T1 values of micelles were determined using a saturation recovery protocol (multi slice multi 
echo (msme) sequence) with the following parameters: TE 7 ms, TR: 25-20-15-10-8-6-5-4-
3-2-1.6-1.2-1.0-0.8-0.6-0.4-0.3 s, excitation hermite 1 ms, ref hermite 0.75 ms, band width 
100kHz, matrix 128*128, resolution (195)2 μm, 2*1mm slices. 
The T1 values of the various ROIs were determined using a 3-parameter fit function: 
M(t) = M0 (1-exp (-t/t1))       [eq1]
Mri Analysis
Aortic arch images were analyzed using ImageJ software. Black blood images in 3 to 4 adjacent 
slices of cross-sections through the aortic arch were analyzed. ROIs were drawn around the 
plaque region in the vessel wall (Iwall). A 2nd ROI was drawn in the surrounding muscle tissue of the 
shoulder girdle (Imuscle). Furthermore, an ROI was placed outside the animal to measure the noise 
level (stdevnoise) (Figure 2). 
The contrast–to-noise ratio was defined as
Cnr= (iwall – imuscle)/stdevnoise      [eq2] 
which is a measure how well the lesioned wall can be discriminated from the surrounding tissue. 
CNR values are shown as mean ± standard deviation.
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histology
Aortic arches, aortae and carotid arteries were fixed in 4% PFA, subsequently paraffin embedded 
and cut into serial 5 μm sections. Sections were stained with hematoxilin and eosin (H&E), followed 
by bright-field microscopy.
statistical analysis
Data are represented as the mean ± standard deviation. Statistical analyses were performed using 
SPSS 17.0.2 (SPSS, Inc., Chicago, IL, USA). Statistical significance between all four groups was 
assessed using one-way analysis of variance (ANOVA), followed by a Bonferroni correction for 
multiple testing in case of significance. Results were considered statistically significant at 
p < 0.05.
RESultS
nanoparticle characteristics
The mean size of the rosiglitazone micelles was 16.8 nm, the control micelles were 16.1 nm. Both 
batches had a polydispersity index of 0.1, indicating a narrow size distribution, as was determined 
by dynamic light scattering. Longitudinal relaxation values (r1) obtained at 9.4 T at room 
temperature was 5.67 s-1 mM-1 for rosiglitazone micelles which was comparable to the relaxivity 
of 5.8 s-1 mM-1 of control micelles, in line with what we recently described 14. Fluorescence spectra 
recorded for both micelles indicated that the amount of fluorescent near-infrared 664 was similar 
for both formulations. 
in vitro PPAr-γ activation measurements
Human blood was incubated up to 240 minutes with rosiglitazone, PBS, rosiglitazone micelles, 
control micelles or PBS. Both rosiglitazone and rosiglitazone micelles had the potential to activate 
monocytes (CD11b+CD62L- cells of CD14+ population (figure 1A). The percentage of CD11b+ 
CD62L- monocytes increased up to 92.04% of the CD14+ cell population after rosiglitazone micelle 
incubation similar to free rosiglitazone in solution. The PBS control did not show any activation; 
neither did the control micelles without rosiglitazone.
Subsequently, we tested the capacity to activate PPAR-γ transcription. A PPAR-γ deficient 
osteoblast cell-line transfected with a dual luciferase construct was used to assess PPAR-γ 
activating potential. Rosiglitazone (positive control) showed an increase in PPAR-γ activation. Two 
different batches of rosiglitazone micelles showed similar activation of PPAR-γ. The control 
micelles (without rosiglitazone) showed no activation after 24 hours of incubation (figure 1B). 
in vivo passive targeting of micelles to atherosclerotic plaques.
The in vivo passive targeting of Gd-containing rosiglitazone micelles was investigated ApoE-/- and 
ApoE-/--eNOS-/- mouse models of experimental atherosclerosis on a high fat diet. Figure 2A and 
B depict representative MRI images of the aortic arch from ApoE-/- and ApoE-/--eNOS-/- animals 
obtained before (figure 2A) and 24 hours (figure 2B) after injection of micelles. There was 
approximately a 5 fold increase in enhancement of the aortic arch wall compared to muscle with 
both control and rosiglitazone micelles in ApoE-/- and ApoE-/--eNOS-/- mice (figure 2C). Contrast 
enhancement was observed in areas where atherosclerotic lesions were detectable on HE staining 
(figure 2D). No contrast enhancement was observed in areas without atherosclerotic lesions, 
demonstrating that both formulations are selectively retained in areas with endothelial damage.
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therapeutic properties of rosiglitazone micelles
Having demonstrated the passive homing of rosiglitazone micellse to atherosclerotic lesions, and 
the capacity of rosiglitazone micelle to activate PPAR-γ in vitro, we further explored whether 
rosiglitazone micelle can serve as targeted therapeutics for atherosclerosis.
ApoE-/- and ApoE-/--eNOS-/- mice were exposed to a Western diet. Subsequently, from both 
genotypes mice were randomized in 4 groups according to their body weight and plasma lipid 
levels (table 2). Mice were exposed for 6 weeks to either 1) a Western diet alone, or a Western diet 
with 2) control micelles, 3) rosiglitazone micelles or 4) oral rosiglitazone supplementation. At the 
end of the 6-week-therapeutical intervention period all ApoE-/- mice were alive. ApoE-/--eNOS-/- 
mice are known to have a high mortality, therefore groups of n=15 mice were initially used. Mice 
were exposed to either a Western diet supplemented with rosiglitazone or a Western diet with 
rosiglitazone micelles had a significantly higher survival chance than ApoE-/--eNOS-/- mice exposed 
to a Western diet or a Western diet supplemented with control micelles (figure 3A). Five surviving 
mice per group were analyzed. Mice from both genotypes exposed to a Western diet supplemented 
with rosiglitazone developed a ruffled fur after ~ 4 weeks of exposure (figure 3B). Body weight of 
the control mice and of those receiving control micelles increased over the 6-week-intervention 
period (table 2). Mice exposed to a Western diet supplemented with rosiglitazone, gained 
significantly more weight than control animals, a known side-effect of rosiglitazone treatment. 
Also plasma cholesterol levels were increased compared to control mice (table 2). Interestingly, 
the weight gain and plasma cholesterol of mice on micelle-mediated rosiglitazone treatment and 
Western diet was similar to that of the control groups). MRI was performed after 6 weeks 
therapeutic intervention. Contrast-to-noise ratios (CNR) of atherosclerotic lesions on the inner 
curvature of the aortic arch were determined (figure 3C). ApoE-/--eNOS-/- mice had significantly 
higher CNR and larger atherosclerotic lesions than ApoE-/- mice. Treatment with rosiglitazone 
supplemented in the diet as well as rosiglitazone micelles led to a decrease in lesion area and 
consequently in CNR compared to mice exposed to a Western diet. Immunohistochemical 
assessment of plaque area (HE) and CD68 distribution confirmed the MRI results. The lesion area 
was significantly reduced in mice exposed to a Western diet supplemented with rosiglitazone and 
in mice exposed to rosiglitazone micelles compared to untreated mice (figure D and E). Both on 
MRI images and ex vivo the occurrence of aortic aneurysms was assessed. As expected, no 
aneurysms could be observed in the groups of ApoE-/- mice. In ApoE-/--eNOS-/- mice exposed to 
a Western diet or a Western diet with control micelles, aneurysms were detected in the abdominal 
aorta of all mice (figure 3F). Aneurysms were significantly reduced in size in mice treated with 
rosiglitazone micelles, and to a lesser extent also in mice exposed to a Western diet supplemented 
with rosiglitazone.
DISCuSSIoN
In the current study we successfully demonstrated the feasibility of a theragnostic approach using 
micelles as a carrier system for efficient anti-atherosclerotic drug delivery to atherosclerotic 
lesions as well as for plaque MR imaging in both the ApoE-/- and ApoE-/--eNOS-/- mouse model 
of atherosclerosis. Using MRI, we showed that homing of micelles to undiseased vessel walls was 
low, whereas micelles passively accumulated in atherosclerotic lesions. Both ex vivo tests and in 
vivo imaging showed that micelles are suitable as drug carrier for delivery of rosiglitazone to 
atherosclerotic lesions. The method of “targeted” delivery and accumulation is attributed to the 
enhanced permeability and retention (EPR) effect 13,14 that is observed in atherosclerotic lesions 
2012110 proefschrift Brigit den Adel_def.indd   146 22-01-13   21:50
rosiglitasone micelles
| 147
characterized by a disrupted endothelial layer. Moreover, we demonstrated that rosiglitazone 
micelle treatment led to decreased mortality, reduced plaque load and reduced aneurysm 
formation, similar to rosiglitazone, while preventing significant weight gain during the 
treatment. 
nanoparticles as imaging and drug carriers 
Long-circulating particles, such as PEGylated micelles, are able to extravasate from the bloodstream 
and subsequently accumulate at sites with leaky endothelium where they are retained and act 
locally11,15. This targeting effect results in an enhanced delivery of the drug to the desired site, 
which theoretically enables the use of lower dosages to achieve the same efficacy. Due to the 
long-circulating properties of the micelles, a higher proportion of the injected dose of the micelle-
encapsulated drug as compared to the orally delivered drug ends up in the atherosclerotic plaques. 
As a next step, targeted delivery of drugs to sites with enhanced permeability can be even further 
improved by conjugation of targeting ligands to the micelle surface. Several studies have shown 
that micelles can be actively targeted to entities of interest by conjugating targeting molecules 
to the surface15,16. To that end, it is also possible to actively target atherosclerotic plaques by e.g. 
targeting macrophages via the macrophage scavenger receptor15, neovessels via αvβ3-integrin16,17 
or any other target of choice that is up-regulated in atherosclerotic lesions 17. 
figure 1 | in vitro validation of rosiglitazone micelles. A. Fraction activated CD11b+ CD62L- monocytes from the 
CD14+ population after 2 hours incubation with rosiglitazone, rosiglitazone micelles, control micelles or 
PBS. B. Activating potential of rosiglitazone and rosiglitazone micelles was tested in a PPAR-γ deficient 
osteoblast cell-line transfected with a dual luciferase construct was used to assess PPAR-γ activating 
potential
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figure 2 | Proof of principle of imaging potential of gd-loaded rosiglitazone and control micelles. A. T1 weighted 
MRI of the aortic arch before injection of micelles. B. T1 weighted MRI 24 hours after rosiglitazone micelle 
injection. C. Contrast-to-Noise ratios of ApoE-/- and ApoE-/- eNOS-/- mice 24 hours after injection of either 
control micelles or rosiglitazone micelles. D. Representative Haematoxilin Eosin staining of the inner 
curvature of the aortic arch of an ApoE-/- eNOS-/- mouse. Atherosclerotic plaques are observed in areas 
with contrast enhancement on MRI. ** p< 0.01.
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figure 3 | the effect of rosiglitazone on atherosclerosis and aneurysm formation. A. Kaplan-Meier survival curve 
of ApoE-/- (in red) and ApoE-/-eNOS-/- (in black/gray) mice exposed for 4 weeks to a Western diet and 
subsequently treated with rosiglitazone, rosiglitazone micelles, control micelles or left untreated. B. Ruffled 
fur of an ApoE-/- mouse exposed to a Western diet supplemented with rosiglitazone. C. Contrast to Noise 
Ratios of the different groups of animals after 6 weeks treatment. D. D1 Immunohistochemical DAB staining 
of the aortic arch of a rosiglitazone treated ApoE-/- mouse, 400x. D2. Percentage CD68+ cells per lesion 
area on the innercurvature of the aortic arch of the different treatment groups. E. Histological determination 
of plaque size in the different treatment groups. F. En face preparation of the aortic arch and aorta of 
ApoE-/--eNOS-/- mice from the 4 treatment groups. * p< 0.05
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Nevertheless, “simple” long circulating micelles without the conjugation of targeting ligands are 
attractive for several reasons. They are easier to synthesize, less expensive, more generally 
applicable, less immunogenic, and most importantly can be translated relatively fast to the clinic. 
In the past this has already led to the approval and clinical application of a variety of lipid-based 
drugs in the field of oncology like clodronate liposomes 21,22. In this study, the micelles were 
administered using osmotic pumps to facilitate the experimental design. However, micelle 
formulations can in principle be stabilized with a sufficiently long shelf life for oral administration. 
Previously, microsphere delivery of rosiglitazone in diabetic rats already showed that nanoparticle 
delivery allows for better glycemic control at lower dose than immediate-release formulations18, 
suggesting that our current approach could also be an interesting alternative for a large group of 
patients with comorbid diabetes and vascular disease. 
rosiglitazone in the treatment of atherosclerosis
In this study we successfully applied rosiglitazone in a micelle formulation to treat experimental 
atherosclerosis and the occurrence of aneurysms. Rapidly increasing mounts of evidence have 
underscored the importance of PPAR-γ in cardiovascular disease 19, in particular in diabetes 
mellitus20 and atherosclerosis21. Treatment with PPAR-γ agonists leads to a reduction of insulin 
resistance by sensitizing muscle, liver, and adipose tissue to insulin. Largely consistent results 
from preclinical studies using in vivo and in vivo models, suggest that PPAR-γ and its selective 
agonists including rosiglitazone have an atheroprotective role via their effect on inflammatory 
cells, endothelial cells and lipid metabolism22. These mechanisms are also the basis of its potential 
to reduce the occurrence of aneurysms9. We confirmed the potential of rosiglitazone to modulate 
the immune system ex vivo by facs analysis of circulating monocytes/macrophages as well as in 
vivo by addressing the plaques macrophage load. 
Treatment with rosiglitazone has been associated with weight gain in patients with type 2 
diabetes as well as in animal models, mainly attributable to an increase in abdominal adipose 
tissue without a significant gain in body water23,24. Moreover, an increase in total cholesterol 
and triglyceride plasma levels occurs with rosiglitazone treatment. We observe indeed an 
increase in body weight and plasma cholesterol and triglyceride levels in mice treated with a 
western diet supplemented with rosiglitazone. In contrast, this effect was not observed though 
in the groups of mice exposed to a Western diet and treated with rosiglitazone micelles. This 
suggests the mode of action of the rosiglitazone micelles on atherosclerosis progression is 
indeed a local rather than a systemic effect. It would be of interest to assess whether the insulin-
sensitizing mode of action is also still present using rosiglitazone micelles. The slow-release 
study by Kamila et al. and the pharmacokinetic profile of micelles (long circulation times, 
clearance via the liver 14 would suggest that it is very well possible that micelle-mediated delivery 
also has a beneficial effect on glycaemic control.
In this study we administered a similar dose of rosiglitazone orally and in micelles to the mice. The 
effect on atherosclerotic lesions and mortality was comparable. The effect on systemic side-effects 
remains to be investigated, although the lack of weight gain and cholesterol increase in the 
rosiglitazone micelle-treated group is an indication that severe edema probably does not occur.
We observed a significant increase in survival chance in ApoE-/--eNOS-/- mice treated with 
rosiglitazone. Several ApoE-/--eNOS-/- mice exposed to a Western diet died, probably because of 
myocardial infarction and aneurysm rupture, which introduced a bias in the control group, as we 
chose to maintain the group size at n=5 after the 6 weeks treatment period. The strongest mice 
were thus included in the analysis of the treatment effects, and therefore we are probably 
underestimating the treatment effect. 
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The effects of TZDs on vascular disease in clinical trials are at this stage conflicting. Several 
studies have reported a beneficial effect on atherosclerosis progression, whereas other studies 
reported no effect22. Recent meta-analyses even suggest an increased risk of myocardial 
infarction using rosiglitazone23. Unveiling the background of these confusing clinical results will 
be complicated given that the patient population often suffers from multiple morbidities and 
receives several drugs. A nanoparticle approach may help to locally treat the atherosclerotic 
lesion, allowing image guided follow-up as well as lower dosing and thereby reducing the risk 
of severe adverse effects.
Comparison to other theragnostic particles
A combined approach of MR imaging and drug targeting has recently gained more attention and 
has been demonstrated previously in experimental atherosclerosis. Lobatto et al. recently 
developed liposomes loaded with anti-inflammatory glucocorticoids27,28. The liposomes were 
intravenously applied in a rabbit model of atherosclerosis. 18F-fluoro-deoxy-glucose positron 
emission tomography and dynamic contrast enhanced MRI, were applied to longitudinally assess 
therapeutic efficacy. Significant anti-inflammatory effects were observed as early as 2 days that 
lasted up to at least 7 days after administration of a single dose of liposomes. 
Winter et al. documented results on a combined approach of molecular MRI and drug targeting 
of atherosclerosis using αvβ3-specific nanoparticles29,30. They used these nanoparticles to target 
atherosclerotic lesions of rabbits. For therapeutic purposes, they included fumagillin in the lipid 
monolayer of the nanoparticles and observed an anti-angiogenic effect with MRI that was 
confirmed histologically. Moreover Maiseyeu et al. developed a multivalent theragnostic 
nanoparticle composed of phosphatidyl-serine (PS), ω-carboxynonanoyl-cholesteryl ester and 
Gd lipids which were targeted to M2 macrophages using an anti-Mrp14 polyclonal antibody30,31. 
Overall, these studies as well as this current work hold great promise for nanoparticles-based 
treatment of atherosclerosis.
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AbStRACt
MRI using targeted contrast agents (CA) has emerged as a promising technique to study 
atherothrombotic disease in vivo. Particularly, the use of targeted Gd and lipid-based nanoparticles 
has enabled detailed in vivo imaging of various molecular markers of atherosclerotic plaque 
pathophysiology. For validation purposes, it is crucial that nanoparticle accumulation in the plaque, 
cellular association and localization can be assessed by ex vivo immuno-histology or fluorescence 
microscopy of tissue sections.
In this review we discuss the various methods that are available for histological evaluation of 
targeted MRI contrast agents such as lipid-based nanoparticles and iron oxide particles. We discuss 
the detection of these contrast agents in paraffin-embedded and in cryopreserved tissue sections 
of atherosclerotic plaques. During the embedding procedure in paraffin, most components of 
targeted lipid-based nanoparticles are generally washed out, though the actual targeting moieties 
may be retained in the embedded sections. Therefore staining of the antibody-antigen complex 
provides a suitable way to visualize the presence of the nanoparticle in the plaque. Cryopreservation 
preserves nanoparticle presence in the plaque. In cryosections, the localization of nanoparticles 
can be assessed directly by measuring the fluorescence of an incorporated fluorophore or by 
secondary stainings of the Gd-containing DTPA lipids or the iron oxide particles. With certain 
secondary stainings, be it for the contrast agent or for co-localization with the target, the contrast 
agent itself may interfere with standard histological protocols, yielding false positive results.
The here presented techniques enable proper visualization of MR contrast agent accumulation 
and localization in atherosclerotic plaque, which will provide the validation necessary to advance 
these lipid-based nanoparticles to the clinic. 
 
INtRoDuCtIoN
Atherosclerosis and its thrombotic complications are a major cause of morbidity and mortality in 
the industrialized countries, despite the clinical advances that have been made over the past 20 
years in the prevention and treatment of this disease1. The main components of the 
atherothrombotic plaques are: (i) connective tissue extracellular matrix, including collagen, 
proteoglycans, fibronectin, and elastic fibers; (ii) crystalline cholesterol, cholesteryl esters, and 
phospholipids; (iii) cells including monocyte-derived macrophages, T-lymphocytes, and smooth 
muscle cells, and in advanced or ruptured plaques (iv) thrombotic material with platelets and 
fibrin. Varying proportions of these components are present in different plaques, thus giving rise 
to heterogeneity of the lesions2-4. Vulnerable plaques, which are prone to rupture, contain a high 
frequency of inflammatory cells and may cause clinically manifest problems. Vulnerable plaque 
composition varies depending on the anatomical site, with striking heterogeneity even within the 
same individual. Therefore reliable non-invasive clinically available imaging is needed, which is 
able to detect and characterize atherothrombotic disease in its various stages and at different 
anatomical sites5. An ideal clinical imaging modality for atherosclerotic vascular disease is safe, 
inexpensive, non- or minimally invasive, accurate, and reproducible, while the imaging readouts 
should correlate with the extent of atherosclerotic disease and have high predictive value for the 
occurrence of future clinical events5;6. 
In this respect, high-resolution magnetic resonance imaging (MRI) has emerged as a promising 
technique to study atherothrombotic disease in vivo7. MRI does not involve ionizing radiation and 
provides high-resolution images of various vascular regions. An MR image is based on 
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radiofrequency signals, typically from water protons, following administration of a radiofrequency 
pulse, while the subject is placed in a strong magnetic field. The emitted signal varies according 
to the water concentration and the relaxation times (T1 and T2). Using combined analysis of 
different tissue signal intensities generated by the application of T1-weighted (T1W), T2-weighted 
(T2W), and proton-density-weighted (PDW) images, it is possible to generate detailed images of 
plaque anatomy and morphology8. The use of (targeted) contrast agents enables visualization of 
plaque permeability and disease-specific cellular and molecular processes.
In the past decade, the development of MRI contrast agents has seen a tremendous progress. 
The application of T1 and T2 non-targeted and targeted contrast agents (CA) is commonly 
explored in animal models of human atherosclerosis7. Currently, there are no clinically established 
methods to non-invasively differentiate between stable and vulnerable plaques and to identify 
rupture prone plaques. Therefore, there has been much activity in the development of targeted 
MRI contrast agents (9). Validation of the MR molecular images in pre-clinical models of 
atherosclerosis by comparison with “gold standard” histology images is at these stages of utmost 
importance. In many cases histological validation is difficult or even flawed because of several 
reasons. First of all, the tissue preparation method, such as embedding in parafin or freezing, may 
render detection of contrast agent in a native state impossible. Secondly, lipid-based nanoparticles 
generally consist of a mixture of building blocks – e.g. phospholipids, targeting ligands, fluorescent 
moieties, Gd-containing lipids, cholesterol. Histological visualization of one of these componenents, 
e.g. the targeting ligand, does not automatically imply copresence of the other components. 
Thirdly, autofluorescence of tissue may interfere with specific detection of fluorescent moieties 
in tissue. Fourthly, the contrast agent itself may interfere with standard histological protocols.
This review will discuss several existing strategies and validated histological methods for the 
detection of contrast agents in tissue sections of mouse atherosclerotic plaque. We will discuss 
Gd-based nanoparticle contrast agents that generate contrast on T1W MR images (T1 contrast 
agents), as well as FeO-based agents, which are more suitable for detection using T2W MR imaging 
techniques (T2 contrast agents).
t1 contrast agents
Most clinically applied MRI contrast agents are based on Gd3+-DTPA or -DOTA chelates. Because 
the potency of one Gd-DTPA molecule to generate contrast in the MR images (i.e. the relaxivity) 
is rather low, (preclinically) the Gd is often incorporated in nanoparticles, such as micelles and 
liposomes, to increase the payload and improve the detection sensitivity. It becomes more and 
more apparent that post-processing techniques of harvested tissues determine to a large extent 
whether one can validate the accumulation of these lipid-based nanoparticles; they generally 
wash out during embedding in paraffin, however any incorporated peptide/antibody remains 
attached to its ligand. To verify ligand binding, embedding in paraffin and subsequent staining of 
the antibody-antigen complex is a suitable approach. However, to verify whether the entire lipid-
based nanoparticle entered the vessel wall, cryopreservation is required to either stain for the 
presence of DTPA or to visualize an incorporated fluorophore in the nanoparticle. 
Ex vivo histological visualization of Gd in tissue sections is complicated. Indirect detection is 
possible by replacing Gd with Europium (Eu), which enables imaging of the Eu chelate by 
fluorescence microscopy10 or as paraCEST agent11. Inductively coupled plasma mass spectroscopy 
(ICP-MS) of tissue homogenates can also be used to quantify Gd content in tissues. However, 
with this technique information on the cellular localization of the CA is lost12. 
Recently several anti-DOTA and anti-DTPA antibodies became commercially available that allow 
detection of Gd-chelates in their native cellular environment12. Staining of the Gd-chelate requires 
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the presence of a stable and accessible chelate (without spherical hindrance) in the contrast 
agent. Here we report for the first time on the use of these antibodies to detect the Gd-chelates 
in atherosclerotic plaque. Figure 1 demonstrates the application of anti-DTPA antibodies with 
diaminobenzidine (DAB) enhancement to stain cryosections of plaques in the carotid artery of 
an ApoE-/- mouse that was injected with Gd-DTPA containing micelles. DAB positive areas (figure 
1A and C) in tissue cryosections of the carotid arteries were in agreement with a positive signal 
enhancement observed on in vivo MR images (figure 1B and D). This Gd staining method may not 
be suitable for tissue sections prepared by paraformaldehyde fixation and paraffin embedding, as 
Gd-DTPA will wash out during preparation.
figure 1 | Detection of gd-DtPA  in an atherosclerotic plaque of an Apoe-/- mouse. Application of anti-DTPA 
antibodies to stain cryosections of plaques in the carotid artery of an ApoE-/- mouse that was injected with 
Gd-DTPA containing micelles. In panel A DAB positive areas showing Gd-DTPA micelles in tissue 
cryosections of the carotid arteries are visible in the intima of the carotid artery. Red asterisk in panel B 
indicates the area with positive contrast enhancement in an MR image of a mouse carotid artery with 
atherosclerosis after injection of Gd-containing micelles. The area with positive contrast enhancement is 
in agreement with the DAB positive area in panel A. In panel C, an enhanced version of the histological 
slide of panel A for better distinction of lumen, intima and adventitia of the histological slide from panel A 
indicates the vessel lumen, intima and adventitia. Arrows point at the elastic lamellae. The asterisks contour 
the DAB positive area. In panel D an MR angiogram of an ApoE-/- mouse is shown. The white arrow indicates 
the area where a constrictive collar has been placed around the left carotid artery to induce atherosclerosis. 
The green arrow points at the region of the left carotid artery where the histological slices originate 
from.
2012110 proefschrift Brigit den Adel_def.indd   158 22-01-13   21:50
Histology of MRi contRast agents
| 159
Most of the micellular and liposomal Gd-based MRI contrast agents also contain a lipid-bound 
fluorophore in the membrane for ex vivo visualization by fluorescence microscopy. Originally, 
rhodamine-PE was the fluorophore of choice13. However, detection of rhodamine-PE in 
atherosclerotic plaques in ApoE-/- mice fails due to autofluorescence of elastic lamellae at 
approximately the same emission wavelength (580 nm), leading to images that are difficult to 
interpret14. As an alternative, a near infrared fluorophore (NIR-664) has been used to visualize 
micelles accumulated in atherosclerotic plaques in the carotid arteries of ApoE-/- mice15. 
Autofluorescence of tissue is now an advantage as it enables visualization of the elastic lamellae 
without additional stainings. Figure 2B shows a confocal microscopy image of an aortic arch 
(figure 2A) plaque with in green the elastic lamellae and in red the NIR-664 lipids of the micelles. 
The corresponding MRI of the aortic arch with positive contrast enhancement on the inner 
curvature of the aortic arch is shown in figure 2C. When using a different atherosclerotic mouse 
model (ApoE-/-eNOS-/- double knockout mice16 in which intra-plaque hemorrhage and the 
spontaneous development of aneurysms (in males) can be observed, erythrocytes cause additional 
autofluorescence, especially in the near infrared spectral region (figure 2D). Therefore, in this 
mouse model fluorescence microscopy in the NIR regime does not completely solve the problem 
with autofluorescence.
To circumvent flawed histological validation due to autofluorescence overlapping with the 
fluorescent spectrum of fluorophores incorporated in nanoparticles, a different approach could 
be used to detect micelles/liposomes indirectly with a secondary histological staining of the 
targeting ligands (e.g. antibodies). Antibodies bound to a target survive the paraffin embedding 
procedure and therefore a secondary antibody can be applied, after which a DAB or alkaline 
phosphatase (AF) step visualizes the bound antibodies and thus indirectly reveals the presumed 
location of the micelles17. An example of this staining method is shown in figure 3. NGAL staining 
displayed a wide-spread distribution of this protein in the plaque (figure 3A). The staining to detect 
bound primary antibodies, previously coupled to the injected micelles (figure 3B), showed a partial 
overlap in AF signal. We conclude that the micelles specifically binds to NGAL, yet the target is 
also present in different areas of the plaque that do not show the presence of micelles, possible 
because the micelles do not penetrate into these areas.
Van Tilborg et al.18 designed a targeting approach in tumors with liposomes containing lipids 
conjugated to biotin or streptavidin. An avidin chase was used in vivo to increase the clearance 
rate of unbound particles. However, when these particles were used for histological evaluation 
using an avidin method it gave rise to considerable background staining. Normally, a blocking 
step is used to block biotin in any staining procedure (both cryo- or paraffin-sections). However, 
this is not suitable to stain the biotin present in the nanoparticle contrast agent. So though this 
method may be very useful in vivo in experimental animals, it cannot be used in conjunction with 
standard histological validation of contrast agents.
Another promising approach to circumvent hindrance by autofluorescence in atherosclerotic 
vessels is the development of dual histology/MRI contrast agents in which the same molecule 
acts as an MRI contrast agent and as an optical histological stain. Thus far this has only been 
described for brain MRI contrast agents19;20. Luxol Fast Blue (LFB), a classical staining for myelin, 
contains copper, a paramagnetic metal that acts as an MRI contrast agent. Both the macroscopic 
and microscopic distributions of LFB were found to mimic those of traditional histological 
preparations and the ex vivo use of the compound allowed detailed co-registration of histology 
and MRI. Congo Red, a histological fluorescent staining for amyloid plaque, was modified by 
Higuchi et al. to contain 19F for 19F-MRI and T1W detection. In vivo and ex vivo MRI and histology 
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showed targeting of fibrillar plaques using this agent. We postulate that a similar approach could 
be used with a modified Oil Red O stain or classical collagen staining to detect atherosclerotic 
plaques.
t2 contrast agents
USPIO (18-30 nm) and SPIO (100-200 nm) are superparamagnetic particles made of an iron-oxide 
crystalline core. Because of their large magnetic moment, the iron-oxide containing particles 
create strong local magnetic field gradients, which leads to rapid signal loss in T2 weighted images.
figure 2 | Detection of nir664 lipid in an atherosclerotic plaque of atherosclerotic mice. A: Oil Red O staining of 
the entire aortic arch of an ApoE-/- mouse displaying lipid depositions in red. B: confocal microscopy image 
(zoomed frame of A, indicated by dashed lines), depicting the elastic lamellae in green (white arrows) and 
the micelles with a NIR664 lipid in red (asterisks). C. MRI of the aortic arch depicted in A and B after injection 
of Gd-containing micelles. Positive contrast enhancement of the micelles is observed on the inner curvature 
of the arch (red arrow), correlating to the regions where atherosclerotic plaques can be observed in panel 
A. D. In ApoE-/- eNOS-/- mouse autofluorescence of excessive lipid deposition and intraplaque hemorrhage 
generate autofluorescence in the vessel thereby preventing detection of NIR664. Autofluorescence can 
be observed at several wavelengths due to the presence of intra-plaque erythrocytes: red (ex543, em590), 
green (ex488, em518), and far red (depicted in blue; ex633, em670), overlapping with the emission spectrum 
of NIR664. Ex: excitation; em: emission
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In black, negative contrast in the surrounding of the particle the classical dipole shape can be 
recognized, which is coined the “blooming” effect21. This blooming effect stresses the need to 
histologically validate the cellular localization of the contrast agent, as the blooming effect is 
often too large to appreciate the exact location of the particles in the MR images. Iron oxide 
nanoparticles are typically classified according to their size, which impacts their magnetic and 
biological properties. The coating is often dextran, citrate, or a polymer such as polyethylene 
glycol or polyvinyl alcohol. 
Iron oxide-based contrast agents can be reliably detected using a Prussian blue staining, if needed 
with an amplification step. When using molecularly targeted iron oxides it is difficult to discriminate 
specific binding from aspecific cellular uptake. Therefore it is preferable to combine the widely 
applied Prussian blue staining to detect iron with a secondary staining for the molecular target 
of the CA. Staining with 3,3’-diaminobenzidine (DAB), a commonly used chromogen for 
immunohistochemical stainings, is widely applied as secondary detection method for a molecular 
target, in the presence of iron oxides22. However, development of a DAB staining requires a redox 
reaction to obtain its typical brown color. The redox reaction is performed with a peroxidase 
enzyme, yet iron oxides may also act as a reducing agent. We tested this hypothesis on aortic 
arch tissue of ApoE-/- mice that were injected with USPIOs and subsequently sacrificed. We found 
that a DAB step in the presence of iron oxide nanoparticles leads to false-positive results for the 
secondary staining and difficulties to discriminate between the presence of the molecular target 
or merely the iron particle (figure 4A). To circumvent this problem, we tested several other 
classical staining methods. Double staining of iron oxide particles with Prussian blue and a 
molecular target with alkaline phosphatase substrate turned out to be the most suitable method 
for detection of multiple targets without interference of iron oxides with the secondary staining 
(figure 4B and 4C).
imaging gene expression
An emerging new imaging field is the use of (MRI) contrast agents that can be activated by the 
expression of an endogenous receptor or enzyme. Alternatively, reporter genes are used that are 
co-expressed with the gene of interest. MRI reporter genes are unique among all reporter genes 
used with the various imaging modalities because they can provide information on gene expression 
that can be co-registered with anatomic/histological and functional information23. 
figure 3 | ngAl  and micelle staining in an atherosclerotic plaque from a Apoe-/-/enos-/- mouse. A: NGAL staining 
is depicted in red (AF) in an atherosclerotic plaque, red areas are indicated with asterisks; B: micelle staining 
depicted in red (AF)(white asterisks). Some overlap between the staining can be observed, with more NGAL 
present than micelles. NGAL: neutrophil gelatinase-associated lipocalin; AF: alkaline phosphatase 
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This approach, of course purely used for research purposes, is already commonly used in the 
optical-imaging field, where GFP transgenic mice have been utilized to visualize a myriad of 
genes (24. For MRI, this field is relatively new. A number of candidate reporter genes have previously 
been used for detection of gene expression by MRI. Several groups have presented candidate 
MRI-detectable substrates for classical reporter genes, such as the histologically applied 
β-galactosidase25;26 and the enzymes arginine and creatine kinase27;28. The principle of these agents 
is based on a change in MR relaxivity of the probe after cleavage by the reporter enzyme, leading 
to a local contrast change in the image. Though potentially very interesting, the sensitivity of 
these probes is currently too low for routine use.
As an alternative to the use of activatable probes, reporter genes have been proposed to image 
gene expression directly. For MRI recent advances have allowed the use of genes associated with 
iron homeostasis such as the transferrin receptor29;30, tyrosinase31 and ferritin32;33, resulting in 
(endogenous) iron accumulation at the site of gene expression, which can be visualized using 
T2W or T2*W sequences in vivo, and Prussian Blue stainings in post-mortem histological material. 
Obviously, as described above, the presence of high concentrations of iron in the tissue may 
result in false-positive DAB enhancement of histological stainings. 
outlook
Histological validation of contrast agent accumulation is an essential step in the validation process 
of a contrast agent. Evaluation of the specificity of targeted contrast agent accumulation to detect 
atherosclerotic lesions can be challenging because the enhanced permeability of the plaque itself 
also may lead to significant amounts of non-specific uptake and retention of contrast agents, 
and the balance between target-specific and aspecific contrast agent enhancement is strongly 
dependent on the time passed after injection. To discriminate specific uptake from non-specific 
uptake, the timing of imaging and tissue harvesting after the administration of the contrast agent 
is of utmost importance to assure that the interpretation of MRI data is not obscured by changes 
in contrast agent accumulation over time or ambiguity in the histology.
Different mouse models of atherosclerosis ask for different validation solutions. Although this 
review is written in the context of atherosclerosis, extrapolation of these findings to other tissue 
types and pathologies is possible as autofluorescence, washing out of particles and chemical 
interferences are general challenges encountered when working with MRI contrast agents.
figure 4 | staining of usPio in an atherosclerotic plaque from an Apoe-/- mouse. A: A false positive double staining 
(both stainings turn brown) for macrophages due to reactivity of USPIO and DAB. Note that the USPIOs 
and CD68+ cells cannot be differentiated from each other in this panel. B: Double staining of USPIO with 
Prussian Blue and secondary CD68+ target with alkaline phosphatase allows visualization of both USPIO 
and CD68 in the same histological slice. Black arrows indicate the CD68+ cells, black asterisks indicate the 
USPIO. C. T2* weighted MR image of the aortic arch, the red arrows indicate the region with the USPIO 
induced Blooming effect in the inner curvature of the aortic arch. USPIO: ultra small particle of iron oxide; 
AF: alkaline phosphatase
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The use of contrast agents for the in vivo detection of atherosclerotic plaques, either targeted or 
non-targeted, has so far not reached the clinic. However, molecular MRI is one of the most 
promising non-invasive screening tools for identification of patients at risk of a clinical event. 
Before clinical implementation of molecular MRI of atherosclerosis 3 main aspects need to be 
considered: 1) technical constraints that currently hamper clinical applications, in particular for 
imaging of the coronary arteries, 2) potential toxic or adverse effects of the in vivo use of MR 
contrast agents and 3) the potential clinical impact in terms of managing strategies to ultimately 
reduce the occurrence of cardiac events. These translational challenges are enormous, and many 
of the developed contrast agent will fail to reach the clinic, but the few nanoparticles that so far 
have reached clinical status show substantial benefit over conventional imaging approaches (34. 
One of the main concerns for the clinical application of MRI contrast agents as diagnostic 
compound for atherosclerosis is the potential toxicity. Gd-based contrast agents are associated 
with rare cases of nephrogenic systemic fibrosis (NSF) in patients with renal failure35;36. The exact 
mechanism of gadolinium-induced skin fibrosis in these patients is unknown, although it is 
suggested that free gadolinium (Gd-chelates are not 100% stable) may cause changes in fibroblast 
characteristics. Since the first reports of NSF, clinical guidelines have been adapted and the 
occurrence has been minimalized37. 
Lipid-based contrast agents such as micelles and liposomes also pose several challenges, such 
as instability of the carrier in vivo, eventual release of their content including Gd-DTPA, and rapid 
blood clearance by the reticulo-endothelial system (RES), mostly liver and spleen34. To improve 
the stability and prevent opsonization by the liver, the surfaces of liposomes and micelles have 
been coated with hydrophilic and inert polymers, mostly PEG. In turn such non-biodegradable 
contrast agent components may accumulate in certain organs, mostly in the RES, and may cause 
potential harm including immune-mediated toxicity, teratogenicity and potentially even 
carcinogenicity38. 
Finally, iron-oxide containing particles are known to accumulate in phagocytic cells and may 
accumulate in the body for weeks. Iron oxides themselves are considered to be safe, as free iron 
enters the body’s iron storage. The main toxicological concern lies in the molecules that are used 
to improve the stability and prevent opsonization. Their toxicological profiles need to be assessed 
in depth before clinical translation is possible. 
Clinical impact
Nevertheless, the opportunity to identify noninvasively the vulnerable patients and the vulnerable 
plaques is of tremendous clinical interest and from available pathophysiological and clinical studies 
of potential applications of molecular imaging may be foreseen.
Firstly, evaluation of asymptomatic patients classified at intermediate risk by current risk 
stratification algorithms may be useful to reclassify those with elevated coronary inflammatory 
activity in whom treatment is desired. Prognostic value and cost-effectiveness need to be 
compared to other currently applied techniques. Secondly, molecular imaging of atherosclerotic 
plaques allows a type of personalized medicine, with potential to tailor therapy to the presence/
absence of specific targets in individual patients, as is already done in some cancer studies. 
Molecular imaging may also allow monitoring of the therapeutic efficiency of these drugs or 
changes in lifestyle. Thirdly, the nanoparticle approach that is central to most molecular imaging 
developments also allows delivery of drugs, leading to a theragnostic approach of atherosclerosis 
management.
The key point to understand is that the clinical translation of MRI contrast agents for the diagnosis 
of atherosclerosis requires a complete understanding of the relationship between the human 
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body and particle size, composition, formulation, supramolecular structure, chemical reactivity, 
and biomechanical strength and stability. To advance this knowledge correct histological validation 
of accumulation patterns is of utmost importance in the pre-clinical stages. Although a full 
comprehension of the fate of contrast agents in vivo is very complex, we do foresee clinical 
approval of targeted MRI contrast agents albeit in the medium- to long-term future. 
CoNCluSIoN
To successfully implement molecular MRI as a clinical screening tool, it is of utmost importance 
for the ex vivo validation methods to be as efficient and transparent as possible. In this paper we 
have described various approaches for histological validation of molecular MRI contrast agents. 
We have also demonstrated several pitfalls that may give confounding or false-positive results, 
and provided strategies to circumvent these pitfalls. Thus, this paper provides a reference 
framework for future validation of molecular MRI contrast agents.
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Cardiovascular disease (CVD) is the number one cause of death globally and is expected to remain 
so according to numbers of the World Health Organization1. CVD imposes a significant healthcare 
burden, particularly in the industrialized countries. The single most important contributor to the 
growing burden of CVD is atherosclerosis, a progressive inflammatory disease characterized by 
the accumulation of lipids and fibrous elements in the large and medium-sized arteries2, 3. 
Atherosclerosis is considered to be a multifactorial disease in which lipids and inflammation play 
major roles. Noninvasive screening for subclinical atherosclerosis as well as detection of high-risk 
atherosclerotic plaques in an established population of cardiovascular patients is important for 
patient management. This thesis presented and discussed the validation of a variety of pre-clinical 
MRI contrast agents that can be used for the early detection and differentiation of atherosclerotic 
plaque in murine models of atherosclerosis.
Molecular imaging
As recently as the mid-1990s, a new field in medical imaging was emerging. The term molecular 
imaging was adopted to describe the noninvasive characterization of biological processes at the 
molecular (and cellular) level. The progress of this field was driven by contemporary developments 
in multiple disciplines, including genomics, proteomics, molecular biology, imaging and 
nanotechnology. The promise of molecular imaging incorporates both early as well as “at risk” 
disease detection. Molecular imaging has gained increasing interest in the research field of 
cardiovascular diseases the last couple of years, mainly because atherosclerotic plaque 
composition turned out to be important as a predictor for clinical events, even more so than the 
degree of stenosis(4.
Molecular MRI offers the potential to image events at the cellular and subcellular level which has, 
depending on the target of choice, added value over traditional contrast agents5-7. The introduction 
of targeted MR contrast agents has enabled the imaging of relatively sparsely expressed biological 
targets in vivo. During the development of atherosclerotic plaques, many potential biomarkers, 
such as adhesion molecules [vascular cell adhesion molecules (VCAMs), intercellular adhesion 
molecules (ICAMs), selectins], macrophages and their scavenger receptors, matrix 
metalloproteinases (MMPs), oxidized low-density lipoprotein (oxLDL), αvβ3 integrin, extracellular 
matrix, and fibrin, are up-regulated4. In chapter 2 the current development status of vulnerable 
atherosclerotic plaque detection with MRI contrast agents is discussed. The review deals with the 
interplay between the complex vascular biology involved in plaque vulnerability and the potential 
use of MR contrast agents. The identification of suitable target-ligand combinations specific for 
a vulnerable plaque (or other pathology) is complex. At this point multiple MRI contrast agents 
have been developed that allow the detection of different markers and stages in 
atherosclerosis. 
In this thesis, we investigated three main targeting approaches: passive accumulation in 
macrophages (chapter 3, 4, 7 and 8), active targeting towards a macrophage marker such as the 
scavenger receptor AI (chapter 5) or VCAM-1 (chapter 6), and endothelial targeting using markers 
for endothelial activation, namely VCAM-1 (Chapter 6) and E-selectin (Chapter 7). 
imaging of endothelial activation
Dysfunctional endothelium is one of the first and crucial pathophysiological factors in 
atherosclerosis, causing increased permeation of macromolecules such as lipoproteins, increased 
expression of chemotactic molecules (for example, monocyte chemotactic protein 1) and 
adhesion molecules (for example, intercellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1), as well as E-selectin and P-selectin), and enhanced recruitment 
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and accumulation of monocytes8. Markers of endothelial activation are present on the 
atherosclerotic vessel wall and therefore easily reached by contrast agents. Some adhesion 
molecules are differentially expressed during atherosclerotic plaque development. In chapter 7 
E-selectin expression was shown to increase with atherosclerotic plaque progression and targeted 
USPIO allowed to visualize plaque progression. VCAM-1 on the other hand was in chapter 6 shown 
to decrease with plaque progression. VCAM-1 USPIO imaging short after injection thus mainly 
allowed visualizing the early lesion.
Macrophage imaging
One of the main points of interest in the field of molecular imaging of atherosclerosis are rupture-
prone atherosclerotic lesions. As inflammatory processes are involved in all stages of atherosclerotic 
lesion development and the inflammatory status of the plaque is closely associated with plaque 
vulnerability, inflammatory cells and their derivatives are the primary targets for vulnerable plaque 
imaging5. One of the most obvious cells to focus on is the plaque macrophage. Macrophages 
form the most abundantly present inflammatory cell in the atherosclerotic plaque. Moreover, the 
infiltration of monocytes and their differentiation into macrophages and functional phenotype 
(i.e. M1/M2) are considered crucial hallmarks in atherogenesis9, 10. In mouse models it has been 
shown that in the absence of monocyte and macrophage migration into the vessel wall, 
atherosclerosis development is delayed, even in the presence of severe hyperlipidemia11. In man, 
high macrophage content in plaques is even associated with vulnerability to rupture12, 13. In chapter 
6 and 7 treatment with atorvastatin and fenofibrate led to a decrease in endothelial activation 
together with a reduction in plaque macrophage load. Treatment with fenofibrate also led to a 
decrease in endothelial activation, however did not result in a reduction of the macrophage load, 
a phenomenon observed by passive targeting the macrophage pool by late USPIO imaging. 
Macrophages as markers for vulnerable plaque
Macrophage phenotypic polarization towards M1 or M2-type macrophages has recently become 
a major point of interest as the macrophage phenotype plays a role in the fate of an atherosclerotic 
lesion. Classically activated macrophages (or M1) and alternatively activated macrophages (or M2) 
are two extremes representing inflammatory and reparative macrophage phenotypes14. The 
phenotypic change of plaque macrophages might depend upon the type (innate or adaptive) of 
immune cells infiltrating a developing atherosclerotic lesion. The initial M2 macrophage phenotype 
present at the site of inflammation develops independently of the adaptive immune system 
whereas the maintenance of the M2 macrophage phenotype requires IL-4-producing T cells, in 
the absence of which M2 macrophages normally switch to the M1 phenotype14. Further 
extrapolation of this mechanism to atherosclerosis suggests that the pro-inflammatory T helper 
cell type 1 (Th1) phenotype might trigger the M2-M1 phenotypic switch in advanced atherosclerotic 
plaques9. In a therapeutic perspective, controlling the local milieu within atherosclerotic plaques 
in vivo will be difficult to achieve due to the myriad of factors implicated in the balance between 
M1 and M2 macrophages. However, several recent studies have suggested that pharmacological 
treatments may skew macrophage polarization toward the M2 phenotype, thereby stabilizing 
atherosclerotic lesions10, 15. 
In the current thesis we applied different clinically approved therapies to validate the MRI contrast 
agents. One of the results in this thesis is the dual imaging of macrophage load and E-selectin 
expression on the endothelium described in chapter 7. Treatment of ApoE-/- mice with atorvastatin 
or fenofibrate resulted in both cases in less advanced plaques; atorvastatin treated mice had 
smaller plaques with less E-selectin as well as macrophages. Fenofibrate-treated mice on the 
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other hand had plaques that had a lower E-selectin expression however practically unchanged 
macrophage load. Both drugs are known to exert their actions in apoE-/- mice mainly through 
their pleiotrophic effects on the immune system, the lipid regulating effect does not occur in 
these mice. This characteristic of statins has also been used in chapter 6 where we differentiate 
plaque stages based on endothelium and intraplaque VCAM-1 expression. 
The exact mechanism behind this difference in treatment effect between statins and fibrates 
remains speculative yet it is tempting to think the drugs either reduce the pool of M1 macrophages 
or induce a phenotypic change. Once these mechanisms of action are known, imaging of 
macrophage load may have clinical potential to monitor treatment response. 
Mouse models and techniques for vulnerable plaque imaging
Contrast agents are developed to target molecules or cells known from human studies to be 
involved in plaque rupture and vulnerability. For this purpose a mouse model, which develops 
rupture-prone plaques, would be desirable, but unfortunately mouse physiology does not allow 
for the development of real vulnerable plaques. There have been few descriptions of myocardial 
infarction or stroke in mice as a consequence of atherosclerotic lesion formation, despite the 
presence of extensive lesions that display characteristics similar to that of “vulnerable” lesions in 
humans. Several “surrogate” mouse models have been developed trying to mimic the development 
of a vulnerable plaque. In the current work we chose to use the most commonly applied mouse 
models of atherosclerosis, i.e. ApoE-/- and LDLr-/- based athero-prone animals, because of their 
reproducible atherosclerotic lesion development with expression patterns comparable to humans. 
For the development and validation of contrast agents to detect atherosclerotic lesions these 
models have proven their use. 
Despite the lack of vulnerable mouse models, mice remain the preclinical model of choice 
because of the wide array of transgenic models available. The studies in this thesis required 
dedicated high-resolution MRI sequences to visualize the murine atherosclerotic vessel wall. The 
small size of mouse arteries and their close proximity to the heart cause unpredictable flow 
artifacts, motion of the thin artery wall and problems with flow suppression in the presence of a 
circulating contrast agent. In chapter 3 we therefore validated the value of retrospective-gated 
cine MRI of the aortic arch for atherosclerotic plaque detection and assessment of wall stiffness 
after injection of both T1 and T2*contrast agents. The retrospective-gated cine MRI provides a 
robust and simple way to detect and quantify contrast enhancement in atherosclerotic plaques 
in the aortic wall of ApoE-/- mice. 
For validation purposes, it is crucial that nanoparticle accumulation in the plaque, cellular 
association and localization can be assessed by ex vivo immunohistochemistry or fluorescence 
microscopy of tissue sections. In chapter 9 various methods are described that are available, 
including the pitfalls that may give confounding or false-positive results, for histological evaluation 
of MRI contrast agent accumulation such as lipid-based nanoparticles and iron oxide particles. 
theragnostics
Particles that integrate diagnostic imaging and therapeutic components, or “theragnostic” agents, 
gained much recent interest as a valuable advance for drug delivery16, 17. Although this strategy is 
still in its infancy for CVD, it has numerous potential advantages, which are being extensively 
investigated in the field of cancer nanomedicine. Combining a diagnostic imaging moiety with a 
targeted therapeutic nanoparticle allows for precise, temporal and spatial monitoring of the 
therapeutic agent as well as treatment outcomes. Its advantages include — but are not limited to 
— improving drug pharmacokinetics and enabling the therapeutic use of drugs that exhibit certain 
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drawbacks, such as low water-solubility, poor bioavailability, fast metabolism, limited specificity 
or severe adverse effects18, 19. One of the first clinically approved nanomedicinal therapies was a 
liposomal formulation of doxorubicin, a cytotoxic drug used for cancer chemotherapy. This 
formulation, branded Doxil, was approved by the US Food and Drug Administration in 1995 for 
the treatment of Kaposi’s sarcoma and later approved for other cancer types20. Subsequently, 
several other nanomedicinal therapeutics have been approved. Although still in its infancy, 
nanomedicine is likely to have a substantial role in the management of CVD in general and 
atherosclerosis in particular21. In chapter 8 we describe the in vitro and in vivo validation of Gd-
loaded micelles incorporating rosiglitazone to allow passive delivery of the drug into atherosclerotic 
lesions. It was of particular interest to use rosiglitazone in a theragnostic context as the drug was 
recently withdrawn from the market owing to severe cardiac side effects in a small subset of 
patients. The drug is known to exert its anti-atherosclerotic action independent of its metabolic 
effects, which made us postulate that local delivery could be beneficial. Significant anti-
atherosclerotic effects were observed upon treatment with rosiglitazone micelles, holding promise 
to apply the drug in the treatment of atherosclerosis.
Perspectives
One of the aims of molecular imaging of atherosclerosis is to provide a means for the determination 
of plaque vulnerability and subsequent risk for plaque rupture. Ongoing developments in molecular 
biology have resulted in the identification of numerous molecular targets that allow for the 
identification and staging of atherosclerosis. It is generally accepted that plaque rupture has a 
multi-factorial origin. In this respect, MRI may in the future become the imaging modality of 
choice since it can provide information on plaque morphology, hemodynamic conditions, as well 
as on molecular processes. MRI is already frequently applied in all fields of cardiovascular research 
and in clinical evaluation. The increasing use is mainly due to its non-invasive nature and ability 
to differentiate between all sorts of tissues. The main drawback is the relatively low sensitivity for 
contrast agents, which is decreasing even more at higher magnetic fields. However, atherosclerosis 
is one of few applications where targets are readily accessible from the blood stream, allowing 
the use of large nanoparticles with a high payload of contrast moieties to compensate for the 
lack of sensitivity, as was shown in this thesis.
Of all the suggested markers for vulnerability, three appear to give robust pre-clinical results that 
should translate to the clinic given their potential to recognize efficiently vulnerability markers, 
those are fibrin, integrins and VCAM-1, with a good toxicological and biodistribution profile22-26 
and chapter 6. It is important to point out that these molecules are not unique to atherosclerosis 
or cardiovascular diseases, but they are present at increased levels under these disease conditions 
as compared to disease free conditions. 
With the development of targeted contrast agents to visualize the vulnerable atherosclerotic 
plaque, MRI may become even more important in the future, when clinical decision making is 
based on atherosclerotic plaque composition and not only on the degree of stenosis. An added 
value could most definitely be found in combined imaging techniques, such as MRI/SPECT and 
MRI/PET, in which the anatomical detail of MRI and high sensitivity of PET and SPECT tracers can 
be combined. This field is currently developing very fast both regarding the imaging equipment 
as well as the development of nanoparticles.
Unfortunately, many of the exciting preclinical findings with nanoparticles in animal models of 
atherosclerosis have not progressed from the developmental phase, as is often the case in drug 
development. One of the reasons for this is the accelerated development of atherosclerosis in 
animal models, thereby creating atherosclerotic lesions with somewhat different characteristics 
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to those found in humans27. Moreover the physiology and lipid metabolism are different to those 
in humans. 
There is also a need to further work on the development of less toxic and immunogenic contrast 
agents. A major set-back for the molecular imaging field was the withdrawal of a number of iron 
oxide nanoparticles from the market around 2008-2009, mainly because of marketing reasons. 
As a result approval of targeted agents for clinical use also became more unlikely. These limitations 
are among the current reasons that have motivated several groups to issue recommendations 
for accelerating the translation of nanoparticles into the clinic28, 29. Nevertheless, the use of 
nanoparticles in cardiovascular disease has nowadays already led to a better understanding of 
atherosclerosis, the role of imaging and the evaluation of pharmacotherapy, and will continue to 
do so in the near future.
CoNCluSIoN
In this thesis several contrast agents to detect and stage atherosclerotic lesions were validated. I 
envision that molecular imaging in 20 years from now is likely to play a pivotal role in the 
evaluation, risk stratification, and management of patients with cardiovascular disease. In patients 
in the chronic phase of the disease and in the prevention of plaque build-up, the injection of 
nanoparticles for prolonged periods of time is unrealistic and impractical as the disease may 
remain asymptomatic. Screening for asymptomatic atherosclerotic lesions to prevent future 
plaque rupture has not yet been proven to be beneficial in patients, but it is hoped that the 
accurate identification of patients with an impending risk of cardiovascular events can be achieved 
using molecular imaging techniques30. Targeted molecular MRI in combination with more 
conventional physiological imaging will allow a more “personalized” approach to the management 
of cardiac disease. The use of molecular imaging for the evaluation of the early molecular and 
cellular events associated with cardiovascular disease will allow early detection of disease and 
potentially improve patient outcome. The non-invasive in vivo evaluation of molecular and cellular 
processes could potentially also serve as endpoints for all therapies whether they are 
pharmacological, surgical, or even molecular targeted therapeutics.
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SuMMERy 
Molecular imaging has gained increasing interest in the research of cardiovascular diseases the 
last couple of years, mainly since it became apparent that atherosclerotic plaque composition is 
an important predictor for clinical events, even more so than the degree of (luminal) stenosis. 
Molecular MRI holds great potential for detection of different stages of atherosclerosis and 
differentiation of vulnerable lesions. Its application potential will depend on comprehensive 
knowledge of the detection possibilities and behavior of targeted and untargeted contrast agents 
in vivo.
To begin to address this, in chapter 2 the current development status of (vulnerable) atherosclerotic 
plaque detection with MRI contrast agents is discussed.
In this thesis, we investigated three main targeting approaches: 1) passive accumulation in 
macrophages (chapter 3, 4, 7 and 8), 2) active targeting towards the macrophage using 
scavenger receptor AI (chapter 5) and VCAM-1 (chapter 6) targeted USPIOs, and 3) endothelial 
targeting using markers for endothelial activation, namely VCAM-1 (Chapter 6) and E-selectin 
(Chapter 7). 
In chapter 3 we first validated the value of retrospective-gated CINE MRI of the aortic arch for 
atherosclerotic plaque detection and assessment of wall stiffness after injection of both T1 and 
T2*contrast agents. The retrospective-gated cine MRI provided a robust and simple way to detect 
and quantify contrast enhancement in atherosclerotic plaques in the aortic wall of ApoE-/- 
mice.
When using (targeted) contrast agents it is important, for correct interpretation of the data, to 
know their pharmacokinetic and pharmacodynamic properties. In chapter 4 the in vivo behavior 
of paramagnetic micelles and liposomes was assessed in atherosclerotic mice for several days. 
This time course illustrates that paramagnetic micelles and liposomes are able to accumulate in 
atherosclerotic plaques, yet have a complex kinetic behavior when followed for longer periods 
of time.
Scavenger receptor-AI (SR-AI) is highly expressed by lesional macrophages and linked to an 
effective internalization machinery. In chapter 5 evidence is given that SR-AI targeted molecular 
imaging of USPIO holds great promise for in situ detection of inflammatory, potentially vulnerable, 
plaques in manifest atherosclerosis.
In chapter 6 the targeting potential of VCAM-1 is explored using VCAM-1 targeted USPIOs. Early 
stage atherosclerotic plaques showed the largest contrast change at 1.5 hours after VCAM-1 
USPIO injection. The reverse was true for advanced lesions: the largest contrast change was 
observed at 6 hours after injection of VCAM-1 USPIO. The ratio between early and late 
enhancement provides a reliable measure of plaque progression.
In chapter 7 E-selectin expression was shown to increase with atherosclerotic plaque progression 
and targeted USPIO allowed to visualize stages of plaque progression.
In chapter 8 we describe the preliminary results of the in vitro and in vivo validation of Gd-loaded 
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micelles incorporating rosiglitazone to allow passive delivery of the drug into atherosclerotic 
lesions. ApoE-/- and ApoE-/--eNOS-/- mice treated with rosiglitazone had significantly smaller 
atherosclerotic lesions without the occurrence of the classical cardiac side effects often observed 
upon rosiglitazone treatment.
In chapter 9 the histological validation of several contrast agents (targeted and untargeted) in 
murine models of atherosclerosis is described. The evaluation of tissue accumulation of contrast 
agents is very important, however choosing the correct histological evaluation method might be 
of similar importance, to rule out false-positive or negative results.
In Chapter 10 the results described in this thesis are discussed and I speculated on the future 
perspectives of molecular MRI to detect atherosclerotic lesions.
In conclusion, the availability and rapid development of several MRI contrast agents is now 
expected to accelerate atherosclerosis research and offers a clinically relevant research tool for 
human disease prediction.
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SAMENVAttING
Bij atherosclerose, ook wel slagaderverkalking genoemd, veranderen de kenmerken van de 
vaatwand als gevolg van een ontstekingsproces. Er ontstaan verdikkingen, zogenaamde plaques, 
in de vaatwand met ophopingen aan vetstoffen en cellen van het immuunsysteem. Sommige 
plaques kunnen scheuren, de zogenaamde kwetsbare plaques, en daardoor voor klinische 
problemen zorgen. De grootte en dikte van plaques kan met verschillende beeldvormende 
technieken goed vastgesteld worden. Deze parameters zijn echter een slechte voorspeller voor 
plaque ruptuur. Moleculaire MRI is een veelbelovende techniek waarbij gebruik gemaakt wordt 
van moleculaire eigenschappen van plaques voor de detectie van verschillende stadia van 
atherosclerose en het opsporen van plaques die kunnen ruptureren. Om verschillende plaques 
te onderscheiden, zonder operatief ingrijpen, hebben wij contrastmiddelen ontwikkeld die in de 
bloedbaan geïnjecteerd kunnen worden en vervolgens hechten aan een molecuul dat kenmerkend 
is voor een bepaald plaque type.
In dit proefschrift beschrijf ik de preklinische ontwikkeling van verschillende contrastmiddelen 
waarbij 3 benaderingen gevolgd zijn om plaques te visualiseren in atherosclerotische muizen: 1) 
passieve ophoping van contrastmiddelen in macrofagen (hoofdstuk 3, 4, 7 en 8), 2) actieve binding 
van macrofagen door contrastmiddelen gericht tegen scavenger receptor AI (hoofdstuk 5), VCAM-
1 (hoofdstuk 6) gerichte ijzeroxide deeltjes (USPIO) , en 3)actieve beeldvorming van het endotheel 
aan de binnenkant van een bloedvat met VCAM-1 (hoofdstuk 6) en E-selectine (hoofdstuk 7). We 
onderscheiden hiermee vroege van meer gevorderde plaques zonder alleen naar de grootte en 
dikte van de plaque te kijken zoals tot op heden in de kliniek gedaan wordt.
In hoofdstuk 2 wordt de huidige literatuur kennis besproken van de MRI contrastmiddelen die 
ontwikkeld zijn om plaques te detecteren. 
hoofdstuk 3 beschrijft de waarde van een MRI techniek waarbij opgenomen beelden achteraf 
toegekend worden aan een fase van de hartslag om zowel atherosclerotische plaques te 
detecteren na contrastmiddel injectie als de elasticiteit van de vaatwand te bestuderen.
Het gedrag van (gerichte) contrastmiddelen na injectie zoals de tijd waarin een middel in de 
bloedstroom aanwezig blijft, ophoping in organen, is erg belangrijk voor de juiste interpretatie 
van resultaten. In hoofdstuk 4 is het gedrag van vetachtige contrastmiddelbolletjes van 
verschillende groottes (micellen en liposomen) gedurende een week bestudeerd. De tijdscurve 
illustreert dat dit soort contrastmiddelen ophopen in atherosclerotische plaques maar tevens een 
complex gedragspatroon hebben.
Scavenger receptor AI (SR-AI) is een eiwit dat hoog tot expressie komt op immuuncellen in de 
plaque, de macrofagen. Moleculaire beeldvorming met USPIO gericht tegen SR-AI in hoofdstuk 
5 toont aan dat deze geschikt zijn om plaques en potentieel kwetsbare plaques op te sporen.
In hoofdstuk 6 wordt het gebruik van USPIO gericht tegen VCAM-1 beschreven. VCAM-1 komt 
op de vaatwand tot expressie in vroege plaques maar komt op in vergevorderde plaques ook tot 
expressie om macrofagen en gladde spiercellen binnenin de plaque. Door zowel relatief kort als 
laat na injectie van het contrastmiddel MRI beelden te maken van de aortaboog en halsslagader 
van atherosclerotische muizen kunnen vroege en meer gevorderde plaques van elkaar 
onderscheiden worden.
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In hoofdstuk 7 worden verschillende stadia van plaque progressie in beeld gebracht met 
E-selectine gerichte USPIO. De expressie van E-selectine neemt gradueel toe op de vaatwand 
van ontwikkelende plaques. Het contrastmiddel signaal van E-selectine gerichte USPIO vertoont 
dezelfde trent.
In hoofdstuk 8 beschrijf ik de preliminaire resultaten van de validatie van Gd-micellen geladen 
met het medicijn roziglitazone voor de lokale behandeling van atherosclerose door de passieve 
ophoping van deze micellen in de plaque.
In hoofdstuk 9 worden de verschillende histologische validatie technieken beschreven om 
contrastmiddelen toegepast in muizen met atherosclerose te detecteren. Het komt erg nauw de 
juiste techniek te kiezen afhankelijk van het soort contrastmiddel en het soort weefsel om zowel 
vals-positieve als vals-negatieve resultaten te voorkomen.
Tot slot, in hoofdstuk 10 bediscussieer ik de resultaten die in dit proefschrift beschreven zijn en 
speculeer ik over de toekomst van moleculaire MRI om atherosclerotische plaques te 
detecteren. 
Samenvatting
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